(Clinical Focus: The purpose of this value set is to indicate that an appropriate follow-up plan in relation to an elevated (high) BMI is documented by a provider; this value set specifies a follow-up plan that may include one of the following: lifestyle modification, dietary changes, exercise programs, education, or even surgical or procedural referral given to the patient for weight reduction, with an ultimate goal of the follow-up being to reduce BMI.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Above Normal Follow-up valueset (2.16.840.1.113883.3.600.1.1525).
(Clinical Focus: The purpose of this value set is to indicate that an appropriate follow-up plan in relation to an elevated (high) BMI is documented by a provider; this value set specifies a follow-up plan that may include one of the following: lifestyle modification, dietary changes, exercise programs, education, or even surgical or procedural referral given to the patient for weight reduction, with an ultimate goal of the follow-up being to reduce BMI.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Above Normal Follow-up
(Clinical Focus: This set of values contains a medication with various dosages, that is commonly used for weight reduction.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Above Normal Medications valueset (2.16.840.1.113883.3.600.1.1498).
(Clinical Focus: This set of values contains a medication with various dosages, that is commonly used for weight reduction.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Above Normal Medications
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObjectTypeCode constrained to codes in the ACE Inhibitor or ARB valueset (2.16.840.1.113883.3.526.3.1139).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the ACE Inhibitor or ARB
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the ACE Inhibitor or ARB Ingredient valueset (2.16.840.1.113883.3.526.3.1489)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the ACE Inhibitor or ARB
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Acetaminophen / Butalbital valueset (2.16.840.1.113883.3.464.1003.196.12.1317).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Acetaminophen / Butalbital / Caffeine valueset (2.16.840.1.113883.3.464.1003.196.12.1363).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Acetaminophen / Butalbital / Caffeine / Codeine valueset (2.16.840.1.113883.3.464.1003.196.12.1326).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Acetaminophen / Butalbital / Caffeine / Codeine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Acetaminophen / Butalbital / Caffeine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Acetaminophen / Butalbital
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Acetaminophen / Chlorpheniramine / Dextromethorphan valueset (2.16.840.1.113883.3.464.1003.196.12.1421).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Acetaminophen / Chlorpheniramine / Dextromethorphan
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Acetaminophen / Chlorpheniramine / Dextromethorphan / Phenylephrine valueset (2.16.840.1.113883.3.464.1003.196.12.1310).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Acetaminophen / Chlorpheniramine / Dextromethorphan / Phenylephrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Acetaminophen / Chlorpheniramine / Dextromethorphan / Pseudoephedrine valueset (2.16.840.1.113883.3.464.1003.196.12.1321).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Acetaminophen / Chlorpheniramine / Dextromethorphan / Pseudoephedrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Acetaminophen / Chlorpheniramine / Phenylephrine valueset (2.16.840.1.113883.3.464.1003.196.12.1328).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Acetaminophen / Chlorpheniramine / Phenylephrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Acetaminophen / Chlorpheniramine / Pseudoephedrine valueset (2.16.840.1.113883.3.464.1003.196.12.1316).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Acetaminophen / Chlorpheniramine / Pseudoephedrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Acetaminophen / Dexbrompheniramine valueset (2.16.840.1.113883.3.464.1003.196.12.1405).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Acetaminophen / Dexbrompheniramine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Acetaminophen / Dextromethorphan / Diphenhydramine / Phenylephrine valueset (2.16.840.1.113883.3.464.1003.196.12.1399).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Acetaminophen / Dextromethorphan / Diphenhydramine / Phenylephrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Acetaminophen / Dextromethorphan / Doxylamine valueset (2.16.840.1.113883.3.464.1003.196.12.1338).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Acetaminophen / Dextromethorphan / Doxylamine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Acetaminophen / Dextromethorphan / Doxylamine / Phenylephrine valueset (2.16.840.1.113883.3.464.1003.196.12.1287).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Acetaminophen / Dextromethorphan / Doxylamine / Phenylephrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Acetaminophen / Diphenhydramine valueset (2.16.840.1.113883.3.464.1003.196.12.1350).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Acetaminophen / Diphenhydramine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Acetaminophen / Diphenhydramine / Phenylephrine valueset (2.16.840.1.113883.3.464.1003.196.12.1318).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Acetaminophen / Diphenhydramine / Phenylephrine
(Clinical Focus: This set of values contains procedures used to represent patients who receives emergency medical system education.),(Data Element Scope: The intent of this data element is to identify patients who receive education on the activation of emergency medical system. Using the Quality Data Model, this particular element will map to the 'Communication' category.),(Inclusion Criteria: Only SNOMED CT codes representing emergency medical system education should be included.),(Exclusion Criteria: None) -- ObservableCode constrained to codes in the Activation of Emergency Medical System Education valueset (2.16.840.1.113883.3.117.1.7.1.377)
When the order indicates the first immunization administration should occur. Active dateTime is most often used to specify immunizations for which administration is intended at a specific time in the future. If Active dateTime is not specified, it defaults to the Author (signed) dateTime.
-- ObservableCode constrained to codes in the Activities of daily living score [HOOS] valueset (drc-d3a1c3c2991cb637ba39a39544acd32d472260d8a6be6baa895ba5b30b06da25).
-- Subject constrained to the Activities of daily living score [HOOS]
A statement that asserts an action relating to the subject. The subject is often the patient, but may….
A code describing the aspect or property of the subject being observed or measured. The ObservableCode is the 'question code' that pairs to the 'answer' contained in the ResultValue.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Acute and Subacute Iridocyclitis valueset (2.16.840.1.113883.3.526.3.1241)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Acute Myocardial Infarction valueset (2.16.840.1.113883.3.464.1003.104.12.1001)
(Clinical Focus: This grouping value set contains diagnoses used to identify patients with an acute or evolving myocardial infarction.),(Data Element Scope: The intent of this data element is to identify patients with an acute or evolving myocardial infarction. Using the Quality Data Model, this particular element would map to the Result attribute.),(Inclusion Criteria: Include codes that identify patients with an acute myocardial infarction. This is a grouping of ICD10CM and SNOMEDCT codes.),(Exclusion Criteria: None.)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Acute Pharyngitis valueset (2.16.840.1.113883.3.464.1003.102.12.1011)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Acute Tonsillitis valueset (2.16.840.1.113883.3.464.1003.102.12.1012)
(Clinical Focus: This set of values captures an intervention or actual procedure where an adolescent depression screen was completed or depression was evaluated by a health care professional within this age group.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Additional evaluation for depression - adolescent valueset (2.16.840.1.113883.3.600.1542).
(Clinical Focus: This set of values captures an intervention or actual procedure where an adolescent depression screen was completed or depression was evaluated by a health care professional within this age group.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Additional evaluation for depression - adolescent
(Clinical Focus: This set of values captures an intervention or actual procedure where an adult depression screen was completed or depression was evaluated by a health care professional within this age group.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Additional evaluation for depression - adult valueset (2.16.840.1.113883.3.600.1545).
(Clinical Focus: This set of values captures an intervention or actual procedure where an adult depression screen was completed or depression was evaluated by a health care professional within this age group.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Additional evaluation for depression - adult
An address expressed using postal conventions (as opposed to GPS or other location definition formats). This data type may be used to convey addresses for use in delivering mail as well as for visiting locations and which might not be valid for mail delivery. There are a variety of postal address formats defined around the world. (Source: HL7 FHIR).
Part of an address that contains the house number, apartment number, street name, street direction, P.O. Box number, delivery hints, and similar address information. (Source: HL7 FHIR).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the ADHD Medications valueset (2.16.840.1.113883.3.464.1003.196.12.1171).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the ADHD Medications
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the ADHD Medications
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Adhesions and Disruptions of Iris and Ciliary Body valueset (2.16.840.1.113883.3.526.3.1405)
Administrative gender as defined in FHIR
The location from which the patient was admitted (e.g., physician referral, facility from which the patient was transferred).
-- ObservableCode constrained to codes in the Adolescent depression screening assessment valueset (drc-fec6b5f1ff0f36c2e1c6be90526b2d05b731d9a14790b7f6edbc5c530289c823).
-- Subject constrained to the Adolescent depression screening assessment
-- ObservableCode constrained to codes in the Adult depression screening assessment valueset (drc-314b12a3535a78752f5a6a7ed3301608579e3caf3cf723284d20594a01b0011b).
-- Subject constrained to the Adult depression screening assessment
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Adult Outpatient Visit valueset (2.16.840.1.113883.3.464.1003.101.12.1065).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Adult Outpatient Visit
Adverse Event is used to define any untoward medical occurrence associated with the clinical care delivery, whether or not considered drug related.
How long someone has been alive, or something has existed.
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Alcohol and Drug Dependence valueset (2.16.840.1.113883.3.464.1003.106.12.1001)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Alcohol and Drug Dependence Treatment valueset (2.16.840.1.113883.3.464.1003.106.12.1005).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Alcohol and Drug Dependence Treatment
Allergy is used to address immune-mediated reactions to a substance such as type 1 hypersensitivity reactions, other allergy-like reactions, including pseudo-allergy. Intolerance is a record of a clinical assessment of a propensity, or a potential risk to an individual, to have a non-immune mediated adverse reaction on future exposure to the specified substance, or class of substance.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Allergy to ACE Inhibitor or ARB valueset (2.16.840.1.113883.3.526.3.1211)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Allergy to Beta Blocker Therapy valueset (2.16.840.1.113883.3.526.3.1177)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Allergy to Eggs valueset (2.16.840.1.113883.3.526.3.1253)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Allergy to Influenza Vaccine valueset (2.16.840.1.113883.3.526.3.1256)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Amblyopia valueset (2.16.840.1.113883.3.526.3.1448)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Ambulatory/ED Visit valueset (2.16.840.1.113883.3.464.1003.101.12.1061).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Ambulatory/ED Visit
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: )
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Ambulatory Status valueset (2.16.840.1.113883.3.464.1003.118.11.1219).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Ambulatory Status
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Amitriptyline / Chlordiazepoxide valueset (2.16.840.1.113883.3.464.1003.196.12.1286).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Amitriptyline / Chlordiazepoxide
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Amitriptyline Hydrochloride valueset (2.16.840.1.113883.3.464.1003.196.12.1373).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Amitriptyline Hydrochloride
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Amitriptyline / Perphenazine valueset (2.16.840.1.113883.3.464.1003.196.12.1428).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Amitriptyline / Perphenazine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Amoxapine valueset (2.16.840.1.113883.3.464.1003.196.12.1273).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Amoxapine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Anaphylactic Reaction to Common Baker's Yeast valueset (2.16.840.1.113883.3.464.1003.199.12.1032)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Anaphylactic Reaction to DTaP Vaccine valueset (2.16.840.1.113883.3.464.1003.199.12.1031)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Anaphylactic Reaction to Hepatitis A Vaccine valueset (2.16.840.1.113883.3.464.1003.199.12.1026)
-- ResultValue constrained to codes in the Anaphylaxis due to Haemophilus influenzae type b vaccine (disorder) valueset (drc-b41ab1424e0ae3530a3994371ce756dd057208ea91c2718500a0e0ae61be5d04)
-- ResultValue constrained to codes in the Anaphylaxis due to Hepatitis B vaccine (disorder) valueset (drc-6f0c918ce56bb7d3b6754dcd76c5a278811761fb92069dc23f648e7ae120deb4)
-- ResultValue constrained to codes in the Anaphylaxis due to rotavirus vaccine (disorder) valueset (drc-1dab6ca050d2860f753c6859a09cf2dbadca63aef96f10f912101205be31f62a)
The anatomical site or structure where the diagnosis/problem manifests itself (a). The anatomical site or structure where that is the focus of the action represented by the datatype (b).
An observation of the location of something on or in the body of the subject, including tissues, regions, cavities, and spaces; for example, right elbow, or left ventricle of the heart. May involve a measurement
The anatomical site or structure where the diagnosis/problem manifests itself (a). The anatomical site or structure where that is the focus of the action represented by the datatype (b).
(Clinical Focus: Androgen deprivation therapy as identified for UrologyCare),(Data Element Scope: This data element is to list androgen deprivation therapy for urology care for prostate cancer.),(Inclusion Criteria: Androgen deprivation therapy medications),(Exclusion Criteria: Medications that are not androgen deprivation therapy) -- ObjectTypeCode constrained to codes in the Androgen deprivation therapy for Urology Care valueset (2.16.840.1.113762.1.4.1151.48).
(Clinical Focus: Androgen deprivation therapy as identified for UrologyCare),(Data Element Scope: This data element is to list androgen deprivation therapy for urology care for prostate cancer.),(Inclusion Criteria: Androgen deprivation therapy medications),(Exclusion Criteria: Medications that are not androgen deprivation therapy) -- Subject constrained to the Androgen deprivation therapy for Urology Care
(Clinical Focus: This set of values contains codes that identify patients with a diagnosis of ankylosing spondylitis.),(Data Element Scope: This value set is developed for the diagnosis QDM datatype. It can potentially be used for other datatypes as well.),(Inclusion Criteria: Include all diagnosis codes associated with ankylosing spondylitis with comorbidities and associated system involvement.),(Exclusion Criteria: Exclude all diagnosis codes associated with juvenile ankylosing spondylitis.) -- ResultValue constrained to codes in the Ankylosing Spondylitis valueset (2.16.840.1.113883.3.464.1003.113.12.1045)
(Clinical Focus: This value set contains concepts related to annual wellness visits.),(Data Element Scope: The intent of this data element is to identify patients who have had an annual wellness visit. Using the Quality Data Model, this particular data element would be classified under the 'Encounter' category.),(Inclusion Criteria: Includes encounters specific to annual wellness visits.),(Exclusion Criteria: None) -- ActivityCode constrained to codes in the Annual Wellness Visit valueset (2.16.840.1.113883.3.526.2.1363).
(Clinical Focus: This value set contains concepts related to annual wellness visits.),(Data Element Scope: The intent of this data element is to identify patients who have had an annual wellness visit. Using the Quality Data Model, this particular data element would be classified under the 'Encounter' category.),(Inclusion Criteria: Includes encounters specific to annual wellness visits.),(Exclusion Criteria: None) -- ActivityCode constrained to codes in the Annual Wellness Visit1 valueset (2.16.840.1.113883.3.526.3.1240).
(Clinical Focus: This value set contains concepts related to annual wellness visits.),(Data Element Scope: The intent of this data element is to identify patients who have had an annual wellness visit. Using the Quality Data Model, this particular data element would be classified under the 'Encounter' category.),(Inclusion Criteria: Includes encounters specific to annual wellness visits.),(Exclusion Criteria: None) -- Subject constrained to the Annual Wellness Visit1
(Clinical Focus: This value set contains concepts related to annual wellness visits.),(Data Element Scope: The intent of this data element is to identify patients who have had an annual wellness visit. Using the Quality Data Model, this particular data element would be classified under the 'Encounter' category.),(Inclusion Criteria: Includes encounters specific to annual wellness visits.),(Exclusion Criteria: None) -- Subject constrained to the Annual Wellness Visit
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Anomalies of Pupillary Function valueset (2.16.840.1.113883.3.526.3.1406)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Antibiotic Medications for Pharyngitis valueset (2.16.840.1.113883.3.464.1003.196.12.1001).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Antibiotic Medications for Pharyngitis
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Antibiotic Medications for Pharyngitis
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObjectTypeCode constrained to codes in the Anticoagulant Medications valueset (2.16.840.1.113883.3.464.1003.196.12.1283).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Anticoagulant Medications
(Clinical Focus: This set of values contains medications that are prescribed for anticoagulant therapy at hospital discharge for patients following acute ischemic stroke.),(Data Element Scope: The intent of this data element is to identify patients who are prescribed anticoagulant therapy at discharge following acute ischemic stroke. Using the Quality Data Model, this particular element would map to the Medication category.),(Inclusion Criteria: Include oral and injectable drug forms. Include Warfarin, heparins and direct thrombin inhibitors.),(Exclusion Criteria: Exclude enoxaparin and heparin codes generally given for VTE prophylaxis.) -- ObjectTypeCode constrained to codes in the Anticoagulant Therapy valueset (2.16.840.1.113883.3.117.1.7.1.200).
(Clinical Focus: This set of values contains medications that are prescribed for anticoagulant therapy at hospital discharge for patients following acute ischemic stroke.),(Data Element Scope: The intent of this data element is to identify patients who are prescribed anticoagulant therapy at discharge following acute ischemic stroke. Using the Quality Data Model, this particular element would map to the Medication category.),(Inclusion Criteria: Include oral and injectable drug forms. Include Warfarin, heparins and direct thrombin inhibitors.),(Exclusion Criteria: Exclude enoxaparin and heparin codes generally given for VTE prophylaxis.) -- Subject constrained to the Anticoagulant Therapy
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Antidepressant Medication valueset (2.16.840.1.113883.3.464.1003.196.12.1213).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Antidepressant Medication
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Antidepressant Medication
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Anti Hepatitis A IgG Antigen Test valueset (2.16.840.1.113883.3.464.1003.198.12.1033).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Anti Hepatitis A IgG Antigen Test
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Anti Hepatitis B Virus Surface Ab valueset (2.16.840.1.113883.3.464.1003.198.12.1073).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Anti Hepatitis B Virus Surface Ab
(Clinical Focus: This value set contains medications that are commonly used to reduce blood pressure in patients that have a diagnosis of hypertension.),(Data Element Scope: ),(Inclusion Criteria: Included are medications and dosages commonly prescribed for the treatment of hypertension.),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Anti-Hypertensive Pharmacologic Therapy valueset (2.16.840.1.113883.3.600.1476).
(Clinical Focus: This value set contains medications that are commonly used to reduce blood pressure in patients that have a diagnosis of hypertension.),(Data Element Scope: ),(Inclusion Criteria: Included are medications and dosages commonly prescribed for the treatment of hypertension.),(Exclusion Criteria: ) -- Subject constrained to the Anti-Hypertensive Pharmacologic Therapy
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Anti Infectives, other valueset (2.16.840.1.113883.3.464.1003.196.12.1481).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Anti Infectives, other
(Clinical Focus: This set of values contains anticoagulant and antiplatelet drugs used to reduce stroke mortality and morbidity.),(Data Element Scope: The intent of this data element is to identify patients who receive antithombotic therapy following stroke. Using the Quality Data Model, this particular element would map to the Medication category.),(Inclusion Criteria: Include single and multi-ingredient drugs. Oral, rectal, and injectable dose forms should be included. Antithrombotic medications include anticoagulants and antiplatelet drugs.),(Exclusion Criteria: Exclude enoxaparin and heparin codes generally given for VTE prophylaxis.) -- ObjectTypeCode constrained to codes in the Antithrombotic Therapy valueset (2.16.840.1.113883.3.117.1.7.1.201).
(Clinical Focus: This set of values contains anticoagulant and antiplatelet drugs used to reduce stroke mortality and morbidity.),(Data Element Scope: The intent of this data element is to identify patients who receive antithombotic therapy following stroke. Using the Quality Data Model, this particular element would map to the Medication category.),(Inclusion Criteria: Include single and multi-ingredient drugs. Oral, rectal, and injectable dose forms should be included. Antithrombotic medications include anticoagulants and antiplatelet drugs.),(Exclusion Criteria: Exclude enoxaparin and heparin codes generally given for VTE prophylaxis.) -- Subject constrained to the Antithrombotic Therapy
(Clinical Focus: This set of values contains anticoagulant and antiplatelet drugs used to reduce stroke mortality and morbidity.),(Data Element Scope: The intent of this data element is to identify patients who receive antithombotic therapy following stroke. Using the Quality Data Model, this particular element would map to the Medication category.),(Inclusion Criteria: Include single and multi-ingredient drugs. Oral, rectal, and injectable dose forms should be included. Antithrombotic medications include anticoagulants and antiplatelet drugs.),(Exclusion Criteria: Exclude enoxaparin and heparin codes generally given for VTE prophylaxis.) -- Subject constrained to the Antithrombotic Therapy
(Clinical Focus: This set of values contains anticoagulant and antiplatelet drugs used to reduce stroke mortality and morbidity.),(Data Element Scope: The intent of this data element is to identify patients who receive antithombotic therapy following stroke. Using the Quality Data Model, this particular element would map to the Medication category.),(Inclusion Criteria: Include single and multi-ingredient drugs. Oral, rectal, and injectable dose forms should be included. Antithrombotic medications include anticoagulants and antiplatelet drugs.),(Exclusion Criteria: Exclude enoxaparin and heparin codes generally given for VTE prophylaxis.) -- Subject constrained to the Antithrombotic Therapy
(Clinical Focus: This set of values contains procedures used to identify aortic balloon pump insertion.),(Data Element Scope: The intent of this data element is to identify patients with the procedure aortic balloon pump insertion. Using the Quality Data Model, this particular element would map to the Procedure, Performed data type.),(Inclusion Criteria: Include codes that describe insertion of the aortic balloon pump.),(Exclusion Criteria: Exclude codes that describe complications and procedures removing the device.) -- ObservableCode constrained to codes in the Aortic balloon pump insertion valueset (2.16.840.1.113883.3.666.5.1151).
(Clinical Focus: This set of values contains procedures used to identify aortic balloon pump insertion.),(Data Element Scope: The intent of this data element is to identify patients with the procedure aortic balloon pump insertion. Using the Quality Data Model, this particular element would map to the Procedure, Performed data type.),(Inclusion Criteria: Include codes that describe insertion of the aortic balloon pump.),(Exclusion Criteria: Exclude codes that describe complications and procedures removing the device.) -- Subject constrained to the Aortic balloon pump insertion
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Aphakia and Other Disorders of Lens valueset (2.16.840.1.113883.3.526.3.1407)
(Clinical Focus: This value set identifies patients who were prescribed a aromatase inhibitor.),(Data Element Scope: This value set was intended to map to the QDM data type of Medication, but has the potential to be used in additional ways.),(Inclusion Criteria: Includes both steroidal and non-steroidal inhibitors. Includes non-selective and selective inhibitors.),(Exclusion Criteria: Excludes selective inhibitors vorozole, formestane, and fadrozole.) -- ObjectTypeCode constrained to codes in the Aromatase Inhibitors valueset (2.16.840.1.113883.3.464.1003.196.12.1265).
(Clinical Focus: This value set identifies patients who were prescribed a aromatase inhibitor.),(Data Element Scope: This value set was intended to map to the QDM data type of Medication, but has the potential to be used in additional ways.),(Inclusion Criteria: Includes both steroidal and non-steroidal inhibitors. Includes non-selective and selective inhibitors.),(Exclusion Criteria: Excludes selective inhibitors vorozole, formestane, and fadrozole.) -- Subject constrained to the Aromatase Inhibitors
(Clinical Focus: This value set identifies patients who were prescribed a aromatase inhibitor.),(Data Element Scope: This value set was intended to map to the QDM data type of Medication, but has the potential to be used in additional ways.),(Inclusion Criteria: Includes both steroidal and non-steroidal inhibitors. Includes non-selective and selective inhibitors.),(Exclusion Criteria: Excludes selective inhibitors vorozole, formestane, and fadrozole.) -- Subject constrained to the Aromatase Inhibitors
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Arrhythmia valueset (2.16.840.1.113883.3.526.3.366)
(Clinical Focus: This set of values contains procedures that represent the artificial rupture of membranes.),(Data Element Scope: The intent of this data element is to identify artificial rupture of membranes as a mechanism to induce labor. Using the Quality Data Model, this particular element will map to the 'procedure' category.),(Inclusion Criteria: Include SNOMED CT codes that identify artificial rupture of membranes.),(Exclusion Criteria: None) -- ObservableCode constrained to codes in the Artificial Rupture of Membranes valueset (2.16.840.1.113762.1.4.1045.57).
(Clinical Focus: This set of values contains procedures that represent the artificial rupture of membranes.),(Data Element Scope: The intent of this data element is to identify artificial rupture of membranes as a mechanism to induce labor. Using the Quality Data Model, this particular element will map to the 'procedure' category.),(Inclusion Criteria: Include SNOMED CT codes that identify artificial rupture of membranes.),(Exclusion Criteria: None) -- Subject constrained to the Artificial Rupture of Membranes
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Aspiration and Injection Procedures valueset (2.16.840.1.113883.3.526.3.1408).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Aspiration and Injection Procedures
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObjectTypeCode constrained to codes in the Aspirin and Other Antiplatelets valueset (2.16.840.1.113883.3.464.1003.196.12.1211).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Aspirin and Other Antiplatelets
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Aspirin / Butalbital / Caffeine valueset (2.16.840.1.113883.3.464.1003.196.12.1347).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Aspirin / Butalbital / Caffeine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Aspirin / Caffeine / Orphenadrine valueset (2.16.840.1.113883.3.464.1003.196.12.1302).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Aspirin / Caffeine / Orphenadrine
Assessment is a resource used to define specific observations that clinicians use to guide treatment of the patient. An assessment can be a single question, or observable entity with an expected response, an organized collection of questions intended to solicit information from patients, providers or other individuals, or a single observable entity that is part of such a collection of questions.
Data elements that meet criteria using this datatype should document completion of the assessment indicated by the QDM category and its corresponding value set. Timing: The time the assessment is completed; Author dateTime.
(Clinical Focus: This grouping value set contains codes indicative of a diagnosis of asthma.),(Data Element Scope: The intent of this data element is to identify patients who have a diagnosis of asthma. Using the Quality Data Model, this particular element will map to the Diagnosis attribute for the Encounter category.),(Inclusion Criteria: Include codes representing any form of asthma. This is a grouping of ICD-9-CM, ICD-10-CM and SNOMED-CT codes.),(Exclusion Criteria: None)
-- ObservableCode constrained to codes in the Asthma action plan valueset (drc-0b4e501256dea10e614683faecb602ae078e6d7aec8d85908d2c4fcce0613359)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Asthma valueset (2.16.840.1.113883.3.526.3.362)
(Clinical Focus: This set of values is intended to capture that a patient has a diagnosis, condition, or disorder of Atherosclerosis or Peripheral Arterial Disease (PAD).),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by diagnosis codes.),(Inclusion Criteria: Conditions that indicate arterial blood flow is restricted putting patients at higher risk for heart disease are included.),(Exclusion Criteria: Other vascular conditions that are not diagnosed as part of Atherosclerosis and Peripheral Artery Disease are excluded.) -- ResultValue constrained to codes in the Atherosclerosis and Peripheral Arterial Disease valueset (2.16.840.1.113762.1.4.1047.21)
(Clinical Focus: This grouping value set represents atrial ablation procedures.),(Data Element Scope: The intent of this data element is to identify patients with a history of atrial ablation procedure. Using the Quality Data Model, this particular element would map to the Procedure category.),(Inclusion Criteria: Include codes that identify patients with a history of atrial ablation procedure. This is a grouping of ICD10CM and SNOMEDCT codes.),(Exclusion Criteria: Exclude codes that do not meet the inclusion criteria.) -- ObservableCode constrained to codes in the Atrial Ablation valueset (2.16.840.1.113883.3.117.1.7.1.203).
(Clinical Focus: This grouping value set represents atrial ablation procedures.),(Data Element Scope: The intent of this data element is to identify patients with a history of atrial ablation procedure. Using the Quality Data Model, this particular element would map to the Procedure category.),(Inclusion Criteria: Include codes that identify patients with a history of atrial ablation procedure. This is a grouping of ICD10CM and SNOMEDCT codes.),(Exclusion Criteria: Exclude codes that do not meet the inclusion criteria.) -- Subject constrained to the Atrial Ablation
(Clinical Focus: This grouping value set contains diagnoses used to identify patients with a history of atrial fibrillation/flutter or a current finding of atrial fibrillation/flutter.),(Data Element Scope: The intent of this data element is to identify patients with a diagnosis of atrial fibrillation or flutter. Using the Quality Data Model, this particular element would map to the Diagnosis category or the Diagnosis attribute for the Encounter category.),(Inclusion Criteria: Include codes that identify patients with a history of atrial fibrillation/flutter or a current finding of atrial fibrillation/flutter. This is a grouping of ICD10CM, ICD9CM and SNOMEDCT codes.),(Exclusion Criteria: None.)
(Clinical Focus: This grouping value set contains diagnoses used to identify patients with a history of atrial fibrillation/flutter or a current finding of atrial fibrillation/flutter.),(Data Element Scope: The intent of this data element is to identify patients with a diagnosis of atrial fibrillation or flutter. Using the Quality Data Model, this particular element would map to the Diagnosis category or the Diagnosis attribute for the Encounter category.),(Inclusion Criteria: Include codes that identify patients with a history of atrial fibrillation/flutter or a current finding of atrial fibrillation/flutter. This is a grouping of ICD10CM, ICD9CM and SNOMEDCT codes.),(Exclusion Criteria: None.) -- ResultValue constrained to codes in the Atrial Fibrillation/Flutter valueset (2.16.840.1.113883.3.117.1.7.1.202)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Atrioventricular Block valueset (2.16.840.1.113883.3.526.3.367)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Atropine / Diphenoxylate valueset (2.16.840.1.113883.3.464.1003.196.12.1274).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Atropine / Diphenoxylate
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Atropine / Hyoscyamine / Phenobarbital / Scopolamine valueset (2.16.840.1.113883.3.464.1003.196.12.1355).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Atropine / Hyoscyamine / Phenobarbital / Scopolamine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Audiology Visit valueset (2.16.840.1.113883.3.464.1003.101.12.1066).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Audiology Visit
The time the data element was entered into the clinical software. Note, some datatypes include both Relevant Time and Author dateTime attributes. The purpose is to accommodate Author dateTime if the actual start and stop times are not available when evaluating for feasibility, and also to allow specification of a time for Negation Rationale.
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Average Number of Drinks per Drinking Day valueset (2.16.840.1.113883.3.464.1003.106.12.1018).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Average Number of Drinks per Drinking Day
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Behavioral Health Follow-up Visit valueset (2.16.840.1.113883.3.464.1003.101.12.1054).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Behavioral Health Follow-up Visit
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Behavioral/Neuropsych Assessment valueset (2.16.840.1.113883.3.526.3.1023).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Behavioral/Neuropsych Assessment
(Clinical Focus: The purpose of this value set is that the provider documents a follow-up plan for those with a below normal BMI that indicates a patient is underweight.),(Data Element Scope: ),(Inclusion Criteria: This value set includes lifestyle modification, dietary and nutritional education, or interventions as documented in the medical record by a provider as a follow-up plan to increase BMI or support weight gain.),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Below Normal Follow up valueset (2.16.840.1.113883.3.600.1.1528).
(Clinical Focus: The purpose of this value set is that the provider documents a follow-up plan for those with a below normal BMI that indicates a patient is underweight.),(Data Element Scope: ),(Inclusion Criteria: This value set includes lifestyle modification, dietary and nutritional education, or interventions as documented in the medical record by a provider as a follow-up plan to increase BMI or support weight gain.),(Exclusion Criteria: ) -- Subject constrained to the Below Normal Follow up
(Clinical Focus: This set of values contains a medication with various dosages, that is commonly used for weight gain.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Below Normal Medications valueset (2.16.840.1.113883.3.600.1.1499).
(Clinical Focus: This set of values contains a medication with various dosages, that is commonly used for weight gain.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Below Normal Medications
The person, place, event, condition, other statement that derives advantage from something/
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Benztropine valueset (2.16.840.1.113883.3.464.1003.196.12.1361).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Benztropine
-- ObservableCode constrained to codes in the Best corrected visual acuity (observable entity) valueset (drc-c165b007cbd4a8cf3bf4068e36fa9ff12f59281f8e23276d271c64dc8da701c9).
-- Subject constrained to the Best corrected visual acuity (observable entity)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObjectTypeCode constrained to codes in the Beta Blocker Therapy valueset (2.16.840.1.113883.3.526.3.1174).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Beta Blocker Therapy
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObjectTypeCode constrained to codes in the Beta Blocker Therapy for LVSD valueset (2.16.840.1.113883.3.526.3.1184).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Beta Blocker Therapy for LVSD
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Beta Blocker Therapy for LVSD
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Beta Blocker Therapy Ingredient valueset (2.16.840.1.113883.3.526.3.1493)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Beta Blocker Therapy
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- ObjectTypeCode constrained to codes in the BH Antidepressant Medication valueset (2.16.840.1.113883.3.1257.1.972).
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- Subject constrained to the BH Antidepressant Medication
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- Subject constrained to the BH Antidepressant Medication
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- ObservableCode constrained to codes in the BH Assessment for Alcohol or Other Drugs valueset (2.16.840.1.113883.3.1257.1.1604).
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- Subject constrained to the BH Assessment for Alcohol or Other Drugs
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- ResultValue constrained to codes in the BH Condition Involving Bipolar Disorder valueset (2.16.840.1.113883.3.1257.1.1504)
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- ResultValue constrained to codes in the BH Condition Involving Unipolar Depression valueset (2.16.840.1.113883.3.1257.1.1505)
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- ObservableCode constrained to codes in the BH Counseling for Depression valueset (2.16.840.1.113883.3.1257.1.1616).
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- Subject constrained to the BH Counseling for Depression
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- Subject constrained to the BH Counseling for Depression
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- ObservableCode constrained to codes in the BH Electroconvulsive Therapy valueset (2.16.840.1.113883.3.1257.1.1533).
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- Subject constrained to the BH Electroconvulsive Therapy
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- Subject constrained to the BH Electroconvulsive Therapy
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- ObjectTypeCode constrained to codes in the BH Mood Stabilizer Medication valueset (2.16.840.1.113883.3.1257.1.950).
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- Subject constrained to the BH Mood Stabilizer Medication
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- Subject constrained to the BH Mood Stabilizer Medication
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the BH Outpatient encounter valueset (2.16.840.1.113883.3.464.1.49).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the BH Outpatient encounter
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- ActivityCode constrained to codes in the BH Outpatient Psychotherapy valueset (2.16.840.1.113883.3.1257.1.973).
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- Subject constrained to the BH Outpatient Psychotherapy
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Bilateral amputation of leg below or above knee valueset (2.16.840.1.113883.3.464.1003.113.12.1056)
(Clinical Focus: This value set contains codes to identify a bilateral mastectomy.),(Data Element Scope: This value set was intended to identify patients who had a bilateral mastectomy.),(Inclusion Criteria: Includes codes that indicate a bilateral mastectomy.),(Exclusion Criteria: Excludes codes that indicate a unilateral mastectomy or are unspecified.) -- ObservableCode constrained to codes in the Bilateral Mastectomy valueset (2.16.840.1.113883.3.464.1003.198.12.1005).
(Clinical Focus: This value set contains codes to identify a bilateral mastectomy.),(Data Element Scope: This value set was intended to identify patients who had a bilateral mastectomy.),(Inclusion Criteria: Includes codes that indicate a bilateral mastectomy.),(Exclusion Criteria: Excludes codes that indicate a unilateral mastectomy or are unspecified.) -- Subject constrained to the Bilateral Mastectomy
The data itself.
(Clinical Focus: This set of values includes various diagnoses of Bipolar disorder that could be documented in the medical record by a health care provider.),(Data Element Scope: ),(Inclusion Criteria: Includes mild to severe cases, brief episodes, or chronic disorders, which would indicate that there is a current diagnosis of bipolar disorder documented by the healthcare provider.),(Exclusion Criteria: Excludes all other depression diagnoses that do not relate to a bipolar diagnosis.) -- ResultValue constrained to codes in the Bipolar Diagnosis valueset (2.16.840.1.113883.3.600.450)
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- ResultValue constrained to codes in the Bipolar Disorder valueset (2.16.840.1.113883.3.67.1.101.1.128)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Blood Pressure Visit valueset (2.16.840.1.113883.3.464.1003.101.12.1056).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Blood Pressure Visit
(Clinical Focus: This value set is intended to capture any encounter where BMI could be documented encompassing various examinations or assessments where BMI could be collected and documented by a health care provider.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the BMI Encounter Code Set valueset (2.16.840.1.113883.3.600.1.1751).
(Clinical Focus: This value set is intended to capture any encounter where BMI could be documented encompassing various examinations or assessments where BMI could be collected and documented by a health care provider.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the BMI Encounter Code Set
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the BMI percentile valueset (2.16.840.1.113883.3.464.1003.121.12.1012).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the BMI percentile
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the BMI Ratio valueset (2.16.840.1.113883.3.600.1.1490).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the BMI Ratio
-- ObservableCode constrained to codes in the Body mass index (BMI) [Ratio] valueset (drc-b1db35b04284126f3ab8045b4488e5d0a498b5c000798b42a8df87340bd99e88).
-- Subject constrained to the Body mass index (BMI) [Ratio]
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Bone Scan valueset (2.16.840.1.113883.3.526.3.320).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Bone Scan
(Clinical Focus: This set of values contains encounters where a blood pressure could be performed and documented.),(Data Element Scope: ),(Inclusion Criteria: Includes examinations, assessments, evaluations, or procedure encounters where the actual procedure of taking a blood pressure is performed.),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the BP Screening Encounter Codes valueset (2.16.840.1.113883.3.600.1920).
(Clinical Focus: This set of values contains encounters where a blood pressure could be performed and documented.),(Data Element Scope: ),(Inclusion Criteria: Includes examinations, assessments, evaluations, or procedure encounters where the actual procedure of taking a blood pressure is performed.),(Exclusion Criteria: ) -- Subject constrained to the BP Screening Encounter Codes
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Bradycardia valueset (2.16.840.1.113883.3.526.3.412)
(Clinical Focus: The intent of this value set is to capture that a patient is planning to or actively breastfeeding.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by diagnosis codes.),(Inclusion Criteria: Included are codes to indicate lactation and the actual finding or intention of breastfeeding or nursing.),(Exclusion Criteria: Excluded are codes that would not indicate the possibility of breastfeeding.) -- ResultValue constrained to codes in the Breastfeeding valueset (2.16.840.1.113762.1.4.1047.73)
(Clinical Focus: This set of values represent the concept of breast milk.),(Data Element Scope: The intent of this data element is to identify breast milk. Using the Quality Data Model, this particular element will map to the 'substance' category.),(Inclusion Criteria: Include SNOMED CT codes that identify breast milk.),(Exclusion Criteria: None) -- ObjectTypeCode constrained to codes in the Breast Milk valueset (2.16.840.1.113883.3.117.1.7.1.30).
(Clinical Focus: This set of values represent the concept of breast milk.),(Data Element Scope: The intent of this data element is to identify breast milk. Using the Quality Data Model, this particular element will map to the 'substance' category.),(Inclusion Criteria: Include SNOMED CT codes that identify breast milk.),(Exclusion Criteria: None) -- Subject constrained to the Breast Milk
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Brompheniramine valueset (2.16.840.1.113883.3.464.1003.196.12.1427).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Brompheniramine / Codeine / Phenylephrine valueset (2.16.840.1.113883.3.464.1003.196.12.1409).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Brompheniramine / Codeine / Phenylephrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Brompheniramine / Codeine / Pseudoephedrine valueset (2.16.840.1.113883.3.464.1003.196.12.1450).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Brompheniramine / Codeine / Pseudoephedrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Brompheniramine / Dextromethorphan / Phenylephrine valueset (2.16.840.1.113883.3.464.1003.196.12.1325).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Brompheniramine / Dextromethorphan / Phenylephrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Brompheniramine / Dextromethorphan / Pseudoephedrine valueset (2.16.840.1.113883.3.464.1003.196.12.1339).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Brompheniramine / Dextromethorphan / Pseudoephedrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Brompheniramine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Brompheniramine / Phenylephrine valueset (2.16.840.1.113883.3.464.1003.196.12.1327).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Brompheniramine / Phenylephrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Brompheniramine / Pseudoephedrine valueset (2.16.840.1.113883.3.464.1003.196.12.1332).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Brompheniramine / Pseudoephedrine
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Burn Confined to Eye and Adnexa valueset (2.16.840.1.113883.3.526.3.1409)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Butabarbital valueset (2.16.840.1.113883.3.464.1003.196.12.1402).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Butabarbital
(Clinical Focus: This grouping of value sets identifies patients who have a CABG surgical procedure.),(Data Element Scope: The intent of this data element is to identify patients who have a CABG surgical procedure. Using the Quality Data Model, this particular element will map to the Procedure category.),(Inclusion Criteria: Only use codes which represent CABG surgical procedures. Codes used are to be ICD10PCS, ICD9 or SNOMED-CT codes only.),(Exclusion Criteria: Exclude codes that represent a CABG performed using a scope.) -- ObservableCode constrained to codes in the CABG Surgeries valueset (2.16.840.1.113883.3.666.5.694).
(Clinical Focus: This grouping of value sets identifies patients who have a CABG surgical procedure.),(Data Element Scope: The intent of this data element is to identify patients who have a CABG surgical procedure. Using the Quality Data Model, this particular element will map to the Procedure category.),(Inclusion Criteria: Only use codes which represent CABG surgical procedures. Codes used are to be ICD10PCS, ICD9 or SNOMED-CT codes only.),(Exclusion Criteria: Exclude codes that represent a CABG performed using a scope.) -- Subject constrained to the CABG Surgeries
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Cancer valueset (2.16.840.1.113883.3.526.3.1010)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Cancer Staging valueset (2.16.840.1.113883.3.526.3.1536).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Cancer Staging
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Carbinoxamine valueset (2.16.840.1.113883.3.464.1003.196.12.1306).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Carbinoxamine
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObjectTypeCode constrained to codes in the Cardiac Pacer valueset (2.16.840.1.113883.3.526.3.1193).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Cardiac Pacer
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Cardiac Pacer in Situ valueset (2.16.840.1.113883.3.526.3.368)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Cardiac Surgery valueset (2.16.840.1.113883.3.526.3.371).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Cardiac Surgery
(Clinical Focus: This set of values contains the diagnosis used to identify patients with a cardiopulmonary arrest.),(Data Element Scope: The intent of this data element is to identify patients with a diagnosis of cardiopulmonary arrest. Using the Quality Data Model, this particular element would map to the Principal Diagnosis attribute for the Encounter category.),(Inclusion Criteria: Include diagnosis codes that identify cardiac arrest.),(Exclusion Criteria: Exclude codes that describe history of cardiac arrest.) -- ResultValue constrained to codes in the Cardiopulmonary arrest valueset (2.16.840.1.113883.3.666.5.748)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Care Services in Long-Term Residential Facility valueset (2.16.840.1.113883.3.464.1003.101.12.1014).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Care Services in Long-Term Residential Facility
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Carisoprodol valueset (2.16.840.1.113883.3.464.1003.196.12.1369).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Carisoprodol
(Clinical Focus: This set of values identifies patients who have undergone a carotid artery surgical procedure.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by procedure codes.),(Inclusion Criteria: Included are codes that represent carotid intervention surgical procedures.),(Exclusion Criteria: Excluded are codes that would not indicate a carotid intervention has been surgically performed.) -- ObservableCode constrained to codes in the Carotid Intervention valueset (2.16.840.1.113883.3.117.1.7.1.204).
(Clinical Focus: This set of values identifies patients who have undergone a carotid artery surgical procedure.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by procedure codes.),(Inclusion Criteria: Included are codes that represent carotid intervention surgical procedures.),(Exclusion Criteria: Excluded are codes that would not indicate a carotid intervention has been surgically performed.) -- Subject constrained to the Carotid Intervention
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Carrier of Predominantly Sexually Transmitted Infection valueset (2.16.840.1.113883.3.464.1003.112.11.1023)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Cataract, Congenital valueset (2.16.840.1.113883.3.526.3.1412)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Cataract, Mature or Hypermature valueset (2.16.840.1.113883.3.526.3.1413)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Cataract, Posterior Polar valueset (2.16.840.1.113883.3.526.3.1414)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Cataract Secondary to Ocular Disorders valueset (2.16.840.1.113883.3.526.3.1410)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Cataract Surgery valueset (2.16.840.1.113883.3.526.3.1411).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Cataract Surgery
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the CD4+ Count valueset (2.16.840.1.113883.3.464.1003.121.12.1004).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the CD4+ Count
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the CD4+ Percentage valueset (2.16.840.1.113883.3.464.1003.121.12.1005).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the CD4+ Percentage
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Central Corneal Ulcer valueset (2.16.840.1.113883.3.526.3.1428)
(Clinical Focus: This value set includes stroke and high risk diagnoses associated with stroke, including TIA and generalized ischemic cerebrovascular disease, which would indicate a patient has Atherosclerotic Cardiovascular Disease (ASCVD) in relation to a cerebrovascular event.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by diagnosis codes.),(Inclusion Criteria: Includes ASCVD diagnoses of cerebrovascular origin.),(Exclusion Criteria: Excludes any other ASCVD diagnoses not related to cerebrovascular disease, stroke, or TIA.) -- ResultValue constrained to codes in the Cerebrovascular disease, Stroke, TIA valueset (2.16.840.1.113762.1.4.1047.44)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Certain Types of Iridocyclitis valueset (2.16.840.1.113883.3.526.3.1415)
(Clinical Focus: This grouping of value sets contain procedures that represent a cesarean section.),(Data Element Scope: The intent of this data element is to identify cesarean section. Using the Quality Data Model, this particular element will map to the 'Procedure' category.),(Inclusion Criteria: Include ICD 9 CM, ICD 10 CM, and SNOMED CT codes that identify cesarean section.),(Exclusion Criteria: None) -- ObservableCode constrained to codes in the Cesarean Birth valueset (2.16.840.1.113883.3.117.1.7.1.282).
(Clinical Focus: This grouping of value sets contain procedures that represent a cesarean section.),(Data Element Scope: The intent of this data element is to identify cesarean section. Using the Quality Data Model, this particular element will map to the 'Procedure' category.),(Inclusion Criteria: Include ICD 9 CM, ICD 10 CM, and SNOMED CT codes that identify cesarean section.),(Exclusion Criteria: None) -- Subject constrained to the Cesarean Birth
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Chemotherapy Administration valueset (2.16.840.1.113883.3.526.3.1027).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Chemotherapy Administration
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Chlamydia valueset (2.16.840.1.113883.3.464.1003.112.12.1003)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Chlamydia Screening valueset (2.16.840.1.113883.3.464.1003.110.12.1052).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Chlamydia Screening
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Chlophedianol / Chlorpheniramine / Phenylephrine valueset (2.16.840.1.113883.3.464.1003.196.12.1412).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Chlophedianol / Chlorpheniramine / Phenylephrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Chlophedianol / Dexchlorpheniramine / Pseudoephedrine valueset (2.16.840.1.113883.3.464.1003.196.12.1447).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Chlophedianol / Dexchlorpheniramine / Pseudoephedrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Chlorpheniramine valueset (2.16.840.1.113883.3.464.1003.196.12.1352).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Chlorpheniramine / Codeine valueset (2.16.840.1.113883.3.464.1003.196.12.1301).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Chlorpheniramine / Codeine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Chlorpheniramine / Dextromethorphan / Phenylephrine valueset (2.16.840.1.113883.3.464.1003.196.12.1312).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Chlorpheniramine / Dextromethorphan / Phenylephrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Chlorpheniramine / Dextromethorphan / Pseudoephedrine valueset (2.16.840.1.113883.3.464.1003.196.12.1337).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Chlorpheniramine / Dextromethorphan / Pseudoephedrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Chlorpheniramine / Hydrocodone valueset (2.16.840.1.113883.3.464.1003.196.12.1330).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Chlorpheniramine / Hydrocodone
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Chlorpheniramine / Hydrocodone / Pseudoephedrine valueset (2.16.840.1.113883.3.464.1003.196.12.1299).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Chlorpheniramine / Hydrocodone / Pseudoephedrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Chlorpheniramine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Chlorpheniramine / Phenylephrine valueset (2.16.840.1.113883.3.464.1003.196.12.1343).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Chlorpheniramine / Phenylephrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Chlorpheniramine / Phenylephrine / Phenyltoloxamine valueset (2.16.840.1.113883.3.464.1003.196.12.1453).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Chlorpheniramine / Phenylephrine / Phenyltoloxamine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Chlorpheniramine / Phenylephrine / Pyrilamine valueset (2.16.840.1.113883.3.464.1003.196.12.1309).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Chlorpheniramine / Phenylephrine / Pyrilamine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Chlorpheniramine / Pseudoephedrine valueset (2.16.840.1.113883.3.464.1003.196.12.1315).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Chlorpheniramine / Pseudoephedrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Chlorpropamide valueset (2.16.840.1.113883.3.464.1003.196.12.1303).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Chlorpropamide
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Chlorzoxazone valueset (2.16.840.1.113883.3.464.1003.196.12.1362).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Chlorzoxazone
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Chorioretinal Scars valueset (2.16.840.1.113883.3.526.3.1449)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Choroidal Degenerations valueset (2.16.840.1.113883.3.526.3.1450)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Choroidal Detachment valueset (2.16.840.1.113883.3.526.3.1451)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Choroidal Hemorrhage and Rupture valueset (2.16.840.1.113883.3.526.3.1452)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Chronic Iridocyclitis valueset (2.16.840.1.113883.3.526.3.1416)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Chronic Kidney Disease, Stage 5 valueset (2.16.840.1.113883.3.526.3.1002)
(Clinical Focus: This set of values contains codes that identify patients with a diagnosis of chronic liver disease.),(Data Element Scope: This value set is developed for the diagnosis QDM datatype. It can potentially be used for other datatypes as well.),(Inclusion Criteria: Include all diagnosis codes associated with chronic liver disease that are not substance-induced.),(Exclusion Criteria: N/A) -- ResultValue constrained to codes in the Chronic Liver Disease valueset (2.16.840.1.113883.3.464.1003.199.12.1035)
(Clinical Focus: This set of values contains codes that identify patients with a diagnosis of chronic malnutrition.),(Data Element Scope: This value set is developed for the diagnosis QDM datatype. It can potentially be used for other datatypes as well.),(Inclusion Criteria: Include all diagnosis codes for specified and unspecified eating disorders.),(Exclusion Criteria: Exclude all diagnosis codes for feeding disorders of infancy or childhood. These include feeding disturbances, developmental delays, loss of appetite, & rumination. Also avoide restrictive food intake disorders, and pica.) -- ResultValue constrained to codes in the Chronic Malnutrition valueset (2.16.840.1.113883.3.464.1003.199.12.1036)
The name of a municipality, city, town, village or other community or delivery center. (Source: HL7 FHIR).
(Clinical Focus: This grouping of value sets contain procedures that represent cesarean section.),(Data Element Scope: The intent of this data element is to identify classical cesarean section. Using the Quality Data Model, this particular element will map to the 'Procedure' category.),(Inclusion Criteria: Include ICD 10 PCS, and SNOMED CT codes that identify the classical cesarean section.),(Exclusion Criteria: None) -- ObservableCode constrained to codes in the Classical Cesarean Birth valueset (2.16.840.1.113883.3.117.1.7.1.421).
(Clinical Focus: This grouping of value sets contain procedures that represent cesarean section.),(Data Element Scope: The intent of this data element is to identify classical cesarean section. Using the Quality Data Model, this particular element will map to the 'Procedure' category.),(Inclusion Criteria: Include ICD 10 PCS, and SNOMED CT codes that identify the classical cesarean section.),(Exclusion Criteria: None) -- Subject constrained to the Classical Cesarean Birth
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Clemastine valueset (2.16.840.1.113883.3.464.1003.196.12.1308).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Clemastine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Clinical Oral Evaluation valueset (2.16.840.1.113883.3.464.1003.125.12.1003).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Clinical Oral Evaluation
-- ObservableCode constrained to codes in the Clinical summary score [KCCQ] valueset (drc-5cd1c18b818269b520a5d664286b5c747b09a32d1f8c28bb112e658ece7a17c0).
-- Subject constrained to the Clinical summary score [KCCQ]
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Clomipramine valueset (2.16.840.1.113883.3.464.1003.196.12.1336).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Clomipramine
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Cloudy Cornea valueset (2.16.840.1.113883.3.526.3.1417)
A collection of statements and groups.
Assessed for Rehabilitation (STK-10). Each year about 700,000 people experience a new or recurrent stroke, which is the nation's third leading cause of death. Approximately two thirds of these individuals survive and require rehabilitation. Stroke is a leading cause of serious, long-term disability in the United States, with about 4.4 million stroke survivors alive today. Forty percent of stroke patients are left with moderate functional impairment and 15 to 30 percent with severe disability. More than 60% of those who have experienced stroke, serious injury, or a disabling disease have never received rehabilitation. Stroke rehabilitation should begin as soon as the diagnosis of stroke is established and life-threatening problems are under control. Among the high priorities for stroke are to mobilize the patient and encourage resumption of self-care activities as soon as possible. A considerable body of evidence indicates better clinical outcomes when patients with stroke are treated in a setting that provides coordinated, multidisciplinary stroke-related evaluation and services. Effective rehabilitation interventions initiated early following stroke can enhance the recovery process and minimize functional disability. The primary goal of rehabilitation is to prevent complications, minimize impairments, and maximize function.
Discharged on Antithrombotic Therapy (STK-02). The effectiveness of antithrombotic agents in reducing stroke mortality, stroke-related morbidity and recurrence rates has been studied in several large clinical trials. While the use of these agents for patients with acute ischemic stroke and transient ischemic attacks continues to be the subject of study, substantial evidence is available from completed studies. Data at this time suggest that antithrombotic therapy should be prescribed at discharge following acute ischemic stroke to reduce stroke mortality and morbidity as long as no contraindications exist. For patients with a stroke due to a cardioembolic source (eg atrial fibrillation, mechanical heart valve), warfarin is recommended unless contraindicated. In recent years, novel oral anticoagulant agents (NOACs) have been developed and approved by the U.S. Food and Drug Administration (FDA) for stroke prevention, and may be considered as an alternative to warfarin for select patients. Anticoagulation therapy is not generally recommended for secondary stroke prevention in patients presumed to have a non-cardioembolic stroke. Anticoagulants at doses to prevent venous thromboembolism are insufficient antithrombotic therapy to prevent recurrent ischemic stroke or TIA.
Discharged on Statin Medication (STK-06). There is an extensive and consistent body of evidence supporting the use of statins for secondary prevention in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD), which includes individuals with ischemic stroke due to large artery atherosclerosis, individuals with ischemic stroke due to intrinsic small vessel disease, and individuals with ischemic stroke not directly due to atherosclerosis but with clinically evident atherosclerotic disease in an uninvolved cerebral or noncerebral bed. Both women and men with clinical ASCVD are at increased risk for recurrent ASCVD and ASCVD death. High-intensity statin therapy should be initiated or continued as first-line therapy in women and men less than or equal to 75 years of age who have clinical ASCVD, unless contraindicated. In patients with clinical ASCVD and a contraindication to high-intensity statin therapy, moderate-intensity therapy should be considered as an alternative if it can be tolerated. In individuals greater than 75 years of age, the potential for ASCVD risk reduction benefits, adverse effects, drug-drug interactions, and patient preferences should be considered, and statin therapy individualized based on these considerations (Stone, 2013).
Stroke Education (STK-08). There are many examples of how patient education programs for specific chronic conditions have increased healthful behaviors, improved health status, and/or decreased health care costs of their participants. Clinical practice guidelines include recommendations for patient and family education during hospitalization as well as information about resources for social support services. Some clinical trials have shown measurable benefits in patient and caregiver outcomes with the application of education and support strategies. The type of stroke experienced and the resulting outcomes will play a large role in determining not only the course of treatment but also what education will be required. Patient education should include information about the event (eg, cause, treatment, and risk factors), the role of various medications or strategies, as well as desirable lifestyle modifications to reduce risk or improve outcomes. Family/caregivers will also need guidance in planning effective and realistic care strategies appropriate to the patient's prognosis and potential for rehabilitation.
Venous Thromboembolism Prophylaxis (VTE-1). Hospitalized patients at high-risk for VTE may develop an asymptomatic deep vein thrombosis (DVT), and die from pulmonary embolism (PE) even before the diagnosis is suspected. The majority of fatal events occur as sudden or abrupt death, underscoring the importance of prevention as the most critical action step for reducing death from PE (Geerts, et al, 2008). The estimated annual incidence of deep-vein thrombosis (DVT) and pulmonary embolism (PE), known collectively as venous thromboembolism (VTE), is approximately 900,000 (Geerts, et al, 2008). Approximately two-thirds of cases of DVT or PE are associated with recent hospitalization. This is consistent with the 2001 report by The Agency for Healthcare Research and Quality (AHRQ). AHRQ indicates that 'the appropriate application of effective preventive measures in hospitals has major potential for improving patient safety by reducing the incidence of venous thromboembolism' (Shojania, 2001). Despite its proven effectiveness, rates of appropriate thromboprophylaxis remain low in both medical and surgical patients. A recent analysis from the ENDORSE survey, which evaluated prophylaxis rates in 17,084 major surgery patients, found that more than one third of patients at risk for VTE (38%) did not receive prophylaxis and that rates varied by surgery type (Cohen, et al., 2008). In a review of evidence-based patient safety practices, the Agency for Healthcare Research and Quality defined thromboprophylaxis against VTE as the 'number one patient safety practice' for hospitalized patients (Shojania, 2001). Updated 'safe practices' published by the National Quality Forum (NQF) recommend routine evaluation of hospitalized patients for risk of VTE and use of appropriate prophylaxis (National Quality Forum. National Voluntary Consensus Standards for Prevention and Care of Venous Thromboembolism, 2006). As noted by the ACCP, a vast number of randomized clinical trials provide irrefutable evidence that thromboprophylaxis reduces VTE events, and there are studies that have also shown that fatal PE is prevented by thromboprophylaxis (Geerts, et al. 2008). Some select surgeries have previously been monitored in the Surgical Care Improvement Project; since performance on these surgeries has achieved very high levels, they are not included in this measure.
Median Admit Decision Time to ED Departure Time for Admitted Patients (ED-2). Reducing the time patients remain in the emergency department (ED) can improve access to treatment and increase quality of care. Reducing this time potentially improves access to care specific to the patient condition and increases the capability to provide additional treatment. In recent times, EDs have experienced significant overcrowding. Although once only a problem in large, urban, teaching hospitals, the phenomenon has spread to other suburban and rural healthcare organizations. According to a 2002 national U.S. survey, more than 90 percent of large hospitals report EDs operating 'at' or 'over' capacity. Approximately one third of hospitals in the U.S. report increases in ambulance diversion in a given year, whereas up to half report crowded conditions in the ED. In a recent national survey, 40 percent of hospital leaders viewed ED crowding as a symptom of workforce shortages. ED crowding may result in delays in the administration of medication such as antibiotics for pneumonia and has been associated with perceptions of compromised emergency care. For patients with non-ST-segment-elevation myocardial infarction, long ED stays were associated with decreased use of guideline-recommended therapies and a higher risk of recurrent myocardial infarction. Overcrowding and heavy emergency resource demand have led to a number of problems, including ambulance refusals, prolonged patient waiting times, increased suffering for those who wait, rushed and unpleasant treatment environments, and potentially poor patient outcomes. When EDs are overwhelmed, their ability to respond to community emergencies and disasters may be compromised.
Elective Delivery (PC-01). For almost 3 decades, the American College of Obstetricians and Gynecologists (ACOG) and the American Academy of Pediatrics (AAP) have had in place a standard requiring 39 completed weeks gestation prior to ELECTIVE delivery, either vaginal or operative (ACOG, 1996). A survey conducted in 2007 of almost 20,000 births in HCA hospitals throughout the U.S. carried out in conjunction with the March of Dimes at the request of ACOG revealed that almost 1/3 of all babies delivered in the United States are electively delivered with 5% of all deliveries in the U.S. delivered in a manner violating ACOG/AAP guidelines. Most of these are for convenience, and result in significant short term neonatal morbidity (neonatal intensive care unit admission rates of 13- 21%) (Clark et al., 2009). According to Glantz (2005), compared to spontaneous labor, elective inductions result in more cesarean births and longer maternal length of stay. The American Academy of Family Physicians (2000) also notes that elective induction doubles the cesarean delivery rate. Repeat elective cesarean births before 39 weeks gestation also result in higher rates of adverse respiratory outcomes, mechanical ventilation, sepsis and hypoglycemia for the newborns (Tita et al., 2009).
Childhood Immunization Status. Infants and toddlers are particularly vulnerable to infectious diseases because their immune systems have not built up the necessary defenses to fight infection (Centers for Disease Control and Prevention 2017a). Most childhood vaccines are between 90 and 99 percent effective in preventing diseases (HealthyChildren 2015). Vaccination of each U.S. birth cohort with the current childhood immunization schedule prevents approximately 42,000 deaths and 20 million cases of disease, and saves nearly $14 billion in direct costs and $69 billion in societal costs each year (Zhou 2014). Immunizing a child not only protects that child's health but also the health of the community, especially for those who are not immunized or are unable to be immunized due to other health complications (Centers for Disease Control and Prevention 2017b). When the majority of the community is immunized against a disease, other members of the community are also protected because herd immunity shields them. (National Institute of Allergy and Infectious Diseases 2014).
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%). As the seventh leading cause of death in the U.S., diabetes kills approximately 79,500 people a year (CDC Health 2017). Diabetes is a long lasting disease marked by high blood glucose levels, resulting from the body's inability to produce or use insulin properly (CDC About Diabetes 2017). People with diabetes are at increased risk of serious health complications including vision loss, heart disease, stroke, kidney failure, amputation of toes, feet or legs, and premature death. (CDC At a Glance 2016). In 2012, diabetes cost the U.S. an estimated $245 billion: $176 billion in direct medical costs and $69 billion in reduced productivity. This is a 41 percent increase from the estimated $174 billion spent on diabetes in 2007 (ADA Economic 2013). Reducing A1c blood level results by 1 percentage point (eg, from 8.0 percent to 7.0 percent) helps reduce the risk of microvascular complications (eye, kidney and nerve diseases) by as much as 40 percent (CDC Estimates 2011).
Diabetes: Foot Exam. As the seventh leading cause of death in the U.S., diabetes kills approximately 79,500 people a year (CDC Health 2017). Diabetes is a long lasting disease marked by high blood glucose levels, resulting from the body's inability to produce or use insulin properly (CDC About Diabetes 2017). People with diabetes are at increased risk of serious health complications including vision loss, heart disease, stroke, kidney failure, amputation of toes, feet or legs, and premature death. (CDC At a Glance 2016). In 2012, diabetes cost the U.S. an estimated $245 billion: $176 billion in direct medical costs and $69 billion in reduced productivity. This is a 41 percent increase from the estimated $174 billion spent on diabetes in 2007 (ADA Economic 2013). Diabetes reduces the blood flow to the extremities of the body such as the legs and feet, which make it harder for the body to heal from injuries to those parts of the body. Patients with diabetes are at higher risks of developing serious problems with their feet, toes, and legs which can lead to difficulty walking or even amputation (CDC Living with Diabetes, 2015). According to research from the Centers for Disease Control and Prevention (CDC), in 2010 approximately 73,000 adults with diabetes had a leg or foot amputated. Furthermore, amputations in adults with diabetes accounts for 60 percent of amputation of legs and feet, not related to an injury (CDC Living with Diabetes, 2015). Adults 45 years and older with diabetes are 10 times more likely to have an amputation of their leg or foot compared to adults without diabetes (CDC Living with Diabetes, 2015).
Cervical Cancer Screening. All women are at risk for cervical cancer, but it occurs most often in women over the age of 30. In 2017, approximately 12,820 women were diagnosed with cervical cancer in the U.S., resulting in an estimated 4,210 deaths (Howlader et al. 2017). If pre-cancerous lesions are detected early by Pap tests and treated, the likelihood of survival is nearly 100 percent (American Cancer Society 2017). In 2015, women with no health insurance and recent immigrants were least likely to have a Pap test (American Cancer Society 2017).
Breast Cancer Screening. Breast cancer is one of the most common types of cancers, accounting for 15 percent of all new cancer diagnoses in the U.S. (Howlader et al, 2016). In 2013, over 3 million women were estimated to be living with breast cancer in the U.S. and it is estimated that 12 percent of women will be diagnosed with breast cancer at some point during their lifetime (Howlader et al, 2016). While there are other factors that affect a woman's risk of developing breast cancer, advancing age is a primary risk factor. Breast cancer is most frequently diagnosed among women ages 55-64; the median age at diagnosis is 62 years (Howlader et al, 2016). The chance of a woman being diagnosed with breast cancer in a given year increases with age. By age 40, the chances are 1 in 235; by age 50 it becomes 1 in 54; by age 60, it is 1 in 25 (National Business Group on Health, 2011). In the U.S., costs associated with a diagnosis of breast cancer range from $451 to $2,520, factoring in continued testing, multiple office visits and procedures. The total costs related to breast cancer add up to nearly $7 billion per year in the U.S., including $2 billion spent on late-stage treatment (National Business Group on Health, 2011). If breast cancer is detected through mammography screening and diagnosed in its earliest stages, treatment may be less expensive (Feig, 2011).
Pneumococcal Vaccination Status for Older Adults. Pneumonia is a common cause of illness and death in the elderly and persons with certain underlying conditions such as heart failure, diabetes, cystic fibrosis, asthma, sickle cell anemia, or chronic obstructive pulmonary disease (NHLBI, 2011). In 1998, an estimated 3,400 adults aged > 65 years died as a result of invasive pneumococcal disease (IPD) (CDC, 2003). Among the 91.5 million US adults aged > 50 years, 29,500 cases of IPD, 502,600 cases of nonbacteremic pneumococcal pneumonia and 25,400 pneumococcal-related deaths are estimated to occur yearly; annual direct and indirect costs are estimated to total $3.7 billion and $1.8 billion, respectively. Pneumococcal disease remains a substantial burden among older US adults, despite increased coverage with 23-valent pneumococcal polysaccharide vaccine, (PPV23) and indirect benefits afforded by PCV7 vaccination of young children (Weycker, et al., 2011). Vaccination has been found to be effective against bacteremic cases (OR: 0.34; 95% CI: 0.27-0.66) as well as nonbacteremic cases (OR: 0.58; 95% CI: 0.39-0.86). Vaccine effectiveness was highest against bacteremic infections caused by vaccine types (OR: 0.24; 95% CI: 0.09-0.66) (Vila-Corcoles, et al., 2009).
Anti-depressant Medication Management. In 2013, over 15 million adults in the United States had at least one major depressive episode in the past 12 months (National Institute of Mental Health 2013), and depression is estimated to affect nearly a quarter of adults in their lifetime (Burcusa and Iacono 2007). Symptoms of depression include appetite and sleep disturbances, anxiety, irritability and decreased concentration (Charbonneau et al. 2005). The American Psychiatric Association recommends use of antidepressant medication and behavioral therapies, such as psychotherapy, to treat depression (American Psychiatric Association 2010). For the past 50 years, antidepressant medication has proven to be effective especially for patients with more severe symptoms (Fournier et al. 2010). Among patients who initiate antidepressant treatment, one in three discontinues treatment within one month, before the effect of medication can be assessed, and nearly one in two discontinues treatment within three months (Simon 2002). Due to increased risky behaviors for chronic disease (eg, physical inactivity, smoking, excessive drinking and insufficient sleep), evidence has shown that depressive disorders are strongly related to the occurrence of many chronic diseases including diabetes, cancer, cardiovascular disease and asthma (Centers for Disease Control and Prevention 2011). Aligning depression quality improvement with methods used in managing other chronic illnesses has been an important step in depression care. Depression management systems have demonstrated improved short- and long-term outcomes of depression severity and persistence, employment retention, functional status and patient satisfaction (Katon et al. 2002; Rost et al. 2001).
Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients. Multiple studies have indicated that a bone scan is not clinically necessary for staging prostate cancer in men with a low (or very low) risk of recurrence and receiving primary therapy. For patients who are categorized as low-risk, bone scans are unlikely to identify their disease. Furthermore, bone scans are not necessary for low-risk patients who have no history or if the clinical examination suggests no bony involvement. Less than 1% of low-risk patients are at risk of metastatic disease. While clinical practice guidelines do not recommend bone scans in low-risk prostate cancer patients, overuse is still common. An analysis of prostate cancer patients in the SEER-Medicare database diagnosed from 2004-2007 found that 43% of patients for whom a bone scan was not recommended received it (Falchook, Hendrix, & Chen, 2015). The analysis also found that the use of bone scans in low-risk patients leads to an annual cost of $4 million dollars to Medicare. The overuse of bone scan imaging for low-risk prostate cancer patients is a concept included on the American Urological Association's (AUA) list in the Choosing Wisely Initiative as a means to promote adherence to evidence-based imaging practices and to reduce health care dollars wasted (AUA, 2013). This measure is intended to promote adherence to evidence-based imaging practices, lessen the financial burden of unnecessary imaging, and ultimately to improve the quality of care for prostate cancer patients in the United States.
Colorectal Cancer Screening. Colorectal cancer represents 8 percent of all new cancer cases and is the second leading cause of cancer deaths in the United States. In 2017, there were an estimated 135,430 new cases of colorectal cancer and an estimated 50,260 deaths attributed to it. According to the National Cancer Institute, about 4.3 percent of men and women will be diagnosed with colorectal cancer at some point during their lifetimes. For most adults, older age is the most important risk factor for colorectal cancer, although being male and black are also associated with higher incidence and mortality. Colorectal cancer is most frequently diagnosed among people 65 to 74 years old (Howlader et al. 2017). Screening can be effective for finding precancerous lesions (polyps) that could later become malignant, and for detecting early cancers that can be more easily and effectively treated. Precancerous polyps usually take about 10 to 15 years to develop into colorectal cancer, and most can be found and removed before turning into cancer. The five-year relative survival rate for people whose colorectal cancer is found in the early stage before it has spread is about 90 percent (American Cancer Society 2017).
Diabetes: Eye Exam. As the seventh leading cause of death in the U.S., diabetes kills approximately 79,500 people a year (CDC Health 2017). Diabetes is a long lasting disease marked by high blood glucose levels, resulting from the body's inability to produce or use insulin properly (CDC About Diabetes 2017). People with diabetes are at increased risk of serious health complications including vision loss, heart disease, stroke, kidney failure, amputation of toes, feet or legs, and premature death. (At a Glance 2016). In 2012, diabetes cost the U.S. an estimated $245 billion: $176 billion in direct medical costs and $69 billion in reduced productivity. This is a 41 percent increase from the estimated $174 billion spent on diabetes in 2007 (ADA Economic 2013). Diabetic retinopathy is progressive damage to the small blood vessels in the retina that may result in loss of vision. It is the leading cause of blindness in adults between 20-74 years of age. Approximately 4.1 million adults are affected by diabetic retinopathy (CDC Common Eye Disorders 2015).
Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures. In the United States, cataracts affect more than 24 million adults over 40 years. (NEI, 2016) According to the American Academy of Ophthalmology (AAO), cataract surgery leads to favorable outcomes and improved vision. (AAO, 2016) Although uncommon, complications from cataract surgery do occur and may result in vision loss. (AAO, 2016) 1. Scientific basis for assessing short-term complications following cataract surgery. This short-term outcome of surgery indicator seeks to identify those complications from surgery that can reasonably be attributed to the surgery and surgeon and which reflect situations which - if untreated - generally result in significant avoidable vision loss that would negatively impact patient functioning. Further, it seeks to reduce surgeon burden and enhance accuracy in reporting by focusing on those significant complications that can be assessed from administrative data alone and which can be captured by the care of another physician or the provision of additional, separately coded, post-operative services. Finally, it focuses on patient safety and monitoring for events that, while hopefully uncommon, can signify important issues in the care being provided. For example, the need to reposition or exchange an intraocular lens (IOL) reflects in part 'wrong power' IOL placement, a major patient safety issue. In order to achieve these ends, the indicator excludes patients with other known, pre-operative ocular conditions that could impact the likelihood of developing a complication. Based on the results of the Cataract Appropriateness Project at RAND, other published studies, and one analysis performed on a national MCO data base, the exclusion codes would preserve over 2/3 of all cataract surgery cases for analysis. Thus, this provides a 'clean' indicator that captures care for the large majority of patients undergoing cataract surgery. 2. Evidence for gap in care. The advances in technology and surgical skills over the last 30 years have made cataract surgery much safer and more effective although complications that threaten vision do occur. For example, a study of more than 220,000 Medicare beneficiaries who underwent cataract surgery between 1994 and 2006 found that more than 1,000, or about 0.5%, of patients had at least one severe post-operative complication. These severe complications were defined as endophthalmitis (0.16%), suprachoroidal hemorrhage (0.06%), and retinal detachment (0.26%). (Stein, 2011) In a review, Taban et al. found a postoperative rate of endophthalmitis of 0.128%. (Taban, 2005) The occurrence of one of these events is associated with a significant potential for vision loss that is otherwise avoidable.
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery. In the United States, cataracts affect more than 24 million adults over 40 years. (NEI, 2016) According to the American Academy of Ophthalmology (AAO), cataract surgery has a substantial beneficial impact on visual function and on quality of life. (AAO, 2016) 1. Scientific basis for measuring visual acuity outcomes after cataract surgery The only reason to perform cataract surgery (other than for a limited set of medical indications) is to improve a patient's vision and associated functioning. The use of a 20/40 visual acuity threshold is based on several considerations. First, it is the level for unrestricted operation of a motor vehicle in the US. Second, it has been consistently used by the FDA in its assessment for approval of intraocular lens (IOL) and other vision devices. Third, it is the literature standard to denote success in cataract surgery. Fourth, work by West et al in the Salisbury Eye Study suggests that 20/40 is a useful threshold for 50th percentile functioning for several vision-related tasks. Most patients achieve excellent visual acuity after cataract surgery (20/40 or better). This outcome is achieved consistently through careful attention through the accurate measurement of axial length and corneal power and the appropriate selection of an IOL power calculation formula. As such, it reflects the care and diligence with which the surgery is assessed, planned and executed. Failure to achieve this after surgery in eyes without comorbid ocular conditions that would impact the success of the surgery would reflect care that should be assessed for opportunities for improvement. The exclusion of patients with other ocular and systemic conditions known to increase the risk of an adverse outcome reflects the findings of the two published prediction rule papers for cataract surgery outcomes, by Mangione et al and Steinberg et al. In both papers, the presence of comorbid glaucoma and macular degeneration negatively impacted the likelihood of successful outcomes of surgery. Further, as noted in the prior indicator, exclusion of eyes with ocular conditions that could impact the success of the surgery would NOT eliminate the large majority of eyes undergoing surgery while also minimizing the potential adverse selection that might otherwise occur relative to those patients with the most complex situations who might benefit the most from having surgery to maximize their remaining vision. 2. Evidence of a gap in care. Cataract surgery successfully restores vision in the majority of people who have the procedure. Data from a study of 368,256 cataract surgeries show that corrected visual acuity (CDVA) of 0.5 (20/40) or better was achieved in 94.3% and CDVA of 1.0 (20/20) or better was achieved in 61.3% of cases. (Lundstrom, 2013) Additionally, data from a UK multi-center Cataract National Dataset found a postoperative visual acuity of 6/12 (20/40) or better was achieved for 94.7% of eyes with no co-pathologies and in 79.9% of eyes with one or more co-pathologies. (Jaycock, 2009) A rate of 85.5-94.7% of patients achieving a 20/40 or better visual acuity in the context of approximately 3 million cataract surgeries in the US annually would mean that between 160,000 to 435,000 individuals would not achieve a 20/40 or better visual acuity which suggests an opportunity for improvement.
Diabetes: Medical Attention for Nephropathy. As the seventh leading cause of death in the U.S., diabetes kills approximately 79,500 people a year (CDC Health 2017). Diabetes is a long lasting disease marked by high blood glucose levels, resulting from the body's inability to produce or use insulin properly (CDC About Diabetes 2017). People with diabetes are at increased risk of serious health complications including vision loss, heart disease, stroke, kidney failure, amputation of toes, feet or legs, and premature death. (CDC At a Glance 2016). In 2012, diabetes cost the U.S. an estimated $245 billion: $176 billion in direct medical costs and $69 billion in reduced productivity. This is a 41 percent increase from the estimated $174 billion spent on diabetes in 2007 (ADA Economic 2013). High blood sugar levels in patients with diabetes put them at a higher risk of damaging their kidneys and causing chronic kidney disease, which can lead to kidney failure (CDC Fact Sheet 2017, CDC At a Glance 2016). During 2011-2012 there were 36.5% new cases of chronic kidney disease (stages 1-4) among 297,000 diabetic patients 20 years and older (Murphy 2016). In 2014, diabetes accounted for 44% of 118,000 new cases of end stage renal disease (USRDS 2016).
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD). In the absence of contraindications, ACE inhibitors or ARBs are recommended for all patients with symptoms of heart failure and reduced left ventricular systolic function. ACE inhibitors remain the first choice for inhibition of the renin-angiotensin system in chronic heart failure, but ARBs can now be considered a reasonable alternative. Both pharmacologic agents have been shown to decrease the risk of death and hospitalization. Additional benefits of ACE inhibitors include the alleviation of symptoms and the improvement of clinical status and overall sense of well-being of patients with heart failure.
Follow-Up Care for Children Prescribed ADHD Medication (ADD). Attention-deficit hyperactivity disorder (ADHD) is one of the most prevalent behavioral health diseases in children. A National Survey of Children's Health study found that, in 2007, about 9.5% of children 4 to 17 years of age, or about 5.4 million, had a history of ADHD (CDC 2010). Of those 5.4 million children with a history of ADHD, 78% had a current diagnosis of ADHD at the time of the survey (CDC 2010) and 66.3% of those children were taking medication for the disorder (CDC 2010). A similar survey conducted in 2013 found that about 10% of American children age 3-17 have been diagnosed with ADHD (Bloom et al., 2013). ADHD also incurs substantial financial costs due to medical care and work loss costs for patients and families. The annual average direct cost per ADHD patient is $1,574 dollars compared to $541 dollars among similar individuals without ADHD (Swensen et al. 2003). Additionally, children with ADHD add a higher cost to the education system - on average $5,000 each year for each student with ADHD (Robb et al., 2011). There are many symptoms associated with ADHD. Children with ADHD may experience significant functional problems, such as school difficulties, academic underachievement, troublesome relationships with family members and peers and behavioral problems (American Academy of Pediatrics 2000). For instance, recent studies have found that parents whose children have a history of ADHD report significantly more peer problems and a higher rate of non-fatal injuries compared to parents whose children do not have a history of ADHD (Strine et al. 2006; Xiang et al. 2005). Additional studies suggest that there is an increased risk for drug use disorders in adolescents with untreated ADHD (National Institute on Drug Abuse, 2010). One of the national objectives of the Department of Health and Human Services Healthy People 2020 initiative is to increase the proportion of children with mental health problems who receive treatment. Medication treatment has been found to be effective for managing ADHD, but treatment requires careful monitoring by physicians. Studies have shown that psychostimulants are highly effective for 75-90% of children with ADHD by reducing symptoms of hyperactivity, impulsivity and inattention; improving classroom performance and behavior; and promoting increased interaction with teachers, parents and peers (U.S. Department of Health and Human Services 1999). Some reported adverse effects of stimulant ADHD medications including appetite loss, abdominal pain, headaches, sleep disturbance, decreasing growth velocity, and less commonly, hallucinations and other psychotic symptoms (Wolraich et al. 2011). Therefore, it is important to assess the presence or absence of potential adverse effects before and after a stimulant drug is initiated (Smucker & Hedayat 2001). Monitoring adverse effects from ADHD medication allows physicians to suggest an optimal, alternative treatment. Studies have also shown that treating children with effective medication management can lead to substantially greater improvements in social skills and peer relations compared to children who are not effectively managed (Jensen et al. 2001). Finally, treatments for children with ADHD are frequently not sustained despite the fact that they are at greater risk of significant problems if they discontinue treatment (Wolraich et al. 2011). Effective management mitigates the risk of discontinuing treatment.
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment. There are more deaths, illnesses and disabilities from substance abuse than from any other preventable health condition. Treatment of medical problems caused by substance use and abuse places a huge burden on the health care system (Schneider Institute 2001). According to a report from the 2001 National Household Survey on Drug Abuse (NHSDA), an estimated 16.6 million Americans aged 12 or older in 2001 were classified with dependence on or abuse of either alcohol or illicit drugs (7.3 percent of the total population) (Substance Abuse and Mental Health Services Administration 2008). Of these, 2.4 million were classified with dependence on or abuse of both alcohol and illicit drugs, 3.2 million were dependent on or abused illicit drugs but not alcohol, and 11.0 million were dependent on or abused alcohol but not illicit drugs (Substance Abuse and Mental Health Services Administration 2008).
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention. This measure is intended to promote adult tobacco screening and tobacco cessation interventions for those who use tobacco products. There is good evidence that tobacco screening and brief cessation intervention (including counseling and/or pharmacotherapy) is successful in helping tobacco users quit. Tobacco users who are able to stop using tobacco lower their risk for heart disease, lung disease, and stroke.
Falls: Screening for Future Fall Risk. As the leading cause of both fatal and nonfatal injuries for older adults, falls are one of the most common and significant health issues facing people aged 65 years or older (Schneider, Shubert and Harmon 2010). Moreover, the rate of falls increases with age (Dykes et al. 2010). Older adults are five times more likely to be hospitalized for fall-related injuries than any other cause-related injury. It is estimated that one in every three adults over 65 will fall each year (Centers for Disease Control and Prevention 2015). In those over age 80, the rate of falls increases to fifty percent (Doherty et al. 2009). Falls are also associated with substantial cost and resource use, approaching $30,000 per fall hospitalization (Woolcott et al. 2011). Identifying at-risk patients is the most important part of management, as applying preventive measures in this vulnerable population can have a profound effect on public health (al-Aama 2011). Family physicians have a pivotal role in screening older patients for risk of falls, and applying preventive strategies for patients at risk (al-Aama 2011).
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care. The primary care physician that manages the ongoing care of the patient with diabetes should be aware of the patient's dilated eye examination and severity of retinopathy to manage the ongoing diabetes care. Such communication is important in assisting the physician to better manage the diabetes. Several studies have shown that better management of diabetes is directly related to lower rates of development of diabetic eye disease (Diabetes Control and Complications Trial -DCCT, UK Prospective Diabetes Study - UKPDS).
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation. Changes in the optic nerve are one of two characteristics which currently define progression and thus worsening of glaucoma disease status (the other characteristic is visual field). There is a significant gap in documentation patterns of the optic nerve for both initial and follow-up care (Fremont, 2003), even among specialists (Lee, 2006). Examination of the optic nerve head and retinal nerve fiber layer provides valuable structural information about glaucomatous optic nerve damage. Visible structural alterations of the optic nerve head or retinal nerve fiber layer and development of peripapillary choroidal atrophy frequently occur before visual field defects can be detected. Careful study of the optic disc neural rim for small hemorrhages is important, since these hemorrhages can precede visual field loss and further optic nerve damage. When initiating therapy, the clinician sets a target range of controlled intraocular pressure (IOP) based on the pretreatment pressure and the presence of optic nerve damage. According to the AAO Glaucoma Preferred Practice Pattern, lowering the pretreatment IOP reduces the risk of developing POAG and slows the progression of POAG to preserve visual function (AAO, 2015).
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD). Beta-blockers are recommended for all patients with stable heart failure and left ventricular systolic dysfunction, unless contraindicated. Treatment should be initiated as soon as a patient is diagnosed with left ventricular systolic dysfunction and does not have low blood pressure, fluid overload, or recent treatment with an intravenous positive inotropic agent. Beta-blockers have been shown to lessen the symptoms of heart failure, improve the clinical status of patients, reduce future clinical deterioration, and decrease the risk of mortality and the combined risk of mortality and hospitalization.
Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%). For patients with coronary artery disease (CAD), beta-blockers are recommended for 3 years after myocardial infarction or acute coronary syndrome. Beta-blockers, particularly carvedilol, metoprolol succinate, or bisoprolol which have been shown to reduce risk of death, are recommended indefinitely for patients with CAD and LV systolic dysfunction. These agents have proven efficacy in reducing angina onset and improving the ischemic threshold during exercise. In patients who have suffered an MI, beta-blockers significantly reduce deaths and recurrent MIs (ACCF/AHA/ACP/AATS/PCNA/SCAI/STS, 2012). Nonadherence to cardioprotective medications is prevalent among outpatients with CAD and can be associated with a broad range of adverse outcomes, including all-cause and cardiovascular mortality, cardiovascular hospitalizations, and the need for revascularization procedures (ACC/AHA, 2002). This measure is intended to promote beta-blocker usage in select patients with CAD.
Appropriate Testing for Children with Pharyngitis. Group A streptococcal bacterial infections and other infections that cause pharyngitis (which are most often viral) often produce the same signs and symptoms (IDSA 2002). The American Academy of Pediatrics, the Centers for Disease Control and Prevention, and the Infectious Diseases Society of America all recommend a diagnostic test for Strep A to improve diagnostic accuracy and avoid unnecessary antibiotic treatment (Linder et al. 2005). Estimated economic costs of pediatric streptococcal pharyngitis in the United States range from $224 million to $539 million per year, including indirect costs related to parental work losses. At a higher level, the economic cost of antibiotic resistance vary but have extended as high as $20 billion in excess direct healthcare costs, with additional costs to society for lost productivity as high as $35 billion a year (2008 dollars) (Roberts et al. 2009).
Preventive Care and Screening: Influenza Immunization. Influenza vaccination is the most effective protection against influenza virus infection (CDC, 2016). Influenza may lead to serious complications including hospitalization or death (CDC, 2016). Influenza vaccine is recommended for all persons aged >=6 months who do not have contraindications to vaccination. However, data indicate that less than half of all eligible individuals receive an influenza vaccination (CDC, 2015). This measure promotes annual influenza vaccination for all persons aged >= 6 months.
Dementia: Cognitive Assessment. Dementia is often characterized by the gradual onset and continuing cognitive decline in one or more domains including memory, executive function, language, judgment, and spatial abilities. (APA, 2007) Cognitive deterioration represents a major source of morbidity and mortality and poses a significant burden on affected individuals and their caregivers. (NIH, 2010) Although cognitive deterioration follows a different course depending on the type of dementia, significant rates of decline have been reported. For example, one study found that the annual rate of decline for Alzheimer's disease patients was more than four times that of older adults with no cognitive impairment. (Wilson et al., 2010) Nevertheless, measurable cognitive abilities remain throughout the course of dementia. (APA, 2007) Initial and ongoing assessments of cognition are fundamental to the proper management of patients with dementia. These assessments serve as the basis for identifying treatment goals, developing a treatment plan, monitoring the effects of treatment, and modifying treatment as appropriate.
Chlamydia Screening for Women. Chlamydia trachomatis is the most common sexually transmitted bacterial infection in the U.S., resulting in roughly 1.6 million cases each year (CDC 2017). Chlamydia infections are often asymptomatic, but, if left untreated, can lead to serious and irreversible complications (USPSTF 2014, CDC 2017). Women are particularly vulnerable when infected with chlamydia. Left untreated, chlamydia can cause pelvic inflammatory disease (PID), which can lead to chronic pelvic pain or infertility. Pregnant women may also transmit the infection to their infant, potentially resulting in neonatal pneumonia (CDC 2017).
Appropriate Treatment for Children with Upper Respiratory Infection (URI). Most URI, also known as the common cold, are caused by viruses that require no antibiotic treatment. Too often, antibiotics are prescribed inappropriately, which can lead to antibiotic resistance (when antibiotics can no longer cure bacterial infections). In the United States, at least 2 million antibiotic-resistant illnesses and 23,000 deaths occur each year, at a cost to the U.S. economy of at least $30 billion.
Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents. One of the most important developments in pediatrics in the past two decades has been the emergence of a new chronic disease: obesity in childhood and adolescence. The rapidly increasing prevalence of obesity among children is one of the most challenging dilemmas currently facing pediatricians. National Health and Nutrition Examination Survey (NHANES) data from Cycle II (1976-1980) compared with data from Cycle III (1988-1994) documents an increase in the prevalence of obesity in all age, ethnic, and gender groups. NHANES data collected from 1999-2000 revealed a continued increase in the number of obese children. In that data collection, the prevalence of obesity (body mass index (BMI) > 95th percentile) was 10 percent among children 2-5 years of age and 15 percent among children 6-19 years of age. When children at risk for obesity (BMI of 85th-94th percentile) were included, the prevalence increased to 20 percent and 30 percent, respectively. Therefore, >1 of every 4 patients examined by pediatricians either is obese or is considered to be at high risk for developing this challenging health problem (O'Brien et al. 2004). In addition to the growing prevalence of obesity in children and adolescents, the number of overweight children at risk of becoming obese is also of great concern. Evidence suggests that overweight children and adolescents are more likely to become obese as adults. For example, one study found that approximately 80 percent of children who were overweight at age 10-15 years were obese adults at age 25 years (Whitaker et al. 1997). Another study found that 25 percent of obese adults were overweight as children. The latter study also found that if overweight begins before 8 years of age, obesity in adulthood is likely to be more severe (Freedman et al. 2001).
Use of High-Risk Medications in the Elderly. Older adults receiving inappropriate medications are more likely to report poorer health status at follow-up, compared to those who receive appropriate medications (Fu, Liu, and Christensen 2004). A study of the prevalence of potentially inappropriate medication use in older adults found that 40 percent of individuals 65 and older filled at least one prescription for a potentially inappropriate medication and 13 percent filled two or more (Fick et al. 2008). While some adverse drug events are not preventable, studies estimate that between 30 and 80 percent of adverse drug events in the elderly are preventable (MacKinnon and Hepler 2003). Reducing the number of inappropriate prescriptions can lead to improved patient safety and significant cost savings. Conservative estimates of extra costs due to potentially inappropriate medications in the elderly average $7.2 billion a year (Fu et al. 2007). Medication use by older adults will likely increase further as the U.S. population ages, new drugs are developed, and new therapeutic and preventive uses for medications are discovered (Rothberg et al. 2008). The annual direct costs of preventable adverse drug events (ADEs) in the Medicare population have been estimated to exceed $800 million (IOM, 2007). By the year 2030, nearly one in five U.S. residents is expected to be aged 65 years or older; this age group is projected to more than double in number from 38.7 million in 2008 to more than 88.5 million in 2050. Likewise, the population aged 85 years or older is expected to increase almost four-fold, from 5.4 million to 19 million between 2008 and 2050. As the elderly population continues to grow, the number of older adults who present with multiple medical conditions for which several medications are prescribed continues to increase, resulting in polypharmacy (Gray and Gardner 2009).
Oncology: Medical and Radiation - Pain Intensity Quantified. Initial and ongoing pain assessments are essential to ensure proper pain management among patients with cancer. An inadequate assessment of pain is linked to poor pain control. Unrelieved pain has a significant impact on patients' quality of life, denying them comfort and greatly affecting their activities, motivation, and interactions with family and friends. Additionally, there is growing evidence that cancer survival is associated with effective pain management. (NCCN, 2017)
Pregnant women that had HBsAg testing. The U.S. Preventive Services Task Force (USPSTF) found good evidence that universal prenatal screening for hepatitis B virus (HBV) infection using hepatitis B surface antigen (HBsAg) substantially reduces prenatal transmission of HBV and the subsequent development of chronic HBV infection (USPSTF 2009). The current practice of vaccinating all infants against HBV infection and post-exposure prophylaxis with hepatitis B immune globulin administered at birth to infants of HBV-infected mothers substantially reduces the risk for acquiring HBV infection.
Depression Remission at Twelve Months. Adults: Depression is a common and treatable mental disorder. The Centers for Disease Control and Prevention states that an estimated 6.6% of the U.S. adult population (14.8 million people) experiences a major depressive disorder during any given 12-month period. Additionally, dysthymia accounts for an additional 3.3 million Americans. In 2006 and 2008, an estimated 9.1% of U.S. adults reported symptoms for current depression (Centers for Disease Control and Prevention, 2010). Persons with a current diagnosis of depression and a lifetime diagnosis of depression or anxiety were significantly more likely than persons without these conditions to have cardiovascular disease, diabetes, asthma and obesity and to be a current smoker, to be physically inactive and to drink heavily (Strine, 2008). People who suffer from depression have lower incomes, lower educational attainment and fewer days working each year, leading to seven fewer weeks of work per year, a loss of 20% in potential income and a lifetime loss for each family who has a depressed family member of $300,000 (Smith, 2010). The cost of depression (lost productivity and increased medical expense) in the United States is $83 billion each year (Greenberg, 2003). Adolescents and Adults: The Centers for Disease Control and Prevention states that during 2009-2012 an estimated 7.6% of the U.S. population aged 12 and over had depression, including 3% of Americans with severe depressive symptoms. Almost 43% of persons with severe depressive symptoms reported serious difficulties in work, home and social activities, yet only 35% reported having contact with a mental health professional in the past year. Depression is associated with higher mortality rates in all age groups. People who are depressed are 30 times more likely to take their own lives than people who are not depressed and five times more likely to abuse drugs. Depression is the leading cause of medical disability for people aged 14 - 44. Depressed people lose 5.6 hours of productive work every week when they are depressed, fifty percent of which is due to absenteeism and short-term disability. Adolescents: In 2014, an estimated 2.8 million adolescents age 12 to 17 in the United States had at least one major depressive episode in the past year. This represented 11.4% of the U.S. population. The same survey found that only 41.2 percent of those who had a Major Depressive Episode received treatment in the past year. The 2013 Youth Risk Behavior Survey of students grades 9 to 12 indicated that during the past 12 months 39.1% (F) and 20.8% (M) indicated feeling sad or hopeless almost every day for at least 2 weeks, planned suicide attempt 16.9% (F) and 10.3% (M), with attempted suicide 10.6% (F) and 5.4% (M). Adolescent-onset depression is associated with chronic depression in adulthood. Many mental health conditions (anxiety, bipolar, depression, eating disorders, and substance abuse) are evident by age 14. The 12-month prevalence of MDEs increased from 8.7% in 2005 to 11.3% in 2014 in adolescents and from 8.8% to 9.6% in young adults (both P < .001). The increase was larger and statistically significant only in the age range of 12 to 20 years. The trends remained significant after adjustment for substance use disorders and sociodemographic factors. Mental health care contacts overall did not change over time; however, the use of specialty mental health providers increased in adolescents and young adults, and the use of prescription medications and inpatient hospitalizations increased in adolescents. In 2015, 9.7% of adolescents in MN who were screened for depression or other mental health conditions, screened positively.
Depression Utilization of the PHQ-9 Tool. Adults: Depression is a common and treatable mental disorder. The Centers for Disease Control and Prevention states that an estimated 6.6% of the U.S. adult population (14.8 million people) experiences a major depressive disorder during any given 12-month period. Additionally, dysthymia accounts for an additional 3.3 million Americans. In 2006 and 2008, an estimated 9.1% of U.S. adults reported symptoms for current depression (Centers for Disease Control and Prevention, 2010). Persons with a current diagnosis of depression and a lifetime diagnosis of depression or anxiety were significantly more likely than persons without these conditions to have cardiovascular disease, diabetes, asthma and obesity and to be a current smoker, to be physically inactive and to drink heavily (Strine, 2008). People who suffer from depression have lower incomes, lower educational attainment and fewer days working each year, leading to seven fewer weeks of work per year, a loss of 20% in potential income and a lifetime loss for each family who has a depressed family member of $300,000 (Smith, 2010). The cost of depression (lost productivity and increased medical expense) in the United States is $83 billion each year (Greenberg, 2003). Adolescents and Adults: The Centers for Disease Control and Prevention states that during 2009-2012 an estimated 7.6% of the U.S. population aged 12 and over had depression, including 3% of Americans with severe depressive symptoms. Almost 43% of persons with severe depressive symptoms reported serious difficulties in work, home and social activities, yet only 35% reported having contact with a mental health professional in the past year. Depression is associated with higher mortality rates in all age groups. People who are depressed are 30 times more likely to take their own lives than people who are not depressed and five times more likely to abuse drugs. Depression is the leading cause of medical disability for people aged 14 - 44. Depressed people lose 5.6 hours of productive work every week when they are depressed, fifty percent of which is due to absenteeism and short-term disability. Adolescents: In 2014, an estimated 2.8 million adolescents age 12 to 17 in the United States had at least one major depressive episode in the past year. This represented 11.4% of the U.S. population. The same survey found that only 41.2 percent of those who had a Major Depressive Episode received treatment in the past year. The 2013 Youth Risk Behavior Survey of students grades 9 to 12 indicated that during the past 12 months 39.1% (F) and 20.8% (M) indicated feeling sad or hopeless almost every day for at least 2 weeks, planned suicide attempt 16.9% (F) and 10.3% (M), with attempted suicide 10.6% (F) and 5.4% (M). Adolescent-onset depression is associated with chronic depression in adulthood. Many mental health conditions (anxiety, bipolar, depression, eating disorders, and substance abuse) are evident by age 14. The 12-month prevalence of MDEs increased from 8.7% in 2005 to 11.3% in 2014 in adolescents and from 8.8% to 9.6% in young adults (both P < .001). The increase was larger and statistically significant only in the age range of 12 to 20 years. The trends remained significant after adjustment for substance use disorders and sociodemographic factors. Mental health care contacts overall did not change over time; however, the use of specialty mental health providers increased in adolescents and young adults, and the use of prescription medications and inpatient hospitalizations increased in adolescents. In 2015, 9.7% of adolescents in MN who were screened for depression or other mental health conditions, screened positively. Please note that this process measure for administration of the PHQ-9 or PHQ-9M depression tool, a PROM that is validated for both the assessment and diagnosis of depression as well as for monitoring ongoing outcomes of treatment, is a PAIRED process measure with RELATED measures of depression remission (PHQ-9/PHQ-9M < 5) and depression response (PHQ-9/PHQ-9M is improved by > 50%) at six and twelve months. To quote a NQF Behavioral Steering Committee member as these measures were initially endorsed 'the best way to avoid being measured is to never give the PHQ-9'. This process measure allows an understanding of the use of the tool in the target population, promotes frequent and follow-up contact with patients whose score indicates a need for treatment and serves as a catalyst in a collaborative care model for patients with major depression or dysthymia. It is estimated that up to 90% of patients diagnosed with depression and anxiety are treated solely in primary care (National Institute for Health and Care Excellence, 2011).
Adult Major Depressive Disorder (MDD): Suicide Risk Assessment. Research has shown that more than 90% of people who kill themselves have depression or another diagnosable mental or substance abuse disorder. Depression is the cause of over two-thirds of the reported suicides in the U.S. each year. The intent of this measure is for a clinician to assess suicide risk at initial intake or at the visit in which depression was diagnosed. As the guidelines state, it is important to assess for additional factors which may increase or decrease suicide risk, such as presence of additional symptoms (eg, psychosis, severe anxiety, hopelessness, severe chronic pain); presence of substance abuse, history and seriousness of previous attempts, particularly, recent suicidal behavior, current stressors and potential protective factors (eg, positive reasons for living, strong social support), family history of suicide or mental illness or recent exposure to suicide, impulsivity and potential for risk to others, including history of violence or violent or homicidal ideas, plans, or intentions, and putting one's affairs in order (eg, giving away possessions, writing a will). In addition, although the measure focuses on the initial visit, it is critical that suicide risk be monitored especially for the 90 days following the initial visit and throughout MDD treatment.
Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet. Cardiovascular disease, including stroke, is the leading cause of death in the United States. More than 92.1 million American adults have one or more types of cardiovascular disease. Specifically, more than 16 million adults (20 years and older) have coronary heart disease (CHD), over 8 million adults have angina, more than 7 million adults have had a myocardial infarction (MI), over 7 million adults have had a stroke, and nearly 7 million adults 40 years of age and older have peripheral artery disease (Benjamin et al., 2017). It is estimated that by 2030 more than 44 percent of Americans will have a form of cardiovascular disease (Heidenreich et al., 2011). In 2011, the total cost of cardiovascular disease and stroke in the United States was estimated to be $320 billion. This total includes direct costs such as the cost of physicians and other health professionals, hospital services, prescribed medications and home health care, as well as indirect costs due to loss of productivity from premature mortality (Benjamin et al., 2017). By 2030, direct medical costs for cardiovascular disease are projected to increase to nearly $918 billion (Heidenreich, 2011). Antiplatelet medications, such as aspirin and clopidogrel, are drugs that inhibit platelets from clumping together and forming clots. Their use in the secondary prevention of cardiovascular events is well established. In patients who are at high risk because they already have occlusive cardiovascular disease, long-term antiplatelet therapy reduces the yearly risk of serious vascular events (MI, stroke, death) by about twenty-five percent (Antiplatelet Trialists' Collaboration, 1994; 2002; 2009). A more recent systematic review of the literature confirmed the benefits of antiplatelet therapy in reducing death from cardiovascular causes, MI, or stroke (Cheng, 2013). Antiplatelet agents also have a beneficial effect in reducing all-cause mortality and fatal cardiovascular events in patients with peripheral arterial disease (Wong et al., 2011).
Controlling High Blood Pressure. Hypertension, or high blood pressure, is a very common and dangerous condition that increases risk for heart disease and stroke, two of the leading causes of death for Americans (Farley et al., 2010). Compared with other dietary, lifestyle, and metabolic risk factors, high blood pressure is the leading cause of death in women and the second-leading cause of death in men, behind smoking (Danaei et al., 2011). Approximately 1 in 3 U.S. adults, or about 70 million people, have high blood pressure but only about half (52%) of these people have their high blood pressure under control. Additionally, data from NHANES 2011 to 2012 found that 17.2% of U.S. adults are not aware they have hypertension (Nwankwo et al., 2013). Projections show that by 2030, approximately 41.4% of US adults will have hypertension, an increase of 8.4% from 2012 estimates (Heidenreich et al., 2011). The estimated direct and indirect cost of high blood pressure for 2011 is $46.4 billion. This total includes direct costs such as the cost of physicians and other health professionals, hospital services, prescribed medications and home health care, as well as indirect costs due to loss of productivity from premature mortality (Mozaffarian et al., 2015). Projections show that by 2030, the total cost of high blood pressure could increase to an estimated $274 billion (Heidenreich et al., 2011). Better control of blood pressure has been shown to significantly reduce the probability that undesirable and costly outcomes will occur. In clinical trials, antihypertensive therapy has been associated with reductions in stroke incidence (35-40%), myocardial infarction (20-25%) and heart failure (>50%) (Chobanian et al., 2003). Thus, the relationship between the measure (control of hypertension) and the long-term clinical outcomes listed is well established.
Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy. Diabetic retinopathy is a leading cause of new cases of legal blindness among working-age Americans and represents a leading cause of blindness in this age group worldwide. (Klein, 2007). In 2005-2008, the estimated prevalence of diabetic retinopathy and vision-threatening diabetic retinopathy was 28.5 percent among persons with diabetes aged 40 years and older (Zhang, 2010). Approximately 1.5% of adults with diabetes had proliferative diabetic retinopathy and 2.7% had clinically significant macular edema (Zhang, 2010). Several level 1 RCT studies demonstrate the ability of timely treatment to reduce the rate and severity of vision loss from diabetes (Diabetic Retinopathy Study -- DRS, Early Treatment Diabetic Retinopathy Study -- ETDRS). Necessary examination prerequisites to applying the study results are that the presence and severity of both peripheral diabetic retinopathy and macular edema be accurately documented. In the RAND chronic disease quality project, while administrative data indicated that roughly half of the patients had an eye exam in the recommended time period, chart review data indicated that only 19% had documented evidence of a dilated examination (McGlynn, 2003). Thus, ensuring timely treatment that could prevent 95% of the blindness due to diabetes requires the performance and documentation of key examination parameters. The documented level of severity of retinopathy and the documented presence or absence of macular edema assists with the on-going plan of care for the patient with diabetic retinopathy.
Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use. Individuals with bipolar disorder or major depression have high rates of co-morbid substance abuse and should be screened for substance use disorders. Between 40-70% of people with bipolar disorder have a history of substance use disorder. A current or past co-morbid substance use disorder may lead to worse outcomes for bipolar disorders, including more symptoms, more suicide attempts, longer episodes and lower quality of life. Substance abuse may obscure or exacerbate mood swings that have no other apparent external cause. Substance abuse may also precipitate mood episodes or be used by patients to self-treat in an attempt to improve the symptoms of episodes. Patients suffering from major depressive disorder with co-morbid addiction are more likely to require hospitalization, more likely to attempt suicide and less likely to comply with treatment than are patients with these disorders of similar severity not complicated by these factors.
Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment. Research has shown that patients with major depressive disorder are at a high risk for suicide attempts and completion - among the most significant and devastating sequelae of the disease. Suicide risk is a critical consideration in children and adolescents with MDD and an important aspect of care that should be assessed at each visit and subsequently managed to minimize that risk. Additionally, the importance of the assessments is underscored by research that indicates that many individuals who die by suicide do make contact with primary care providers and mental health services beforehand. More specifically, approximately 15% of suicide victims aged 35 years or younger had seen a mental health professional within 1 month of suicide while approximately 23% had seen a primary care provider within 1 month of suicide.
Intensive Care Unit Venous Thromboembolism Prophylaxis (VTE-2). Approximately two-thirds of cases of Deep Vein Thrombosis (DVT) or Pulmonary Emboli (PE) are associated with recent hospitalization. This is consistent with the 2001 report by Agency for Healthcare Research and Quality (Shojania, et al., 2001). AHRQ reports that 'the appropriate application of effective preventive measures in hospitals has major potential for improving patient safety, by reducing the incidence of VTE.' Almost all hospitalized patients have at least one risk factor for Venous Thromboembolism (VTE), and approximately 40% have three or more risk factors. Without thromboprophylaxis, the incidence of objectively confirmed, hospital-acquired DVT is approximately 10% to 40% among medical or general surgical patients and 40% to 60% following major orthopedic surgery (Geerts et al., 2008). Commonly, criteria for admission to the Intensive Care Unit (ICU) itself, puts patient's at an increased risk for developing VTE, and subsequent increased risk of morbidity from PE. Some risk factors are related to the acute illness present that allowed for the admission to the ICU unit, and some risk factors may be acquired during the ICU admission due to subsequent medical treatments, for example limitations of mobility, presence of central venous lines or mechanical ventilation and subsequent pharmacological paralysis. Reports of DVT in the population of ICU patients vary in relation to the acuity of the illness in this population. DVT in ICU patients diagnosed with routine venography or Doppler ultrasound found ranges between 10% to 100%. Five studies prospectively screened patients who were not receiving thromboprophylaxis during their ICU stays. The rates of DVT using Fibrinogen Uptake Test, Doppler Ultrasound or venography ranged from 13 to 31% (Geerts et al., 2008). It is essential for all ICUs to assess each patient upon admission to the ICU unit, a change in level of status, for the need for VTE prophylaxis due to the above increased development of risk factors (Geerts, et al., 2004). Some select surgeries have previously been monitored in the Surgical Care Improvement Project; since performance on these surgeries has achieved very high levels, they are not included in this measure.
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented. Hypertension is a prevalent condition that affects approximately 66.9 million people in the United States. It is estimated that about 20-40% of the adult population has hypertension; the majority of people over age 65 have a hypertension diagnosis (Appleton SL, et. al., 2012 and Luehr D, et. al., 2012). Winter (2013) noted that 1 in 3 American adults have hypertension and the lifetime risk of developing hypertension is 90% (Winter KH, et. al., 2013). The African American population or non-Hispanic Blacks, the elderly, diabetics and those with chronic kidney disease are at increased risk of stroke, myocardial infarction and renal disease. Non-Hispanic Blacks have the highest prevalence at 38.6% (Winter KH, et. al., 2013). Hypertension is a major risk factor for ischemic heart disease, left ventricular hypertrophy, renal failure, stroke and dementia (Luehr D, et. al., 2012). Hypertension is the most common reason for adult office visits other than pregnancy. Garrison (2013) stated that in 2007, 42 million ambulatory visits were attributed to hypertension (Garrison GM and Oberhelman S, 2013). It also has the highest utilization of prescription drugs. Numerous resources and treatment options are available, yet only about 40-50% of the hypertensive patients have their blood pressure under control (<140/90) (Appleton SL, et. al., 2012, Luehr D, et. al., 2012). In addition to medication non-compliance, poor outcomes are also attributed to poor adherence to lifestyle changes such as a low-sodium diet, weight loss, increased exercise and limiting alcohol intake. Many adults find it difficult to continue medications and lifestyle changes when they are asymptomatic. Symptoms of elevated blood pressure usually do not occur until secondary problems arise such as with vascular diseases (myocardial infarction, stroke, heart failure and renal insufficiency) (Luehr D, et. al., 2012). Appropriate follow-up after blood pressure measurement is a pivotal component in preventing the progression of hypertension and the development of heart disease. Detection of marginally or fully elevated blood pressure by a specialty clinician warrants referral to a provider familiar with the management of hypertension and prehypertension. The 2010 ACCF/AHA Guideline for the Assessment of Cardiovascular Risk in Asymptomatic Adults continues to support using a global risk score such as the Framingham Risk Score, to assess risk of coronary heart disease (CHD) in all asymptomatic adults (Greenland P, et. al., 2010). Lifestyle modifications have demonstrated effectiveness in lowering blood pressure (JNC 7, 2003). The synergistic effect of several lifestyle modifications results in greater benefits than a single modification alone. Baseline diagnostic/laboratory testing establishes if a co-existing underlying condition is the etiology of hypertension and evaluates if end organ damage from hypertension has already occurred. Landmark trials such as ALLHAT have repeatedly proven the efficacy of pharmacologic therapy to control blood pressure and reduce the complications of hypertension. Follow-up intervals based on blood pressure control have been established by the JNC 7 and the USPSTF.
Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture. This measure is expected to increase recording of patient risk for fracture data and decrease the amount of inappropriate DXA scans. Current osteoporosis guidelines underscore the importance of screening women for osteoporosis if they are 1) 65 years or older or 2) younger than 65 if they have a fracture risk 'equal to or greater than that of a 65-year-old white woman who has no additional risk factors.' Clinical information, such as age, body mass index (BMI), parental fracture history, and tobacco and alcohol use, can be used to determine a woman's fracture risk (USPSTF, 2011). Additionally, there are potentially avoidable harms associated with screening for osteoporosis in general, including exposure to radiation, false positive exams, and resulting side effects from unnecessary osteoporosis medications, which add costs to an already burdened health care system (Lim, 2009).
Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver (CAC-3). Asthma is the most common chronic disease in children and a major cause of morbidity and health care costs nationally (Adams, et al, 2001). In 2005, 5.2% of children with asthma had at least one asthma attack in the previous year (3.8 million children). Nearly two of every three children who currently have asthma had at least one attack in the past 12 months. Chronic asthma in children can account for an annual loss of more than 14 million school days per year, according to the Asthma and Allergy Foundation (Asthma Facts and Figures). It is clear from multiple sources of evidence including the National Heart Lung and Blood Institute (NHLBI) Guidelines that actual self-management of asthma by the patient or caregiver leads to more positive outcomes. Appropriate self-management is completely reliant upon patient education. Patient education is more effective when it aims at training self-management skills that will alter behavior (Norris, et al, 2001). NHLBI notes that review of asthma management by expert clinicians is necessary but not sufficient to improve outcomes. Active learning, participating and verbalization of understanding are all strategies that a healthcare organization must incorporate with parents or caregivers of asthmatic children in order for them to understand and make the appropriate changes that can impact the disease in the child in question. Education programs have been effective in improving lung function, feelings of self-esteem, and consequently decreased missed days of school in children and adolescents (Phipatanakul, 2004). Acute hospitalization follow up is imperative to a successful discharge from the hospital, providing the caretaker with the resource information needed to contact the follow up facility, medical office or clinic setting (Schatz, et al, 2009). Environmental control consists of removal of asthma triggers from the environment. Multiple studies support the positive correlation of household maintenance factors such as control of cockroach dust, and the number of acute asthma attacks in asthmatic children (McConnell, et al, 2005 and Eggleston, et al, 2005). Evidence from Carter et al, (2001) supported by the National Institute of Health (NIH) grant found specifically that reduction in triggers such as household conditions i.e. dust mites, cockroach, cats and presence of molds and fungus, resulted in a decrease in acute care visits and an overall positive outcome of children. Rescue action education related to early recognition of symptoms and proper action to control incidence of asthma attacks is noted to have positive outcomes for asthmatic children (Ducharme and Bhogal, 2008).
Preventive Care and Screening: Screening for Depression and Follow-Up Plan. Depression is a serious medical illness associated with higher rates of chronic disease, increased health care utilization, and impaired functioning (Pratt, Brody 2014). 2014 U.S. survey data indicate that 2.8 million (11.4 percent) adolescents aged 12 to 17 had a major depressive episode (MDE) in the past year and that 15.7 million (6.6 percent) adults aged 18 or older had at least one MDE in the past year, with 10.2 million adults (4.3 percent) having one MDE with severe impairment in the past year (Center for Behavioral Health Statistics and Quality, 2015). Data indicate that severity of depressive symptoms factor into having difficulty with work, home, or social activities. For example, as the severity of depressive symptoms increased, rates of having difficulty with work, home, or social activities related to depressive symptoms increased. For those twelve and older with mild depressive symptoms, 45.7% reported difficulty with activities and those with severe depressive symptoms, 88.0% reported difficulty (Pratt & Brody, 2014). Children and teens with major depressive disorder (MDD) has been found to have difficulty carrying out their daily activities, relating to others, and growing up healthy with an increased risk of suicide (Siu and USPSTF, 2016). Additionally, among pregnant women, especially during the perinatal period, depression and other mood disorders, such as bipolar disorder and anxiety disorders, can have devastating effects on women, infants, and families. Maternal suicide rates rise over hemorrhage and hypertensive disorders as a cause of maternal mortality (American College of Obstetricians and Gynecologists, 2015). Negative outcomes associated with depression make it crucial to screen in order to identify and treat depression in its early stages. While Primary Care Providers (PCPs) serve as the first line of defense in the detection of depression, studies show that PCPs fail to recognize up to 50% of depressed patients (Borner, 2010, p. 948). 'Coyle et al. (2003), suggested that the picture is more grim for adolescents, and that more than 70% of children and adolescents suffering from serious mood disorders go unrecognized or inadequately treated' (Borner, 2010, p. 948). 'In nationally representative U.S. surveys, about 8% of adolescents reported having major depression in the past year. Only 36% to 44% of children and adolescents with depression receive treatment, suggesting that the majority of depressed youth are undiagnosed and untreated' (Sui, A. and USPSTF, 2016). Evidence supports that screening for depression in pregnant and postpartum women is of moderate net benefit and treatment options for positive depression screening should be available for patients twelve and older including pregnant and postpartum women. If preventing negative patient outcomes is not enough, the substantial economic burden of depression for individuals and society alike makes a case for screening for depression on a regular basis. Depression imposes economic burden through direct and indirect costs. 'In the United States, an estimated $22.8 billion was spent on depression treatment in 2009, and lost productivity cost an additional estimated $23 billion in 2011' (Sui, A. and USPSTF, 2016). This measure seeks to align with clinical guideline recommendations as well as the Healthy People 2020 recommendation for routine screening for mental health problems as a part of primary care for both children and adults (U.S. Department of Health and Human Services, 2014) and makes an important contribution to the quality domain of community and population health.
Hearing Screening Prior To Hospital Discharge (EHDI-1a). Birthing facility staff should review the effectiveness and timeliness of screening relative to nursery discharge. Benchmarks set within the EHCP may trigger hospital or jurisdictional compliance activities, such as re-writing of procedural guidelines or re-training of screening staff.
Median Time from ED Arrival to ED Departure for Discharged ED Patients (ED-3). In recent times, EDs have experienced significant overcrowding. Although once only a problem in large, urban, teaching hospitals, the phenomenon has spread to other suburban and rural healthcare organizations. According to a 2002 national U.S. survey, more than 90 percent of large hospitals report EDs operating 'at' or 'over' capacity. Overcrowding and heavy emergency resource demand have led to a number of problems, including ambulance refusals, prolonged patient waiting times, increased suffering for those who wait, rushed and unpleasant treatment environments, and potentially poor patient outcomes. Approximately one third of hospitals in the U.S. report increases in ambulance diversion in a given year, whereas up to half report crowded conditions in the ED. In a recent national survey, 40 percent of hospital leaders viewed ED crowding as a symptom of workforce shortages. ED crowding may result in delays in the administration of medication such as antibiotics for pneumonia and has been associated with perceptions of compromised emergency care. For patients with non-ST-segment-elevation myocardial infarction, long ED stays were associated with decreased use of guideline-recommended therapies and a higher risk of recurrent myocardial infarction. When EDs are overwhelmed, their ability to respond to community emergencies and disasters may be compromised.
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease. 'Cardiovascular disease (CVD) is the leading cause of death in the United States, causing approximately 1 of every 7 deaths in the United States in 2011. In 2011, stroke caused approximately 1 of every 20 deaths in the United States and the estimated annual costs for CVD and stroke were $320.1 billion, including $195.6 billion in direct costs (hospital services, physicians and other professionals, prescribed medications, home health care, and other medical durables) and $124.5 billion in indirect costs from lost future productivity (cardiovascular and stroke premature deaths). CVD costs more than any other diagnostic group' (Mozaffarian et al., 2015). Data collected between 2009 and 2012 indicates that more than 100 million U.S. adults, 20 years or older, had total cholesterol levels equal to 200 mg/dL or more, while almost 31 million had levels 240 mg/dL or more (Mozaffarian et al., 2015). Elevated blood cholesterol is a major risk factor for CVD and statin therapy has been associated with a reduced risk of CVD. Numerous randomized trials have demonstrated that treatment with a statin reduces LDL-C, and reduces the risk of major cardiovascular events by approximately 20 percent (Ference, 2015). In 2013, guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults were published (see Stone et al., 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a Report of the American College of Cardiology [ACC]/American Heart Association [AHA] Task Force on Practice Guidelines). This guideline was published by an Expert Panel, which synthesized evidence from randomized controlled trials to identify people most likely to benefit from cholesterol-lowering therapy. The ACC/AHA Guideline recommendations are intended to provide a strong evidence-based foundation for the treatment of blood cholesterol for the primary and secondary prevention and treatment of Atherosclerotic Cardiovascular Disease (ASCVD) in adult men and women (21 years of age or older). The document concludes the addition of statin therapy reduces the risk of ASCVD among high-risk individuals, defined as follows: individuals with clinical ASCVD, with LDL-C >= 190 mg/dL, or with diabetes and LDL-C 70-189 mg/dL (Stone et al., 2013). However, one study that surveyed U.S. cardiovascular practices participating in the PINNACLE registry, found that 32.4 percent of patients with an indication for statins under the 2013 ACC/AHA cholesterol guidelines were not currently receiving them (Maddox et al., 2014). Although, systematic evidence review found that statins are safe drugs with low incidence of conditions or diseases attributable to statin use (Law et al., 2006). Overall, the Statin Safety Expert Panel that participated in an NLA Statin Safety Task Force meeting in October 2013 reaffirms the general safety of statin therapy. The panel members concluded that for most patients requiring statin therapy, the potential benefits of statin therapy outweigh the potential risks. In general terms, the benefits of statins to prevent non-fatal myocardial infarction, revascularization, stroke, and CVD mortality, far outweighs any potential harm related to the drug (Jacobson, 2014).
HIV Screening. Human immunodeficiency virus (HIV) is a communicable infection that leads to a progressive disease with a long asymptomatic period. Approximately 50,000 persons in the United States are newly infected with HIV each year (Prejean 2011). Without treatment, most persons develop acquired immunodeficiency syndrome (AIDS) within 10 years of HIV infection. Antiretroviral therapy (ART) delays this progression and increases the length of survival, but it is most effective when initiated during the asymptomatic phase. It is estimated that on average an HIV-infected person aged 25 years who receives high quality health care will live an additional 39 years (Lohse 2007). DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents recommends antiretroviral therapy for all HIV-infected individuals to reduce the risk of disease progression (regardless of CD4 cell count at diagnosis) (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2017). CDC estimates that almost 16% of the 1.1 million adults and adolescents living with HIV infection in the United States are unaware of their infection (Centers for Disease Control and Prevention 2013). Among persons diagnosed with HIV in 2011, one quarter were diagnosed with Stage 3 HIV (AIDS) at the time of HIV diagnosis (Centers for Disease Control and Prevention 2010). Median CD4 count at diagnosis is less than 350 cells/mm3 (Althoff 2010). HIV screening identifies infected persons who were previously unaware of their infection, which enables them to seek medical and social services that can improve their health and the quality and length of their lives. Additionally, using ART with high levels of medication adherence has been shown to substantially reduce risk for HIV transmission (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2017). Based on the National Health Interview Survey, fewer than half of persons 18 and older reported ever having been tested for HIV as of 2010 (Centers for Disease Control and Prevention 2014).
Closing the Referral Loop: Receipt of Specialist Report. Problems in the outpatient referral and consultation process have been documented, including lack of timeliness of information and inadequate provision of information between the specialist and the requesting physician (Gandhi, 2000; Forrest, 2000; Stille, 2005). In a study of physician satisfaction with the outpatient referral process, Gandhi et al. (2000) found that 68% of specialists reported receiving no information from the primary care provider prior to referral visits, and 25% of primary care providers had still not received any information from specialists 4 weeks after referral visits. In another study of 963 referrals (Forrest, 2000), pediatricians scheduled appointments with specialists for only 39% and sent patient information to the specialists in only 51% of the time. In a 2006 report to Congress, MedPAC found that care coordination programs improved quality of care for patients, reduced hospitalizations, and improved adherence to evidence-based care guidelines, especially among patients with diabetes and CHD. Associations with cost-savings were less clear; this was attributed to how well the intervention group was chosen and defined, as well as the intervention put in place. Additionally, cost-savings were usually calculated in the short-term, while some argue that the greatest cost-savings accrue over time (MedPAC, 2006). Improved mechanisms for information exchange could facilitate communication between providers, whether for time-limited referrals or consultations, on-going co-management, or during care transitions. For example, a study by Branger et al. (1999) found that an electronic communication network that linked the computer-based patient records of physicians who had shared care of patients with diabetes significantly increased frequency of communications between physicians and availability of important clinical data. There was a 3-fold increase in the likelihood that the specialist provided written communication of results if the primary care physician scheduled appointments and sent patient information to the specialist (Forrest, 2000). Care coordination is a focal point in the current health care reform and our nation's ambulatory health information technology (HIT) framework. The National Priorities Partnership recently highlighted care coordination as one of the most critical areas for development of quality measurement and improvement (NPP, 2008).
HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis. Although advances in the management of HIV and AIDS diseases have been made, Pneumocystis jiroveci pneumonia (PCP) remains an important complication and cause of morbidity. Without PCP prophylaxis, patients with HIV/AIDS are at increased risk of developing PCP, especially when CD4 cell counts falls to 200 cells/mm3-250 cells/mm3 (Kaplan, 1998; Phair, 1990). PCP prophylaxis is very effective and has been demonstrated to prolong life. Data from Kaiser Permanente suggests that there is a gap in care related to the prescription of PCP prophylaxis for patients with HIV. According to 2005-2006 data from Kaiser Permanente California (both Northern and Southern), Georgia, and Oregon, only 71% of HIV-infected persons with a CD4<200 cells/mm3 received PCP prophylaxis (personal communication, 2007).
Primary PCI Received Within 90 Minutes of Hospital Arrival (AMI-8a). The early use of primary angioplasty in patients with ST-segment myocardial infarction (STEMI) results in a significant reduction in mortality and morbidity. The earlier primary coronary intervention is provided, the more effective it is (Brodie, 1998 and DeLuca, 2004). National guidelines recommend the prompt initiation of PCI in patients presenting with ST-elevation myocardial infarction (O'Gara, 2013; and Levine 2011).
Median Time from ED Arrival to ED Departure for Admitted ED Patients (ED-1). In recent times, EDs have experienced significant overcrowding. Although once only a problem in large, urban, teaching hospitals, the phenomenon has spread to other suburban and rural healthcare organizations. According to a 2002 national U.S. survey, more than 90% of large hospitals report EDs operating 'at' or 'over' capacity. Approximately one third of hospitals in the US report increases in ambulance diversion in a given year, whereas up to half report crowded conditions in the ED. In a recent national survey, 40% of hospital leaders viewed ED crowding as a symptom of workforce shortages. ED crowding may result in delays in the administration of medication such as antibiotics for pneumonia and has been associated with perceptions of compromised emergency care. For patients with non-ST-segment-elevation myocardial infarction, long ED stays were associated with decreased use of guideline-recommended therapies and a higher risk of recurrent myocardial infarction. Overcrowding and heavy emergency resource demand have led to a number of problems, including ambulance refusals, prolonged patient waiting times, increased suffering for those who wait, rushed and unpleasant treatment environments, and potentially poor patient outcomes. When EDs are overwhelmed, their ability to respond to community emergencies and disasters may be compromised.
Functional Status Assessment for Total Hip Replacement. Measuring functional status for patients undergoing total hip replacement permits longitudinal assessment - from the patient's perspective - of the impact of surgical intervention on pain, physical function, as well as health-related quality of life (Rothrock 2010).
Bone density evaluation for patients with prostate cancer and receiving androgen deprivation therapy. Androgen suppression as a treatment for prostate cancer can cause osteoporosis(Qaseem, 2008). Men undergoing prolonged androgen deprivation therapy (ADT) incur bone loss at a rate higher than menopausal women (Guise, 2007). In preserving bone health, the goal is to prevent or treat osteopenia/osteoporosis for the patient on ADT and to prevent or delay skeletal related events. The National Osteoporosis Foundation recommendations including a baseline assessment of bone density with a DEXA scan and daily calcium and Vitamin D supplementation (Watts, 2012). The DEXA scan is the gold standard for bone density screening. Men at risk for adverse bone consequences from chronic ADT do not always receive care according to evidence based guidelines. These findings call for improved processes that standardize evidence based practice including baseline and follow up bone density assessment (Watts, 2012).
Hypertension: Improvement in Blood Pressure. Hypertension, or high blood pressure, is a very common and dangerous condition that increases risk for heart disease and stroke, two of the leading causes of death for Americans (Farley et al., 2010). Compared with other dietary, lifestyle, and metabolic risk factors, high blood pressure is the leading cause of death in women and the second-leading cause of death in men, behind smoking (Danaei et al., 2011). Approximately 1 in 3 U.S. adults, or about 70 million people, have high blood pressure but only about half (52%) of these people have their high blood pressure under control. Additionally, data from NHANES 2011 to 2012 found that 17.2% of U.S. adults are not aware they have hypertension (Nwankwo et al., 2013). Projections show that by 2030, approximately 41.4% of US adults will have hypertension, an increase of 8.4% from 2012 estimates (Heidenreich et al., 2011). The estimated direct and indirect cost of high blood pressure for 2011 is $46.4 billion. This total includes direct costs such as the cost of physicians and other health professionals, hospital services, prescribed medications and home health care, as well as indirect costs due to loss of productivity from premature mortality (Mozaffarian et al., 2015). Projections show that by 2030, the total cost of high blood pressure could increase to an estimated $274 billion (Heidenreich et al., 2011). Better control of blood pressure has been shown to significantly reduce the probability that undesirable and costly outcomes will occur. In clinical trials, antihypertensive therapy has been associated with reductions in stroke incidence (35-40%), myocardial infarction (20-25%) and heart failure (>50%) (Chobanian et al., 2003). Thus, the relationship between the measure (control of hypertension) and the long-term clinical outcomes listed is well established.
Functional Status Assessment for Total Knee Replacement. Measuring functional status for patients undergoing total knee replacement permits longitudinal assessment - from the patient's perspective - of the impact of surgical intervention on pain, physical function, as well as health-related quality of life (Rothrock 2010).
Documentation of Current Medications in the Medical Record. Prescription medication use is common among adults of all ages, particularly older adults and adults with chronic conditions. On average, 81% of adults in the U.S. are taking at least one medication (prescription or nonprescription, vitamin/mineral, herbal/natural supplement); 29% are taking five or more. Older adults are the biggest consumers of medications with 17-19% of people 65 and older taking at least ten medications in a given week (Qato et al., 2008). In this context, maintaining an accurate and complete medication list has proven to be a challenging documentation endeavor for various health care provider settings. While most of outpatient encounters (2/3) result in providers prescribing at least one medication, hospitals have been the focus of medication safety efforts (Stock et al., 2009). Nassaralla et al. (2007) caution that this is at odds with the current trend, where patients with chronic illnesses are increasingly being treated in the outpatient setting and require careful monitoring of multiple medications. Additionally Nassaralla et al. (2007) reveal that it is in fact in outpatient settings where more fatal adverse drug events (ADE) occur when these are compared to those occurring in hospitals (1 of 131 outpatient deaths compared to 1 in 854 inpatient deaths). In the outpatient setting, adverse drug events (ADEs) occur 25% of the time and over one-third of these are considered preventable (Tache et al., 2011). Particularly vulnerable are patients over 65 years, with evidence suggesting that the rate of ADEs per 10,000 person per year increases with age; 25-44 years old at 1.3; 45-64 at 2.2, and 65 + at 3.8 (Sarkar et al., 2011). Another vulnerable group are chronically ill individuals. These population groups are more likely to experience ADEs and subsequent hospitalization. A multiplicity of providers and inadequate care coordination among them has been identified as barriers to collecting complete and reliable medication records. Data indicate that reconciliation and documentation continues to be poorly executed with discrepancies occurring in 92% (74 of 80 patients) of medication lists among admittance to the emergency room. Of 80 patients included in the study, the home medications were re ordered for 65% of patients on their admission and of the 65% the majority (29%) had a change in their dosing interval, while 23% had a change in their route of administration, and 13% had a change in dose. A total of 361 medication discrepancies, or the difference between the medications patients were taking before admission and those listed in there admission orders, were identified in at least 74 patients (Poornima et al., 2015). The study found that 'Through an appropriate reconciliation programme, around 80% of errors relating to medication and the potential harm caused by these errors could be reduced.' (Poornima et al., 2015, p. 243). Documentation of current medications in the medical record facilitates the process of medication review and reconciliation by the provider, which are necessary for reducing ADEs and promoting medication safety. The need for provider to provider coordination regarding medication records, and the existing gap in implementation, is highlighted in the American Medical Association's (AMA) Physician's Role in Medication Reconciliation (2007), which states that 'critical patient information, including medical and medication histories, current medications the patient is receiving and taking, and sources of medications, is essential to the delivery of safe medical care. However, interruptions in the continuity of care and information gaps in patient health records are common and significantly affect patient outcomes' (American Medical Association, 2007, p. 7). This is because clinical decisions based on information that is incomplete and/or inaccurate are likely to lead to medication error and ADEs. Weeks et al. (2010) noted similar barriers and identified the utilization of health information technology as an opportunity for facilitating the creation of universal medication lists. One 2015 meta-analysis showed an association between EHR documentation with an overall RR of 0.46 (95% CI = 0.38 to 0.55; P < 0.001) and ADEs with an overall RR of 0.66 (95% CI = 0.44 to 0.99; P = 0.045). This meta-analysis provides evidence that the use of the EHR can improve the quality of healthcare delivered to patients by reducing medication errors and ADEs (Campanella et al., 2016).
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan. BMI Above Normal Parameters. Obesity is a chronic, multifactorial disease with complex psychological, environmental (social and cultural), genetic, physiologic, metabolic and behavioral causes and consequences. The prevalence of overweight and obese people is increasing worldwide at an alarming rate in both developing and developed countries. Environmental and behavioral changes brought about by economic development, modernization and urbanization have been linked to the rise in global obesity. The health consequences are becoming apparent (ICSI 2013. p.6). Hales et al (2017), report that the prevalence of obesity among adults and youth in the United States was 39.8% and 18.5% respectively, from 2015-2016. They note that obesity prevalence was higher among adults in the 40-59 age bracket than those in the 20-39 age bracket, for both men and women. Hales et al. (2017) also disaggregated the data according to ethnicity and noted that obesity prevalence was higher among non-Hispanic black and Hispanic adults and youth when compared with other races ethnicities. While obesity prevalence was lower among non-Hispanic Asian men and women, obesity prevalence among men, was comparable between non-Hispanic black and non-Hispanic white men. Obesity prevalence was higher among Hispanic men compared with non-Hispanic black men. While the prevalence among non-Hispanic black and Hispanic women was comparable, the prevalence for both groups was higher than that of non-Hispanic white women. Most notably, Hales et al (2017), report that the prevalence of obesity in the United States remains higher than the Healthy People 2020 goals of 14.5% among youth and 30.5% among adults. More than a third of U.S. adults have a body mass index [BMI] >= 30 kg/m2; substantially at increased risk for diabetes and cardiovascular disease (CVD) (Flegal et al., 2012; Ogden et al., 2014). Behavioral weight management treatment has been identified as an effective first-line treatment for obesity with an average initial weight loss of 8-10%. This percentage weight loss is associated with a significant risk reduction for diabetes and CVD (Butryn et al., 2011; Wadden et al., 2012). Despite the availability of effective interventions, two-thirds of obese U.S. patients were not offered or referred to weight management treatment during their primary care visit between 2005 and 2006, (Ma et al., 2009). In addition, the rate of weight management counseling in primary care significantly decreased by 10% (40% to 30%) between 1995-1996 and 2007-2008 (Kraschnewski et al., 2013). This suggests that the availability of evidence based clinical guidelines since 2008 obesity management in primary care remains suboptimal (Fitzpatrick S.L., Stevens, V. J., 2017, pp 128-132). BMI continues to be a common and reasonably reliable measurement to identify overweight and obese adults who may be at an increased risk for future morbidity. Although good quality evidence supports obtaining a BMI, it is important to recognize it is not a perfect measurement. BMI is not a direct measure of adiposity and as a consequence it can over- or underestimate adiposity. BMI is a derived value that correlates well with total body fat and markers of secondary complications, eg, hypertension and dyslipidemia (Barlow, 2007). In contrast with waist circumference, BMI and its associated disease and mortality risk appear to vary among ethnic subgroups. Female African American populations appear to have the lowest mortality risk at a BMI of 26.2-28.5 kg/m2 and 27.1-30.2 kg/m2 for women and men, respectively. In contrast, Asian populations may experience lowest mortality rates starting at a BMI of 23 to 24 kg/m2. The correlation between BMI and diabetes risk also varies by ethnicity (LeBlanc, 2011. p.2-3) Screening for BMI and follow-up therefore is critical to closing this gap and contributes to quality goals of population health and cost reduction. However, due to concerns for other underlying conditions (such as bone health) or nutrition related deficiencies providers are cautioned to use clinical judgment and take these into account when considering weight management programs for overweight patients, especially the elderly (NHLBI Obesity Education Initiative, 1998, p. 91). BMI below Normal Parameters: On the other end of the body weight spectrum is underweight (BMI <18.5 kg/m2), which is equally detrimental to population health. When compared to normal weight individuals(BMI 18.5-25 kg/m2), underweight individuals have significantly higher death rates with a Hazard Ratio of 2.27 and 95% confidence intervals (CI) = 1.78, 2.90 (Borrell & Lalitha (2014). Poor nutrition or underlying health conditions can result in underweight (Fryer & Ogden, 2012). The National Health and Nutrition Examination Survey (NHANES) results from the 2007-2010 indicate that women are more likely to be underweight than men (2012). Therefore patients should be equally screened for underweight and followed up with nutritional counselling to reduce mortality and morbidity associated with underweight.
Anticoagulation Therapy for Atrial Fibrillation/Flutter (STK-03). Nonvalvular atrial fibrillation (NVAF) is a common arrhythmia and an important risk factor for stroke. It is one of several conditions and lifestyle factors that have been identified as risk factors for stroke. It has been estimated that over 2 million adults in the United States have NVAF. While the median age of patients with atrial fibrillation is 75 years, the incidence increases with advancing age. For example, The Framingham Heart Study noted a dramatic increase in stroke risk associated with atrial fibrillation with advancing age, from 1.5% for those 50 to 59 years of age to 23.5% for those 80 to 89 years of age. Furthermore, a prior stroke or transient ischemic attack (TIA) are among a limited number of predictors of high stroke risk within the population of patients with atrial fibrillation. Therefore, much emphasis has been placed on identifying methods for preventing recurrent ischemic stroke as well as preventing first stroke. Prevention strategies focus on the modifiable risk factors such as hypertension, smoking, and atrial fibrillation. Analysis of five placebo-controlled clinical trials investigating the efficacy of warfarin in the primary prevention of thromboembolic stroke, found the relative risk of thromboembolic stroke was reduced by 68% for atrial fibrillation patients treated with warfarin. The administration of anticoagulation therapy, unless there are contraindications, is an established effective strategy in preventing recurrent stroke in high stroke risk-atrial fibrillation patients with TIA or prior stroke.
Antithrombotic Therapy By End of Hospital Day 2 (STK-05). The effectiveness of antithrombotic agents in reducing stroke mortality, stroke-related morbidity and recurrence rates has been studied in several large clinical trials. While the use of these agents for patients with acute ischemic stroke and transient ischemic attacks continues to be the subject of study, substantial evidence is available from completed studies. Data at this time suggest that antithrombotic therapy should be administered within 2 days of symptom onset in acute ischemic stroke patients to reduce stroke mortality and morbidity as long as no contraindications exist. Anticoagulants at doses to prevent venous thromboembolism are insufficient antithrombotic therapy to prevent recurrent ischemic stroke or TIA.
Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists. The literature reflects that fluoride varnish when applied to the teeth of high-risk children, reduces, in conjunction with anticipatory guidance provided to the caregiver, the risk of the child developing caries
Children Who Have Dental Decay or Cavities. Dental cavities have been identified as the most common chronic disease for children. Data from the National Health and Nutrition Examination Survey from 2011-2012 showed that approximately 23% of children aged 2-5 years had dental caries in primary teeth. Untreated tooth decay in primary teeth among children aged 2-8 was twice as high for Hispanic and non-Hispanic black children compared with non-Hispanic white children. Among those aged 6-11, 27% of Hispanic children had any dental caries in permanent teeth compared with nearly 18% of non-Hispanic white and Asian children. About three in five adolescents aged 12-19 had experienced dental caries in permanent teeth, and 15% had untreated tooth decay.
Maternal Depression Screening. Maternal depression is a common condition with potentially serious and far-reaching consequences. Rates of depression for pregnant and/or postpartum women range from 12-15%, with postpartum depression rates in some U.S. areas estimated to be as high as 20% (Ko et al. 2017; Gaynes et al. 2005; Bennett et al. 2004). Depression has significant consequences for women, their infants and families. Women with untreated depression during pregnancy are at risk of developing severe postpartum depression and suicidality, and of delivering premature or low birthweight babies (Chan et al. 2014). Postpartum depression hinders infant attachment and bonding and can lead to developmental disorders that last into adolescence (Field 2010; Kingston et al. 2012; Dawson et al. 1999). During infancy, important caregiving activities such as breastfeeding, sleep, adherence to well-child visits and vaccine schedules can be compromised in depressed mothers (Kingston et al. 2012; Gregory et al. 2015; Minkovitz et al. 2005). Clinical guidelines recommend that maternal screenings for depression should occur where there are adequate systems in place (Sui et al. 2016; ACOG 2015; Yonkers et al. 2009). Adequate systems in place means having the appropriate systems and clinical staff to ensure that patients are screened and, if screened positive, are appropriately diagnosed and treated with evidence-based care or referred to a setting that can provide the necessary care (Sui et al. 2016). Guidelines also recommend that providers maintain regular follow-up with patients diagnosed with depression and use a standardized tool to track symptoms (Mitchell et al. 2013). Standardized instruments are useful in identifying meaningful change in clinical outcomes over time. Despite these clinical recommendations, maternal depression is often underdiagnosed and untreated. Nearly 60% of women with depressive symptoms do not receive a clinical diagnosis, and 50% of women with a diagnosis do not receive any treatment (Ko et al. 2012). This measure encourages clinicians to screen new mothers for depression.
Functional Status Assessments for Congestive Heart Failure. Patients living with congestive heart failure (CHF) often have poor functional status and health-related quality of life, which declines as the disease progresses (Allen et al. 2012). In addition, their care is often complicated by multiple comorbidities. To assist in managing these complex patients, the American College of Cardiology Foundation and American Heart Association recommend collecting initial and repeat assessments of a patient's function and ability to complete desired activities of daily living (Hunt et al. 2009). The American Heart Association has also released scientific statements emphasizing the collection of patient-reported health status (for example, functional limitations, symptom burden, quality of life) from CHF patients as an important means of establishing a dynamic conversation between patient and provider regarding care goals and the patient's priorities (Allen et al. 2012; Rumsfeld et al. 2013).
Exclusive Breast Milk Feeding (PC-05). Exclusive breast milk feeding for the first 6 months of neonatal life has long been the expressed goal of World Health Organization (WHO), Department of Health and Human Services (DHHS), American Academy of Pediatrics (AAP) and American College of Obstetricians and Gynecologists (ACOG). ACOG has recently reiterated its position (ACOG, 2007). A recent Cochrane review substantiates the benefits (Kramer et al., 2002). Much evidence has now focused on the prenatal and intrapartum period as critical for the success of exclusive (or any) BF (Centers for Disease Control and Prevention [CDC], 2007; Petrova et al., 2007; Shealy et al., 2005; Taveras et al., 2004). Exclusive breast milk feeding rate during birth hospital stay has been calculated by the California Department of Public Health for the last several years using newborn genetic disease testing data. Healthy People 2010 and the CDC have also been active in promoting this goal.
Abstract eCQM Definition.
A concept represented by a code or codes.
A formal terminology system.
The version of the vocabulary being used, if applicable.
Coding of a concept, drawn from a controlled vocabulary. Includes the vocabulary and version, if applicable. May include a display text, and a descriptor expressing the intended interpretation of the code.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Cognitive Assessment valueset (2.16.840.1.113883.3.526.3.1332).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Cognitive Assessment
(Clinical Focus: This value set contains codes to identify a colonoscopy.),(Data Element Scope: This value set was intended to identify patients who had a colonoscopy.),(Inclusion Criteria: Includes codes that indicate a colonoscopy.),(Exclusion Criteria: None.) -- ObservableCode constrained to codes in the Colonoscopy valueset (2.16.840.1.113883.3.464.1003.108.12.1020).
(Clinical Focus: This value set contains codes to identify a colonoscopy.),(Data Element Scope: This value set was intended to identify patients who had a colonoscopy.),(Inclusion Criteria: Includes codes that indicate a colonoscopy.),(Exclusion Criteria: None.) -- Subject constrained to the Colonoscopy
(Clinical Focus: This set of values contains care regimes used to define comfort measure care.),(Data Element Scope: The intent of this data element is to identify patients receiving comfort measures care. Using the Quality Data Model, this particular element would map to the Intervention category.),(Inclusion Criteria: Include SNOMEDCT regime and therapy codes for comfort measures, terminal care, dying care, and hospice care.),(Exclusion Criteria: None.) -- ActivityCode constrained to codes in the Comfort Measures valueset (1.3.6.1.4.1.33895.1.3.0.45).
(Clinical Focus: This set of values contains care regimes used to define comfort measure care.),(Data Element Scope: The intent of this data element is to identify patients receiving comfort measures care. Using the Quality Data Model, this particular element would map to the Intervention category.),(Inclusion Criteria: Include SNOMEDCT regime and therapy codes for comfort measures, terminal care, dying care, and hospice care.),(Exclusion Criteria: None.) -- Subject constrained to the Comfort Measures
(Clinical Focus: This set of values contains care regimes used to define comfort measure care.),(Data Element Scope: The intent of this data element is to identify patients receiving comfort measures care. Using the Quality Data Model, this particular element would map to the Intervention category.),(Inclusion Criteria: Include SNOMEDCT regime and therapy codes for comfort measures, terminal care, dying care, and hospice care.),(Exclusion Criteria: None.) -- Subject constrained to the Comfort Measures
To meet criteria using this datatype, the communication indicated by the Communication QDM category and its corresponding value set must be communicated from a patient to a provider. Timing: The time the communication occurs, or is sent; Author dateTime.
To meet criteria using this datatype, the communication indicated by the Communication QDM category and its corresponding value set must be communicated from a provider to a patient. Timing: The time the communication occurs, or is sent; Author dateTime.
To meet criteria using this datatype, the communication indicated by the Communication QDM category and its corresponding value set must be communicated from one provider to another. Timing: The time the communication occurs, or is sent; Author dateTime.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Competing Conditions for Respiratory Conditions valueset (2.16.840.1.113883.3.464.1003.102.12.1017)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Complications of Pregnancy, Childbirth and the Puerperium valueset (2.16.840.1.113883.3.464.1003.111.12.1012)
Elements included or documented as part of evaluations or test panels. Examples include: specific questions included in assesments, tests included in a laboratory test panel, observations included in a cardiac exam during a physical examination. Each assessment, diagnostic study, laboratory test, physical exam or procedure may have one or more components.
A set of one or more statements or aggregations that should be interpreted together, exchanged as a collection, or may be aggregregated for the purpose of clinical input or output.
A disorder of structure or function in a human, animal, or plant, especially one that produces specific signs or symptoms, and is not simply a direct result of physical injury
Whether the condition was present when the patient was admitted.
(Clinical Focus: Infectious Conditions),(Data Element Scope: HIV infection as a condition),(Inclusion Criteria: HIV infection as a condition),(Exclusion Criteria: Conditions associated with HIV infection.) -- ResultValue constrained to codes in the Conditions Due To Human Immunodeficiency Virus (HIV) valueset (2.16.840.1.113762.1.4.1056.54)
(Clinical Focus: This set of values contains diagnoses that represent conditions possibly justifying elective delivery prior to 39 weeks gestation.),(Data Element Scope: The intent of this data element is to identify conditions possibly justifying elective delivery prior to 39 weeks gestation. Using the Quality Data Model, this particular element will map to the 'Diagnosis' category.),(Inclusion Criteria: Include ICD 10 CM and SNOMED CT codes that identify conditions possibly justifying elective delivery prior to 39 weeks gestation.),(Exclusion Criteria: None.)
(Clinical Focus: This set of values contains diagnoses that represent conditions possibly justifying elective delivery prior to 39 weeks gestation.),(Data Element Scope: The intent of this data element is to identify conditions possibly justifying elective delivery prior to 39 weeks gestation. Using the Quality Data Model, this particular element will map to the 'Diagnosis' category.),(Inclusion Criteria: Include ICD 10 CM and SNOMED CT codes that identify conditions possibly justifying elective delivery prior to 39 weeks gestation.),(Exclusion Criteria: None.) -- ResultValue constrained to codes in the Conditions Possibly Justifying Elective Delivery Prior to 39 Weeks Gestation valueset (2.16.840.1.113883.3.117.1.7.1.286)
-- ResultValue constrained to codes in the Congenital absence of cervix (disorder) valueset (drc-2aee01847828ef298f92805dcf74e47c73f590a1ce12a00cedb235f1e691e47e)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Conjugated Estrogens valueset (2.16.840.1.113883.3.464.1003.196.12.1357).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Conjugated Estrogens / Medroxyprogesterone valueset (2.16.840.1.113883.3.464.1003.196.12.1324).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Conjugated Estrogens / Medroxyprogesterone
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Conjugated Estrogens
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Consultant Report valueset (2.16.840.1.113883.3.464.1003.121.12.1006)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Contact or Office Visit valueset (2.16.840.1.113762.1.4.1080.5).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Contact or Office Visit
An electronic means of contacting an organization or individual.
Mime type of the content, with charset etc.
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Contraceptive Medications valueset (2.16.840.1.113883.3.464.1003.196.12.1080).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Contraceptive Medications
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Contraceptive Medications
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Corneal Edema valueset (2.16.840.1.113883.3.526.3.1418)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Corneal Opacity and Other Disorders of Cornea valueset (2.16.840.1.113883.3.526.3.1419)
(Clinical Focus: This set of values contains diagnosis that represent a cornual ectopic pregnancy),(Data Element Scope: The intent of this data element is to identify a cornual ectopic pregnancy.),(Inclusion Criteria: Includes codes representing cornual ectopic pregancy),(Exclusion Criteria: Excludes codes representing ectopic pregnancies other than cornual ectopic pregnancies, such as tubal ectopic pregnancies.) -- ResultValue constrained to codes in the Cornual Ectopic Pregnancy valueset (2.16.840.1.113762.1.4.1110.12)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Coronary Artery Bypass Graft valueset (2.16.840.1.113883.3.464.1003.104.12.1002).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Coronary Artery Bypass Graft
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Coronary Artery Disease No MI valueset (2.16.840.1.113883.3.526.3.369)
A correction factor that is applied to the sampled data points before they are added to the origin.
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Counseling for Nutrition valueset (2.16.840.1.113883.3.464.1003.195.12.1003).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Counseling for Nutrition
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Counseling for Physical Activity valueset (2.16.840.1.113883.3.464.1003.118.12.1035).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Counseling for Physical Activity
How many times the event should take place during one recurrence interval, for example, to specify 3-4 times per day, the CountPerInterval should be 3 to 4.
Country - a nation as commonly understood or generally accepted, expressed in ISO 3166 Alpha-2 (2-letter) codes.
The point in time when the information was recorded in the system of record.
(Clinical Focus: This value set contains codes to identify a computed tomography colongraphy.),(Data Element Scope: This value set was intended to identify patients who had a computed tomography colonography.),(Inclusion Criteria: Includes codes that indicate a computed tomography colonography.),(Exclusion Criteria: None.) -- ObservableCode constrained to codes in the CT Colonography valueset (2.16.840.1.113883.3.464.1003.108.12.1038).
(Clinical Focus: This value set contains codes to identify a computed tomography colongraphy.),(Data Element Scope: This value set was intended to identify patients who had a computed tomography colonography.),(Inclusion Criteria: Includes codes that indicate a computed tomography colonography.),(Exclusion Criteria: None.) -- Subject constrained to the CT Colonography
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Cup to Disc Ratio valueset (2.16.840.1.113883.3.526.3.1333).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Cup to Disc Ratio
(Clinical Focus: This set of values is used to distinguish that a patient is a current smoker whether light, heavy, or occasional; the patient has a current history of cigarette, cigar, or pipe smoking as communicated to and documented by the health care provider.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: )
(Clinical Focus: This set of values contains codes that identify patients with a diagnosis of cushings syndrome.),(Data Element Scope: This value set is developed for the diagnosis QDM datatype. It can potentially be used for other datatypes as well.),(Inclusion Criteria: Include all diagnosis codes for hypercortiosolism, pituitary ACTH hypersecretion, and cushings syndrome. Also Include syndrome induced by tumors, alcohol, and depression.),(Exclusion Criteria: N/A) -- ResultValue constrained to codes in the Cushings Syndrome valueset (2.16.840.1.113883.3.464.1003.117.12.1009)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Cyclobenzaprine Hydrochloride valueset (2.16.840.1.113883.3.464.1003.196.12.1372).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Cyclobenzaprine Hydrochloride
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Cyproheptadine valueset (2.16.840.1.113883.3.464.1003.196.12.1277).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Cyproheptadine
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Cysts of Iris, Ciliary Body, and Anterior Chamber valueset (2.16.840.1.113883.3.526.3.1420)
A quotidian landmark, such as rising, mealtime, or bedtime, when an event should take place.
-- ObjectTypeCode constrained to codes in the Dapsone 100 MG / Pyrimethamine 12.5 MG Oral Tablet valueset (drc-e7bcd5fe05acffa0b0210240916ebdd5cb263ec9e30c7f943a055e4f406b38c4).
-- Subject constrained to the Dapsone 100 MG / Pyrimethamine 12.5 MG Oral Tablet
Birth date
A day of the week that the pattern should take place.
(Clinical Focus: This grouping of value sets identifies procedures that are commonly used for capturing an emergency decision to admit a patient to an inpatient hospital setting.),(Data Element Scope: The intent of this data element is to identify an emergency decision to admit a patient to an inpatient hospital setting. Using the Quality Data Model, this particular element will map to the 'Encounter' category.),(Inclusion Criteria: Include codes representing an emergency decision to admit a patient to an inpatient hospital setting utilizing the SNOMED CT system.),(Exclusion Criteria: Exclude codes that do not meet the inclusion criteria.) -- ActivityCode constrained to codes in the Decision to Admit to Hospital Inpatient valueset (2.16.840.1.113883.3.117.1.7.1.295).
(Clinical Focus: This grouping of value sets identifies procedures that are commonly used for capturing an emergency decision to admit a patient to an inpatient hospital setting.),(Data Element Scope: The intent of this data element is to identify an emergency decision to admit a patient to an inpatient hospital setting. Using the Quality Data Model, this particular element will map to the 'Encounter' category.),(Inclusion Criteria: Include codes representing an emergency decision to admit a patient to an inpatient hospital setting utilizing the SNOMED CT system.),(Exclusion Criteria: Exclude codes that do not meet the inclusion criteria.) -- Subject constrained to the Decision to Admit to Hospital Inpatient
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Degeneration of Macula and Posterior Pole valueset (2.16.840.1.113883.3.526.3.1453)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Degenerative Disorders of Globe valueset (2.16.840.1.113883.3.526.3.1454)
(Clinical Focus: This set of values contain codes commonly used in the outpatient setting to identify patients who had a live birth or delivery.),(Data Element Scope: The intent of this data element is identify patients who had a live birth or delivery. Using the Quality Data Model, this particular element would map to the 'Procedure, Performed' element.),(Inclusion Criteria: The codes used in this value set can be reasonably used to identify patients who had a live birth or delivery.),(Exclusion Criteria: None) -- ResultValue constrained to codes in the Delivery - Diagnosis valueset (2.16.840.1.113883.3.67.1.101.1.278)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Delivery Live Births valueset (2.16.840.1.113883.3.464.1003.111.12.1015).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Delivery Live Births
(Clinical Focus: This set of values contain codes commonly used in the outpatient setting to identify patients who had a live birth or delivery.),(Data Element Scope: The intent of this data element is identify patients who had a live birth or delivery. Using the Quality Data Model, this particular element would map to the 'Procedure, Performed' element.),(Inclusion Criteria: The codes used in this value set can be reasonably used to identify patients who had a live birth or delivery.),(Exclusion Criteria: None) -- ObservableCode constrained to codes in the Delivery - Procedure valueset (2.16.840.1.113762.1.4.1078.5).
(Clinical Focus: This set of values contain codes commonly used in the outpatient setting to identify patients who had a live birth or delivery.),(Data Element Scope: The intent of this data element is identify patients who had a live birth or delivery. Using the Quality Data Model, this particular element would map to the 'Procedure, Performed' element.),(Inclusion Criteria: The codes used in this value set can be reasonably used to identify patients who had a live birth or delivery.),(Exclusion Criteria: None) -- Subject constrained to the Delivery - Procedure
(Clinical Focus: This group of value sets contain procedures that represent delivery procedures.),(Data Element Scope: The intent of this data element is to identify delivery procedures. Using the Quality Data Model, this particular element will map to the 'Procedure' category.),(Inclusion Criteria: Include codes that identify delivery procedures.),(Exclusion Criteria: None.) -- ObservableCode constrained to codes in the Delivery Procedures valueset (2.16.840.1.113762.1.4.1045.59).
(Clinical Focus: This group of value sets contain procedures that represent delivery procedures.),(Data Element Scope: The intent of this data element is to identify delivery procedures. Using the Quality Data Model, this particular element will map to the 'Procedure' category.),(Inclusion Criteria: Include codes that identify delivery procedures.),(Exclusion Criteria: None.) -- Subject constrained to the Delivery Procedures
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Dementia & Mental Degenerations valueset (2.16.840.1.113883.3.526.3.1005)
The divisor of a fraction.
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Dental Caries valueset (2.16.840.1.113883.3.464.1003.125.12.1004)
(Clinical Focus: This set of values includes diagnoses of depression, indicating that there is a current diagnosis of a depressed state or actual depressive disorder whether recurrent, chronic, or diagnosed as moderate, major, or severe.),(Data Element Scope: ),(Inclusion Criteria: Included are depression diagnoses as well as depression as indicated as depressed mood or features, a single episode, or type of psychosis, or a reaction as related to depression.),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Depression diagnosis valueset (2.16.840.1.113883.3.600.145)
(Clinical Focus: This set of values contains medications that are commonly used to treat adolescent depression.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Depression medications - adolescent valueset (2.16.840.1.113883.3.600.469).
(Clinical Focus: This set of values contains medications that are commonly used to treat adolescent depression.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Depression medications - adolescent
(Clinical Focus: This set of values contains medications that are commonly used to treat adult depression.),(Data Element Scope: ),(Inclusion Criteria: These medications include antidepressants as well as other recommended depressive management medications.),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Depression medications - adult valueset (2.16.840.1.113883.3.600.470).
(Clinical Focus: This set of values contains medications that are commonly used to treat adult depression.),(Data Element Scope: ),(Inclusion Criteria: These medications include antidepressants as well as other recommended depressive management medications.),(Exclusion Criteria: ) -- Subject constrained to the Depression medications - adult
(Clinical Focus: This set of values contains encounter codes during which a depression screen could be assessed and documented through an exam, assessment, interview, or evaluation.),(Data Element Scope: ),(Inclusion Criteria: Includes wellness visits, annual visits, therapy evaluations, or primary or specialist physician office visits where a depression screen could be conducted.),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Depression Screening Encounter Codes valueset (2.16.840.1.113883.3.600.1916).
(Clinical Focus: This set of values contains encounter codes during which a depression screen could be assessed and documented through an exam, assessment, interview, or evaluation.),(Data Element Scope: ),(Inclusion Criteria: Includes wellness visits, annual visits, therapy evaluations, or primary or specialist physician office visits where a depression screen could be conducted.),(Exclusion Criteria: ) -- Subject constrained to the Depression Screening Encounter Codes
Indicates the source of information in the case the Entry has been created by logical extension or modification of one or more source entries.
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Desiccated Thyroid valueset (2.16.840.1.113883.3.464.1003.196.12.1354).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Desiccated Thyroid
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Desipramine valueset (2.16.840.1.113883.3.464.1003.196.12.1278).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Desipramine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Detoxification Visit valueset (2.16.840.1.113883.3.464.1003.101.12.1059).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Detoxification Visit
Device represents an instrument, apparatus, implement, machine, contrivance, implant, in-vitro reagent, or other similar or related article, including a component part or accessory, intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and not dependent on being metabolized to achieve any of its primary intended purposes.
Data elements that meet criteria using this datatype should document that the device indicated by the QDM category and its corresponding value set is in use, or impacts or alters the treatment, care plan, or encounter (e.g., an antithrombotic device has been placed on the patient's legs to prevent thromboembolism, or a cardiac pacemaker is in place). Timing: The Relevant Period addresses: startTime – When the device is inserted or first used stopTime – when the device is removed or last used
Data elements that meet criteria using this datatype should document an order for the device indicated by the QDM category and its corresponding value set. Timing: The time the order is signed; Author dateTime.
(Clinical Focus: Xray studies to determine bone density.),(Data Element Scope: The intent of this data element is to identify patients with low bone mineral density),(Inclusion Criteria: 1 or more axial sites, axial skeleton (hips, pelvis, spine) or 1 or more appendicular skeleton sites (radius, wrist, heel)),(Exclusion Criteria: Study other than DEXA) -- ObservableCode constrained to codes in the DEXA Dual Energy Xray Absorptiometry, Bone Density for Urology Care valueset (2.16.840.1.113762.1.4.1151.38).
(Clinical Focus: Xray studies to determine bone density.),(Data Element Scope: The intent of this data element is to identify patients with low bone mineral density),(Inclusion Criteria: 1 or more axial sites, axial skeleton (hips, pelvis, spine) or 1 or more appendicular skeleton sites (radius, wrist, heel)),(Exclusion Criteria: Study other than DEXA) -- Subject constrained to the DEXA Dual Energy Xray Absorptiometry, Bone Density for Urology Care
(Clinical Focus: Xray studies to determine bone density.),(Data Element Scope: The intent of this data element is to identify patients with low bone mineral density),(Inclusion Criteria: 1 or more axial sites, axial skeleton (hips, pelvis, spine) or 1 or more appendicular skeleton sites (radius, wrist, heel)),(Exclusion Criteria: Study other than DEXA) -- Subject constrained to the DEXA Dual Energy Xray Absorptiometry, Bone Density for Urology Care
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Dexbrompheniramine valueset (2.16.840.1.113883.3.464.1003.196.12.1375).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Dexbrompheniramine / Dextromethorphan / Phenylephrine valueset (2.16.840.1.113883.3.464.1003.196.12.1426).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Dexbrompheniramine / Dextromethorphan / Phenylephrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Dexbrompheniramine Maleate / Pseudoephedrine Hydrochloride valueset (2.16.840.1.113883.3.464.1003.196.12.1429).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Dexbrompheniramine Maleate / Pseudoephedrine Hydrochloride
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Dexbrompheniramine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Dexbrompheniramine / Pseudoephedrine valueset (2.16.840.1.113883.3.464.1003.196.12.1430).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Dexbrompheniramine / Pseudoephedrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Dexchlorpheniramine / Dextromethorphan / Pseudoephedrine valueset (2.16.840.1.113883.3.464.1003.196.12.1300).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Dexchlorpheniramine / Dextromethorphan / Pseudoephedrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Dexchlorpheniramine / Pseudoephedrine valueset (2.16.840.1.113883.3.464.1003.196.12.1425).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Dexchlorpheniramine / Pseudoephedrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Dextromethorphan / Diphenhydramine / Phenylephrine valueset (2.16.840.1.113883.3.464.1003.196.12.1397).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Dextromethorphan / Diphenhydramine / Phenylephrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Dextromethorphan / Doxylamine valueset (2.16.840.1.113883.3.464.1003.196.12.1452).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Dextromethorphan / Doxylamine
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Diabetes valueset (2.16.840.1.113883.3.464.1003.103.12.1001)
-- ObservableCode constrained to codes in the Diabetic foot examination (regime/therapy) valueset (drc-529dc4d622e3c7acea52e699b35e8154cd879f8e64e48c790de34a6585ea4ba4).
-- Subject constrained to the Diabetic foot examination (regime/therapy)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Diabetic Macular Edema valueset (2.16.840.1.113883.3.526.3.1455)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Diabetic Nephropathy valueset (2.16.840.1.113883.3.464.1003.109.12.1004)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Diabetic Retinopathy valueset (2.16.840.1.113883.3.526.3.327)
Coded diagnoses/problems addressed during the encounter. The diagnoses attribute is intended to capture ALL diagnoses, including principal diagnosis. Use of the Encounter, Performed: diagnoses attribute and the Diagnosis datatype is redundant for relating the diagnosis to the Encounter, Performed. The Encounter, Performed: diagnoses syntax is preferred. Referencing the same diagnosis using Encounter, Performed (diagnoses attribute) and Diagnosis (datatype) should only occur if the measure must define a specified length of a prevalence period, e.g., The measure must assure that the diagnoseis have been present for at least some defined time period before the encounter, and were addressed during the Encounter
Condition/Diagnosis/Problem represents a practitioner’s identification of a patient’s disease, illness, injury, or condition. This category contains a single datatype to represent all of these concepts: Diagnosis. A practitioner determines the diagnosis by means of examination, diagnostic test results, patient history, and/or family history. Diagnoses are usually considered unfavorable, but may also represent neutral or favorable conditions that affect a patient’s plan of care (e.g., pregnancy). The QDM does not prescribe the source of diagnosis data in the EHR. Diagnoses may be found in a patient’s problem list, encounter diagnosis list, claims data, or other sources within the EHR. The preferred terminology for diagnoses is SNOMED-CT, but diagnoses may also be encoded using ICD-9/10. The Diagnosis datatype should not be used for differential diagnoses or rule-out diagnoses (neither of which are currently supported by the QDM).
(Clinical Focus: This set of values contains situations or actual assessment findings where the diagnosis of hypertension is currently documented in the medical record.),(Data Element Scope: ),(Inclusion Criteria: Includes diagnoses that hypertension is ultimately present in, such as renal disease, pregnancy (pre-eclampsia, pregnancy induced hypertension), vascular, malignant, or benign disease. This value set also includes hypertension that may be documented as fear of hypertension or poor or good hypertension control with the intent to capture the patient has an active finding of hypertension.),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Diagnosis of hypertension valueset (2.16.840.1.113883.3.600.263)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Diagnostic Studies During Pregnancy valueset (2.16.840.1.113883.3.464.1003.111.12.1008).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Diagnostic Studies During Pregnancy
Diagnostic Study represents any kind of medical test performed as a specific test or series of steps to aid in diagnosing or detecting disease (e.g., to establish a diagnosis, measure the progress or recovery from disease, confirm that a person is free from disease).12 The QDM defines diagnostic studies as those that are not performed in organizations that perform testing on samples of human blood, tissue, or other substance from the body. Diagnostic studies may make use of digital images and textual reports. Such studies include but are not limited to imaging studies, cardiology studies (electrocardiogram, treadmill stress testing), pulmonary-function testing, vascular laboratory testing, and others.
Data elements that meet criteria using this datatype should document a request by a clinician or appropriately licensed care provider to an appropriate provider or organization to perform the diagnostic study indicated by the QDM category and its corresponding value set. The request may be in the form of a consultation or a direct order to the organization that performs the diagnostic study. Diagnostic studies are those that are not performed in the clinical laboratory. Such studies include but are not limited to imaging studies, cardiology studies (electrocardiogram, treadmill stress testing), pulmonary function testing, vascular laboratory testing, and others. Timing: The time the order is signed; Author dateTime.
Data elements that meet criteria using this datatype should document the completion of the diagnostic study indicated by the QDM category and its corresponding value set. Timing: The Relevant Period addresses: startTime – when the diagnostic study is initiated stopTime – when the diagnostic study is completed Examples: 1) Initiation of a treadmill stress test to the time the treadmill stress test has completed. 2) Initiation of the ultrasound study until completion of the ultrasound study
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Dialysis Education valueset (2.16.840.1.113883.3.464.1003.109.12.1016).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Dialysis Education
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Dialysis Services valueset (2.16.840.1.113883.3.464.1003.109.12.1013).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Dialysis Services
-- ObservableCode constrained to codes in the Diastolic blood pressure valueset (drc-b4bdff81834575092e7f8d5dea158c56df03b046f06adfb7ce4cf4741507294a).
-- Subject constrained to the Diastolic blood pressure
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Dicyclomine valueset (2.16.840.1.113883.3.464.1003.196.12.1279).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Dicyclomine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Dienogest / Estradiol Multiphasic valueset (2.16.840.1.113883.3.464.1003.196.12.1398).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Dienogest / Estradiol Multiphasic
(Clinical Focus: This set of values represent dietary intake other than breast milk.),(Data Element Scope: The intent of this data element is to identify dietary intake other than breast milk. Using the Quality Data Model, this particular element will map to the 'substance' category.),(Inclusion Criteria: Include SNOMED CT codes that identify dietary intake other than breast milk.),(Exclusion Criteria: Exclude codes that represent breast milk.) -- ObjectTypeCode constrained to codes in the Dietary Intake Other than Breast Milk valueset (2.16.840.1.113883.3.117.1.7.1.27).
(Clinical Focus: This set of values represent dietary intake other than breast milk.),(Data Element Scope: The intent of this data element is to identify dietary intake other than breast milk. Using the Quality Data Model, this particular element will map to the 'substance' category.),(Inclusion Criteria: Include SNOMED CT codes that identify dietary intake other than breast milk.),(Exclusion Criteria: Exclude codes that represent breast milk.) -- Subject constrained to the Dietary Intake Other than Breast Milk
(Clinical Focus: This set of values incorporates dietary referrals, diet education or diet recommendation, or nutritional counseling that is documented as discussed or ordered by the health care provider.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Dietary Recommendations valueset (2.16.840.1.113883.3.600.1515).
(Clinical Focus: This set of values incorporates dietary referrals, diet education or diet recommendation, or nutritional counseling that is documented as discussed or ordered by the health care provider.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Dietary Recommendations
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Dimenhydrinate valueset (2.16.840.1.113883.3.464.1003.196.12.1500).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Dimenhydrinate
The number of sample points at each time point. If this value is greater than one, then the dimensions will be interlaced - all the sample points for a point in time will be recorded at once.
(Clinical Focus: This set of values contains medications that represent Dinoprostone, commonly used in the delivery setting for induction of labor.),(Data Element Scope: The intent of this data element is to identify patients who receive dinoprostone for the purpose of inducing labor. Using the Quality Data Model, this particular element will map to the 'Medication' category.),(Inclusion Criteria: Include RxNorm codes that identify medications that contain Dinoprostone as the single ingredient. Drug forms consistent with vaginal administration should be included.),(Exclusion Criteria: Medications that have multiple ingredients should be excluded. Drug forms that are not consistent with vaginal administration should not be included. The codes should be limited to those which are for human use and which are able to be prescribed in the US.) -- ObjectTypeCode constrained to codes in the Dinoprostone valueset (2.16.840.1.113762.1.4.1045.56).
(Clinical Focus: This set of values contains medications that represent Dinoprostone, commonly used in the delivery setting for induction of labor.),(Data Element Scope: The intent of this data element is to identify patients who receive dinoprostone for the purpose of inducing labor. Using the Quality Data Model, this particular element will map to the 'Medication' category.),(Inclusion Criteria: Include RxNorm codes that identify medications that contain Dinoprostone as the single ingredient. Drug forms consistent with vaginal administration should be included.),(Exclusion Criteria: Medications that have multiple ingredients should be excluded. Drug forms that are not consistent with vaginal administration should not be included. The codes should be limited to those which are for human use and which are able to be prescribed in the US.) -- Subject constrained to the Dinoprostone
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Diphenhydramine Hydrochloride valueset (2.16.840.1.113883.3.464.1003.196.12.1371).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Diphenhydramine Hydrochloride
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Diphenhydramine / Ibuprofen valueset (2.16.840.1.113883.3.464.1003.196.12.1293).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Diphenhydramine / Ibuprofen
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Diphenhydramine / Phenylephrine valueset (2.16.840.1.113883.3.464.1003.196.12.1307).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Diphenhydramine / Phenylephrine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Dipyridamole valueset (2.16.840.1.113883.3.464.1003.196.12.1349).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Dipyridamole
(Clinical Focus: This set of values contains codes which identify a select medication-a direct thrombin inhibitor.),(Data Element Scope: The intent of this data element is to identify patients who are on a direct thrombin inhibitor. Using the Quality Data Model, this data element maps to the Medication category.),(Inclusion Criteria: Only include codes which represent direct thrombin inhibitors. These are RxNorm codes.),(Exclusion Criteria: None) -- ObjectTypeCode constrained to codes in the Direct Thrombin Inhibitor valueset (2.16.840.1.113883.3.117.1.7.1.205).
(Clinical Focus: This set of values contains codes which identify a select medication-a direct thrombin inhibitor.),(Data Element Scope: The intent of this data element is to identify patients who are on a direct thrombin inhibitor. Using the Quality Data Model, this data element maps to the Medication category.),(Inclusion Criteria: Only include codes which represent direct thrombin inhibitors. These are RxNorm codes.),(Exclusion Criteria: None) -- Subject constrained to the Direct Thrombin Inhibitor
The disposition, or location to which the patient is transferred at the time of hospital discharge.
(Clinical Focus: This set of values contains procedures used to represent the discharge of a patient to a health care facility for hospice care.),(Data Element Scope: The intent of this data element is to identify the final place or setting to which the patient was discharged on the day of discharge from a particular inpatient encounter. This particular value set intends to identify patients who where discharged to a health care facility for hospice care. Using the Quality Data Model, this particular value set is used with the Attribute of 'Discharge status' used with the 'Encounter' category.),(Inclusion Criteria: Only SNOMED CT codes representing health care facilities for hospice care should be included.),(Exclusion Criteria: None)
(Clinical Focus: This set of values contains procedures used to represent the discharge of a patient to home for hospice care.),(Data Element Scope: The intent of this data element is to identify the final place or setting to which the patient was discharged on the day of discharge from a particular inpatient encounter. This particular value set intends to identify patients who where discharged to home for hospice care. Using the Quality Data Model, this particular value set is used with the Attribute of 'Discharge status' used with the 'Encounter' category.),(Inclusion Criteria: Only SNOMED CT codes representing discharge to home for hospice care should be included.),(Exclusion Criteria: None)
(Clinical Focus: This set of values contains procedures that represent the discharge of a patient to rehabilitation facility.),(Data Element Scope: The intent of this data element is to identify the final place or setting to which the patient was discharged on the day of discharge from a particular inpatient encounter. This particular value set intends to identify patients who where discharged to a rehabilitation facility. Using the Quality Data Model, this particular value set is used with the Attribute of 'Discharge status' used with the 'Encounter' category.),(Inclusion Criteria: Only SNOMED CT codes representing rehabilitation facilities should be included.),(Exclusion Criteria: None)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Discharge Services - Hospital Inpatient valueset (2.16.840.1.113883.3.464.1003.101.12.1007).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Discharge Services - Hospital Inpatient
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Discharge Services - Hospital Inpatient Same Day Discharge valueset (2.16.840.1.113883.3.464.1003.101.12.1006).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Discharge Services - Hospital Inpatient Same Day Discharge
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Discharge Services - Nursing Facility valueset (2.16.840.1.113883.3.464.1003.101.12.1013).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Discharge Services - Nursing Facility1 valueset (2.16.840.1.113883.3.464.1003.101.11.1065).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Discharge Services - Nursing Facility1
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Discharge Services - Nursing Facility
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Discharge Services- Observation Care valueset (2.16.840.1.113883.3.464.1003.101.12.1039).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Discharge Services- Observation Care
(Clinical Focus: This set of values contains procedures used to represent the discharge of a patient to an acute care facility.),(Data Element Scope: The intent of this data element is to identify the final place or setting to which the patient was discharged on the day of discharge from a particular inpatient encounter. This particular value set intends to identify patients who where discharged to an acute care facility. Using the Quality Data Model, this particular value set is used with the Attribute of 'Discharge Disposition' used with the Encounter category.),(Inclusion Criteria: Only SNOMED CT codes representing short-term acute care hospitals, including specialty hospitals, should be included.),(Exclusion Criteria: None)
(Clinical Focus: This set of values contains procedures used to represent the discharge of a patient to home or police custody.),(Data Element Scope: The intent of this data element is to identify the final place or setting to which the patient was discharged on the day of discharge from a particular inpatient encounter. This particular value set intends to identify patients who were discharged to home or police custody. Using the Quality Data Model, this particular value set is used with the Attribute of 'Discharge status' used with the 'Encounter' category.),(Inclusion Criteria: This value set includes concepts that identify a patient's discharge destination as either a home setting or police custody.),(Exclusion Criteria: Discharge concepts that identify a patient's discharge status as to anywhere else other than home or police custody.)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Disopyramide valueset (2.16.840.1.113883.3.464.1003.196.12.1311).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Disopyramide
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Disorders of Optic Chiasm valueset (2.16.840.1.113883.3.526.3.1457)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Disorders of the Immune System valueset (2.16.840.1.113883.3.464.1003.120.12.1001)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Disorders of Visual Cortex valueset (2.16.840.1.113883.3.526.3.1458)
A string meant for reading by a person, for example, accompanying a code.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Disseminated Chorioretinitis and Disseminated Retinochoroiditis valueset (2.16.840.1.113883.3.526.3.1459)
The measure of space separating two objects or points.
The name of the administrative area at a level below that of a state but above that of a city or town. In the US, a county. Outside the US, a district or the equivalent. (Source: HL7 FHIR).
-- ObservableCode constrained to codes in the Documentation of current medications (procedure) valueset (drc-7542bdf7898575dd5dbcc0ef15228f64d5b7e42c83a9ccf6cc8e7085eeb2361e).
-- Subject constrained to the Documentation of current medications (procedure)
Details of how medication is taken or is to be taken, i.e., the quantity (mg, cc, tablets) to be taken at a single administration.
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Drospirenone / Estradiol valueset (2.16.840.1.113883.3.464.1003.196.12.1410).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Drospirenone / Estradiol
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the DTaP Vaccine valueset (2.16.840.1.113883.3.464.1003.196.12.1214).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the DTaP Vaccine Administered valueset (2.16.840.1.113883.3.464.1003.110.12.1022).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the DTaP Vaccine Administered
The length of time that something continues.
A range of durations.
(Clinical Focus: This value set identifies patients with a DXA scan.),(Data Element Scope: This value set was intended to map to the QDM data type of Diagnostic Study, but has the potential to be used in additional ways.),(Inclusion Criteria: Includes scans of the general body, spine, and the limbs.),(Exclusion Criteria: Excludes codes specific to DXA scans of the hip.) -- ObservableCode constrained to codes in the DXA (Dual energy Xray Absorptiometry) Scan valueset (2.16.840.1.113883.3.464.1003.113.12.1051).
(Clinical Focus: This value set identifies patients with a DXA scan.),(Data Element Scope: This value set was intended to map to the QDM data type of Diagnostic Study, but has the potential to be used in additional ways.),(Inclusion Criteria: Includes scans of the general body, spine, and the limbs.),(Exclusion Criteria: Excludes codes specific to DXA scans of the hip.) -- Subject constrained to the DXA (Dual energy Xray Absorptiometry) Scan
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- ResultValue constrained to codes in the Dysthymia valueset (2.16.840.1.113883.3.67.1.101.1.254)
(Clinical Focus: The primary purpose of this value set is capture that a 12 lead EKG was ordered by the health care provider.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the ECG 12 lead or study order valueset (2.16.840.1.113883.3.600.2448).
(Clinical Focus: The primary purpose of this value set is capture that a 12 lead EKG was ordered by the health care provider.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the ECG 12 lead or study order
The date and time span for which something is active, valid, or in force.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Egg Substance valueset (2.16.840.1.113883.3.526.3.1537)
(Clinical Focus: This set of values contains codes that identify patients with a diagnosis of Ehlers Danlos Syndrome.),(Data Element Scope: This value set is developed for the diagnosis QDM datatype. It can potentially be used for other datatypes as well.),(Inclusion Criteria: Include all diagnosis codes for Ehlers-Danlos Syndrome.),(Exclusion Criteria: N/A) -- ResultValue constrained to codes in the Ehlers Danlos Syndrome valueset (2.16.840.1.113883.3.464.1003.113.12.1047)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Ejection Fraction valueset (2.16.840.1.113883.3.526.3.1134).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Ejection Fraction
(Clinical Focus: This value set contains diagnoses and procedures used to define electrocardiogram (ECG).),(Data Element Scope: The intent of this data element is to identify patients who receive the diagnostic test electrocardiogram (ECG). Using the Quality Data Model, this particular element would map to the Diagnostic Study category.),(Inclusion Criteria: Include codes that identify patients receiving an electrocardiogram (ECG).),(Exclusion Criteria: None.) -- ObservableCode constrained to codes in the Electrocardiogram (ECG) valueset (2.16.840.1.113883.3.666.5.735).
(Clinical Focus: This value set contains diagnoses and procedures used to define electrocardiogram (ECG).),(Data Element Scope: The intent of this data element is to identify patients who receive the diagnostic test electrocardiogram (ECG). Using the Quality Data Model, this particular element would map to the Diagnostic Study category.),(Inclusion Criteria: Include codes that identify patients receiving an electrocardiogram (ECG).),(Exclusion Criteria: None.) -- Subject constrained to the Electrocardiogram (ECG)
Abstract class defining the common metadata of all types of encapsulated data, such as images.
(Clinical Focus: This set of values identifies procedures representing an emergency department encounter.),(Data Element Scope: The intent of this data element is to identify patients who have had an emergency department encounter. Using the Quality Data Model, this particular element will map to the 'Encounter' category.),(Inclusion Criteria: Include codes representing an emergency department visit encounter utilizing the SNOMED CT code system.),(Exclusion Criteria: None) -- ActivityCode constrained to codes in the Emergency Department Visit valueset (2.16.840.1.113883.3.117.1.7.1.292).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Emergency Department Visit1 valueset (2.16.840.1.113883.3.464.1003.101.12.1010).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Emergency Department Visit1
(Clinical Focus: This set of values identifies procedures representing an emergency department encounter.),(Data Element Scope: The intent of this data element is to identify patients who have had an emergency department encounter. Using the Quality Data Model, this particular element will map to the 'Encounter' category.),(Inclusion Criteria: Include codes representing an emergency department visit encounter utilizing the SNOMED CT code system.),(Exclusion Criteria: None) -- Subject constrained to the Emergency Department Visit
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Encephalopathy due to Childhood Vaccination valueset (2.16.840.1.113883.3.464.1003.114.12.1007)
Encounter represents an identifiable grouping of healthcare-related activities characterized by the entity relationship between the subject of care and a healthcare provider; such a grouping is determined by the healthcare provider.13 A patient encounter represents interaction between a healthcare provider and a patient with a face-to-face patient visit to a clinician’s office, or any electronically remote interaction with a clinician for any form of diagnostic treatment or therapeutic event. Encounters can be billable events but are not limited to billable interactions. Each encounter has an associated location or modality within which it occurred (such as an office, home, electronic methods, phone encounter, or telemedicine methods). The encounter location is the patient’s location at the time of measurement. Different levels of interaction can be specified in the value associated with the element while modes of interaction (e.g., telephone) may be modeled using the data flow attribute.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Encounter-Influenza valueset (2.16.840.1.113883.3.526.3.1252).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Encounter-Influenza
(Clinical Focus: This set of values identify the most common inpatient encounter types.),(Data Element Scope: The intent of this data element is to identify patients who have had an inpatient encounter. Using the Quality Data Model, this particular element will map to the 'encounter' category.),(Inclusion Criteria: Only SNOMED CT codes representing inpatient encounter should be included.),(Exclusion Criteria: None.) -- ActivityCode constrained to codes in the Encounter Inpatient valueset (2.16.840.1.113883.3.666.5.307).
(Clinical Focus: This set of values identify the most common inpatient encounter types.),(Data Element Scope: The intent of this data element is to identify patients who have had an inpatient encounter. Using the Quality Data Model, this particular element will map to the 'encounter' category.),(Inclusion Criteria: Only SNOMED CT codes representing inpatient encounter should be included.),(Exclusion Criteria: None.) -- Subject constrained to the Encounter Inpatient
Data elements that meet criteria using this datatype should document that an order for the encounter indicated by the QDM category and its corresponding value set has been recommended. Timing: The time the order is signed; Author dateTime.
Data elements that meet criteria using this datatype should document that the encounter indicated by the QDM category and its corresponding value set is in progress or has been completed. Timing: The Relevant Period addresses: startTime – The time the encounter began (admission time) stopTime – The time the encounter ended (discharge time). The Author dateTime addresses when an Encounter is documented. Documentation can occur at the beginning, during, at the end or subsequent to the end of an Encounter. The Author dateTime should be used only if the Relevant Period cannot be obtained. The Location Period is an attribute of the attribute facility location addresses: startTime = the time the patient arrived at the location; stopTime = the time the patient departed from the location
(Clinical Focus: This grouping value set contains procedures used to define endotracheal intubation.),(Data Element Scope: The intent of this data element is to identify patients who receive endotracheal intubation as a medical procedure. Using the Quality Data Model, this particular element would map to the Procedure, Performed datatype.),(Inclusion Criteria: Include codes that identify patients receiving an endotracheal airway inserted into the trachea. This is a grouping of ICD10PCS and SNOMEDCT codes.),(Exclusion Criteria: None) -- ObservableCode constrained to codes in the Endotracheal Intubation valueset (2.16.840.1.113762.1.4.1045.69).
(Clinical Focus: This grouping value set contains procedures used to define endotracheal intubation.),(Data Element Scope: The intent of this data element is to identify patients who receive endotracheal intubation as a medical procedure. Using the Quality Data Model, this particular element would map to the Procedure, Performed datatype.),(Inclusion Criteria: Include codes that identify patients receiving an endotracheal airway inserted into the trachea. This is a grouping of ICD10PCS and SNOMEDCT codes.),(Exclusion Criteria: None) -- Subject constrained to the Endotracheal Intubation
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the End Stage Renal Disease valueset (2.16.840.1.113883.3.526.3.353)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Enophthalmos valueset (2.16.840.1.113883.3.526.3.1421)
Metadata attributes that apply to any item represented in the standard health record. An Entry may not belong exclusively to a single person's health record, but could represent an entity that surfaces in multiple records, such as organizations or practitioners. If the entry belongs to a single person's record, then the identity of the person of record must be recorded.
A persistent, permanent identifier for an entry in a health record, unique within the scope of the health record.
SHR data element identifier, as a URI.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the ESRD Monthly Outpatient Services valueset (2.16.840.1.113883.3.464.1003.109.12.1014).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the ESRD Monthly Outpatient Services
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Essential Hypertension valueset (2.16.840.1.113883.3.464.1003.104.12.1011)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Esterified Estrogens valueset (2.16.840.1.113883.3.464.1003.196.12.1419).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Esterified Estrogens / Methyltestosterone valueset (2.16.840.1.113883.3.464.1003.196.12.1320).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Esterified Estrogens / Methyltestosterone
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Esterified Estrogens
(Clinical Focus: This value set represents the concept of estimated gestational age at birth.),(Data Element Scope: The intent of this data element is to identify estimated gestational age at birth. Using the Quality Data Model, this particular element will map to the Assessment category.),(Inclusion Criteria: Include SNOMED CT codes that identify estimated gestational age at birth.),(Exclusion Criteria: Exclude codes that do not meet the inclusion criteria.) -- ObservableCode constrained to codes in the Estimated Gestational Age at Birth valueset (2.16.840.1.113762.1.4.1045.47).
(Clinical Focus: This value set represents the concept of estimated gestational age at birth.),(Data Element Scope: The intent of this data element is to identify estimated gestational age at birth. Using the Quality Data Model, this particular element will map to the Assessment category.),(Inclusion Criteria: Include SNOMED CT codes that identify estimated gestational age at birth.),(Exclusion Criteria: Exclude codes that do not meet the inclusion criteria.) -- Subject constrained to the Estimated Gestational Age at Birth
(Clinical Focus: This set of values contains 'observable entities' that represent the estimated gestational age at delivery.),(Data Element Scope: The intent of this data element is to identify the fetus's estimated length of gestation at delivery. Using the Quality Data Model, this particular element will map to the 'Assessment' category.),(Inclusion Criteria: Include SNOMED CT codes that identify the estimated gestational age at delivery.),(Exclusion Criteria: None) -- ObservableCode constrained to codes in the Estimated Gestational Age at Delivery valueset (2.16.840.1.113762.1.4.1045.26).
(Clinical Focus: This set of values contains 'observable entities' that represent the estimated gestational age at delivery.),(Data Element Scope: The intent of this data element is to identify the fetus's estimated length of gestation at delivery. Using the Quality Data Model, this particular element will map to the 'Assessment' category.),(Inclusion Criteria: Include SNOMED CT codes that identify the estimated gestational age at delivery.),(Exclusion Criteria: None) -- Subject constrained to the Estimated Gestational Age at Delivery
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Estradiol valueset (2.16.840.1.113883.3.464.1003.196.12.1365).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Estradiol / Norethindrone valueset (2.16.840.1.113883.3.464.1003.196.12.1323).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Estradiol / Norethindrone
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Estradiol
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Estropipate valueset (2.16.840.1.113883.3.464.1003.196.12.1319).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Estropipate
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Ethnicity valueset (2.16.840.1.114222.4.11.837)
The length of the recurring event.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Excision of Adhesions valueset (2.16.840.1.113883.3.526.3.1422).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Excision of Adhesions
An assertion of a physical or conceptual entity, relationship, situation, condition, or phenomenon present or absent.
The particular locations in a facility in which the diagnostic study or encounter occurs or occurred. Examples include, but are not limited to, intensive care units (ICUs), non- ICUs, burn critical-care unit, neonatal ICU, and respiratory-care unit. Each Encounter, Performed may have 1 or more locations. For example, a patient treated in multiple locations during an individual encounter might be expressed as: Encounter, Performed: Inpatient Admission, ICU (location period), Non-ICU Admission (location period), Rehab (location period)
The particular locations in a facility in which the diagnostic study or encounter occurs or occurred. Examples include, but are not limited to, intensive care units (ICUs), non- ICUs, burn critical-care unit, neonatal ICU, and respiratory-care unit. Each Encounter, Performed may have 1 or more locations. For example, a patient treated in multiple locations during an individual encounter might be expressed as: Encounter, Performed: Inpatient Admission, ICU (location period), Non-ICU Admission (location period), Rehab (location period)
(Clinical Focus: This value set contains codes to identify a falls screening tool.),(Data Element Scope: This value set was intended to identify patients who were assessed using a Falls Screening tool.),(Inclusion Criteria: Includes codes that indicate the patient was asked about falls.),(Exclusion Criteria: Excludes questions about children falling, falling in an inpatient setting, and information about falls that would be on a care plan.) -- ObservableCode constrained to codes in the Falls Screening valueset (2.16.840.1.113883.3.464.1003.118.12.1028).
(Clinical Focus: This value set contains codes to identify a falls screening tool.),(Data Element Scope: This value set was intended to identify patients who were assessed using a Falls Screening tool.),(Inclusion Criteria: Includes codes that indicate the patient was asked about falls.),(Exclusion Criteria: Excludes questions about children falling, falling in an inpatient setting, and information about falls that would be on a care plan.) -- Subject constrained to the Falls Screening
(Clinical Focus: This value set contains codes to identify a fecal occult blood test.),(Data Element Scope: This value set was intended to identify patients who had a fecal occult blood test.),(Inclusion Criteria: Includes codes that tests for occult blood in stool.),(Exclusion Criteria: Exclude tests for occult blood in other parts of the body. Exclude order only codes and code that indicate narrative reports.) -- ObservableCode constrained to codes in the Fecal Occult Blood Test (FOBT) valueset (2.16.840.1.113883.3.464.1003.198.12.1011).
(Clinical Focus: This value set contains codes to identify a fecal occult blood test.),(Data Element Scope: This value set was intended to identify patients who had a fecal occult blood test.),(Inclusion Criteria: Includes codes that tests for occult blood in stool.),(Exclusion Criteria: Exclude tests for occult blood in other parts of the body. Exclude order only codes and code that indicate narrative reports.) -- Subject constrained to the Fecal Occult Blood Test (FOBT)
(Clinical Focus: Concepts that represent Female when assessing quality measures),(Data Element Scope: Gender),(Inclusion Criteria: Appropriate female gender concepts),(Exclusion Criteria: Concepts representing Male gender) -- ResultValue constrained to codes in the Female valueset (2.16.840.1.113883.3.560.100.2)
(Clinical Focus: This set of values contains medications that are prescribed for Fibrinolytic therapy in patients with an episode of acute myocardial infarction.),(Data Element Scope: The intent of this data element is to identify patients who are prescribed fibrinolytic therapy during an episode of acute myocardial infarction. Using the Quality Data Model, this particular element would map to the Medication, Administered data type.),(Inclusion Criteria: Include generic and prescribable fibrinolytic agents. Injectable dose forms should be included. Single ingredient.),(Exclusion Criteria: None.) -- ObjectTypeCode constrained to codes in the Fibrinolytic Therapy valueset (2.16.840.1.113883.3.666.5.736).
(Clinical Focus: This set of values contains medications that are prescribed for Fibrinolytic therapy in patients with an episode of acute myocardial infarction.),(Data Element Scope: The intent of this data element is to identify patients who are prescribed fibrinolytic therapy during an episode of acute myocardial infarction. Using the Quality Data Model, this particular element would map to the Medication, Administered data type.),(Inclusion Criteria: Include generic and prescribable fibrinolytic agents. Injectable dose forms should be included. Single ingredient.),(Exclusion Criteria: None.) -- Subject constrained to the Fibrinolytic Therapy
A determination, such as an observation, assertion, opinion, fact, or judgment.
The method used to determine the finding.
Indicates whether the finding is preliminary, amended, final, etc.
(Clinical Focus: This value set contains codes to identify a FIT DNA test.),(Data Element Scope: This value set was intended to identify patients who had a FIT DNA test.),(Inclusion Criteria: Includes codes that indicate noninvasive colorectal cancer DNA and occult blood screening in stool.),(Exclusion Criteria: Exclude order only codes.) -- ObservableCode constrained to codes in the FIT DNA valueset (2.16.840.1.113883.3.464.1003.108.12.1039).
(Clinical Focus: This value set contains codes to identify a FIT DNA test.),(Data Element Scope: This value set was intended to identify patients who had a FIT DNA test.),(Inclusion Criteria: Includes codes that indicate noninvasive colorectal cancer DNA and occult blood screening in stool.),(Exclusion Criteria: Exclude order only codes.) -- Subject constrained to the FIT DNA
(Clinical Focus: This value set contains codes to identify a flexible sigmoidoscopy.),(Data Element Scope: This value set was intended to identify patients who had a flexible sigmoidoscopy.),(Inclusion Criteria: Includes codes that indicate a flexible sigmoidoscopy.),(Exclusion Criteria: Exclude order only codes and code that indicate narrative reports.) -- ObservableCode constrained to codes in the Flexible Sigmoidoscopy valueset (2.16.840.1.113883.3.464.1003.198.12.1010).
(Clinical Focus: This value set contains codes to identify a flexible sigmoidoscopy.),(Data Element Scope: This value set was intended to identify patients who had a flexible sigmoidoscopy.),(Inclusion Criteria: Includes codes that indicate a flexible sigmoidoscopy.),(Exclusion Criteria: Exclude order only codes and code that indicate narrative reports.) -- Subject constrained to the Flexible Sigmoidoscopy
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Fluoride Varnish Application for Children valueset (2.16.840.1.113883.3.464.1003.125.12.1002).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Fluoride Varnish Application for Children
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Focal Chorioretinitis and Focal Retinochoroiditis valueset (2.16.840.1.113883.3.526.3.1460)
(Clinical Focus: This value set contains follow-up plans that are commonly used to document a plan is in place for the treatment of depression that specifically pertains to the adolescent population.),(Data Element Scope: ),(Inclusion Criteria: Incorporates emotional and coping support as well as mental health management in an attempt to follow-up on previously evaluated and diagnosed depression or depressive disorder in the adolescent population.),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Follow-up for depression - adolescent valueset (2.16.840.1.113883.3.600.467).
(Clinical Focus: This value set contains follow-up plans that are commonly used to document a plan is in place for the treatment of depression that specifically pertains to the adolescent population.),(Data Element Scope: ),(Inclusion Criteria: Incorporates emotional and coping support as well as mental health management in an attempt to follow-up on previously evaluated and diagnosed depression or depressive disorder in the adolescent population.),(Exclusion Criteria: ) -- Subject constrained to the Follow-up for depression - adolescent
(Clinical Focus: This value set contains follow-up plans that are commonly used to document a plan is in place for the treatment of depression specifically pertaining to the adult population.),(Data Element Scope: ),(Inclusion Criteria: Incorporates emotional and coping support as well as mental health management in an attempt to follow-up on previously evaluated and diagnosed depression or depressive disorder in the adult population.),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Follow-up for depression - adult valueset (2.16.840.1.113883.3.600.468).
(Clinical Focus: This value set contains follow-up plans that are commonly used to document a plan is in place for the treatment of depression specifically pertaining to the adult population.),(Data Element Scope: ),(Inclusion Criteria: Incorporates emotional and coping support as well as mental health management in an attempt to follow-up on previously evaluated and diagnosed depression or depressive disorder in the adult population.),(Exclusion Criteria: ) -- Subject constrained to the Follow-up for depression - adult
(Clinical Focus: This set of values is meant to capture that a follow-up encounter or visit is in place within four weeks of the initial encounter.),(Data Element Scope: ),(Inclusion Criteria: Included are codes addressing that the follow-up was completed anywhere from 1 day to 1 month of the initial finding.),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Followup within 4 weeks valueset (2.16.840.1.113883.3.600.1537).
(Clinical Focus: This set of values is meant to capture that a follow-up encounter or visit is in place within four weeks of the initial encounter.),(Data Element Scope: ),(Inclusion Criteria: Included are codes addressing that the follow-up was completed anywhere from 1 day to 1 month of the initial finding.),(Exclusion Criteria: ) -- Subject constrained to the Followup within 4 weeks
(Clinical Focus: This set of values is meant to collect data that a follow-up encounter or visit was written or scheduled within the time period of one year of the initial encounter.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Followup within one year valueset (2.16.840.1.113883.3.600.1474).
(Clinical Focus: This set of values is meant to collect data that a follow-up encounter or visit was written or scheduled within the time period of one year of the initial encounter.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Followup within one year
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Fracture - Lower Body valueset (2.16.840.1.113883.3.464.1003.113.12.1037)
Indicates how frequently the medication or substance, Is administered to a patient for an active medication (a), Was administered to the patient (b), Should be taken by the patient or administered to the patient (c), Is recommended to be given to the patient (d).
(Clinical Focus: This grouping value set include diagnoses that represent galactosemia.),(Data Element Scope: The intent of this data element is to identify galactosemia. Using the Quality Data Model, this particular element will map to the 'Diagnosis' categories.),(Inclusion Criteria: Include ICD 10 CM and SNOMED CT codes that identify galactosemia.),(Exclusion Criteria: Exclude codes that do not meet the inclusion criteria.)
(Clinical Focus: This grouping value set include diagnoses that represent galactosemia.),(Data Element Scope: The intent of this data element is to identify galactosemia. Using the Quality Data Model, this particular element will map to the 'Diagnosis' categories.),(Inclusion Criteria: Include ICD 10 CM and SNOMED CT codes that identify galactosemia.),(Exclusion Criteria: Exclude codes that do not meet the inclusion criteria.) -- ResultValue constrained to codes in the Galactosemia valueset (2.16.840.1.113883.3.117.1.7.1.35)
(Clinical Focus: This set of values contains codes that can be used to identify patients who have undergone a partial or total removeal of the stomach by either a laparoscopic or open method.),(Data Element Scope: This value set is developed for the procedure QDM datatype. It can potentially be used for other datatypes as well.),(Inclusion Criteria: Include codes that identify procedures for repair or removal of digestive system organs that include a partial or total removal of the stomach.),(Exclusion Criteria: Exclude endoscopic excision of tissue of stomach, excision/laparoscopic wedge resection of lesion of stomach, and incisional biopsy of stomach.) -- ObservableCode constrained to codes in the Gastric Bypass Surgery valueset (2.16.840.1.113883.3.464.1003.198.12.1050).
(Clinical Focus: This set of values contains codes that can be used to identify patients who have undergone a partial or total removeal of the stomach by either a laparoscopic or open method.),(Data Element Scope: This value set is developed for the procedure QDM datatype. It can potentially be used for other datatypes as well.),(Inclusion Criteria: Include codes that identify procedures for repair or removal of digestive system organs that include a partial or total removal of the stomach.),(Exclusion Criteria: Exclude endoscopic excision of tissue of stomach, excision/laparoscopic wedge resection of lesion of stomach, and incisional biopsy of stomach.) -- Subject constrained to the Gastric Bypass Surgery
(Clinical Focus: This group of value sets identifies patients who have a surgical procedure where a general and/or neuraxial anesthesia is used.),(Data Element Scope: The intent of this data element is to identify patients who have a surgical procedure where general and/or neuraxial anesthesia is used. Using the Quality Data Model, this particular element will map to the Procedure category.),(Inclusion Criteria: Only use codes which represent general and/or neuraxial anesthesia. Codes used are to be ICD10PCS, ICD9 or SNOMED-CT codes only.),(Exclusion Criteria: None.) -- ObservableCode constrained to codes in the General or Neuraxial Anesthesia valueset (2.16.840.1.113883.3.666.5.1743).
(Clinical Focus: This group of value sets identifies patients who have a surgical procedure where a general and/or neuraxial anesthesia is used.),(Data Element Scope: The intent of this data element is to identify patients who have a surgical procedure where general and/or neuraxial anesthesia is used. Using the Quality Data Model, this particular element will map to the Procedure category.),(Inclusion Criteria: Only use codes which represent general and/or neuraxial anesthesia. Codes used are to be ICD10PCS, ICD9 or SNOMED-CT codes only.),(Exclusion Criteria: None.) -- Subject constrained to the General or Neuraxial Anesthesia
(Clinical Focus: This grouping of value sets contains value sets which identify patients who have a general surgery procedure. These surgical procedures are thoracic and abdominal procedures, except for cardiac procedures.),(Data Element Scope: The intent of this data element is to identify patients who have general surgery procedures. Using the Quality Data Model, this data element maps to the Procedure category.),(Inclusion Criteria: Only include codes which represent general surgery. These surgical procedures are thoracic and abdominal procedures, except for cardiac procedures.),(Exclusion Criteria: None.) -- ObservableCode constrained to codes in the General Surgery valueset (2.16.840.1.113883.3.117.1.7.1.255).
(Clinical Focus: This grouping of value sets contains value sets which identify patients who have a general surgery procedure. These surgical procedures are thoracic and abdominal procedures, except for cardiac procedures.),(Data Element Scope: The intent of this data element is to identify patients who have general surgery procedures. Using the Quality Data Model, this data element maps to the Procedure category.),(Inclusion Criteria: Only include codes which represent general surgery. These surgical procedures are thoracic and abdominal procedures, except for cardiac procedures.),(Exclusion Criteria: None.) -- Subject constrained to the General Surgery
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Genital Herpes valueset (2.16.840.1.113883.3.464.1003.110.12.1049)
The countries of the world and major geopolitical subregions, such as US states.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Glaucoma Associated with Congenital Anomalies, Dystrophies, and Systemic Syndromes valueset (2.16.840.1.113883.3.526.3.1461)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Glaucoma valueset (2.16.840.1.113883.3.526.3.1423)
-- ObservableCode constrained to codes in the Gleason score in Specimen Qualitative valueset (drc-1aece65e61ef30cd4c367b07fd4dc6158cfb1bdd4dbcf914fcfb2d89abdb6794).
-- Subject constrained to the Gleason score in Specimen Qualitative
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Glomerulonephritis and Nephrotic Syndrome valueset (2.16.840.1.113883.3.464.1003.109.12.1018)
(Clinical Focus: This set of values contains codes that are used to identify medications used as oral steroids.),(Data Element Scope: This value set is developed for the medication QDM datatype. It can potentially be used for other datatypes as well.),(Inclusion Criteria: Include cortisone, dexamethasone, hydrocortisone, predenisone, methyprednisone, triamcinolone, betamethasone, dexamethasone, fludrocortisone and triamcinolone. Include only glucocorticoids taken orally, i.e., through an tablet, capsule, or oral solution.),(Exclusion Criteria: Exclude all glucocorticoids taken non-orally, i.e., as a nasal inhalant or injectable solution.) -- ObjectTypeCode constrained to codes in the Glucocorticoids (oral only) valueset (2.16.840.1.113883.3.464.1003.196.12.1266).
(Clinical Focus: This set of values contains codes that are used to identify medications used as oral steroids.),(Data Element Scope: This value set is developed for the medication QDM datatype. It can potentially be used for other datatypes as well.),(Inclusion Criteria: Include cortisone, dexamethasone, hydrocortisone, predenisone, methyprednisone, triamcinolone, betamethasone, dexamethasone, fludrocortisone and triamcinolone. Include only glucocorticoids taken orally, i.e., through an tablet, capsule, or oral solution.),(Exclusion Criteria: Exclude all glucocorticoids taken non-orally, i.e., as a nasal inhalant or injectable solution.) -- Subject constrained to the Glucocorticoids (oral only)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Glyburide valueset (2.16.840.1.113883.3.464.1003.196.12.1368).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Glyburide / Metformin valueset (2.16.840.1.113883.3.464.1003.196.12.1360).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Glyburide / Metformin
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Glyburide
(Clinical Focus: This set of values contains codes which identify a select medication-a Glycoprotein Iib/IIIa inhibitor.),(Data Element Scope: The intent of this data element is to identify patients who are on a Glycoprotein Iib/IIIa inhibitor. Using the Quality Data Model, this data element maps to the Medication category.),(Inclusion Criteria: Only include codes which represent a Glycoprotein Iib/IIIa inhibitor. These are RxNorm codes.),(Exclusion Criteria: None) -- ObjectTypeCode constrained to codes in the Glycoprotein IIb/IIIa Inhibitors valueset (2.16.840.1.113762.1.4.1045.41).
(Clinical Focus: This set of values contains codes which identify a select medication-a Glycoprotein Iib/IIIa inhibitor.),(Data Element Scope: The intent of this data element is to identify patients who are on a Glycoprotein Iib/IIIa inhibitor. Using the Quality Data Model, this data element maps to the Medication category.),(Inclusion Criteria: Only include codes which represent a Glycoprotein Iib/IIIa inhibitor. These are RxNorm codes.),(Exclusion Criteria: None) -- Subject constrained to the Glycoprotein IIb/IIIa Inhibitors
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Gonococcal Infections and Venereal Diseases valueset (2.16.840.1.113883.3.464.1003.112.12.1001)
(Clinical Focus: This set of values contains codes and concepts for graduated compression stocking devices which are used to prevent VTEs in patients.),(Data Element Scope: The intent of this data element is to identify patients who have a graduated compression stocking device applied. It may also be used to identify patients who did not have a graduated compression stocking device applied for VTE prophylaxis for an allowable reason when used with a negation rationale attribute. Using the Quality Data Model, this data element maps to the Device category.),(Inclusion Criteria: Only include codes which represent graduated compression stockings.),(Exclusion Criteria: None) -- ObjectTypeCode constrained to codes in the Graduated compression stockings (GCS) valueset (2.16.840.1.113883.3.117.1.7.1.256).
(Clinical Focus: This set of values contains codes and concepts for graduated compression stocking devices which are used to prevent VTEs in patients.),(Data Element Scope: The intent of this data element is to identify patients who have a graduated compression stocking device applied. It may also be used to identify patients who did not have a graduated compression stocking device applied for VTE prophylaxis for an allowable reason when used with a negation rationale attribute. Using the Quality Data Model, this data element maps to the Device category.),(Inclusion Criteria: Only include codes which represent graduated compression stockings.),(Exclusion Criteria: None) -- Subject constrained to the Graduated compression stockings (GCS)
(Clinical Focus: This set of values contains codes and concepts for graduated compression stocking devices which are used to prevent VTEs in patients.),(Data Element Scope: The intent of this data element is to identify patients who have a graduated compression stocking device applied. It may also be used to identify patients who did not have a graduated compression stocking device applied for VTE prophylaxis for an allowable reason when used with a negation rationale attribute. Using the Quality Data Model, this data element maps to the Device category.),(Inclusion Criteria: Only include codes which represent graduated compression stockings.),(Exclusion Criteria: None) -- Subject constrained to the Graduated compression stockings (GCS)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Group A Streptococcus Test valueset (2.16.840.1.113883.3.464.1003.198.12.1012).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Group A Streptococcus Test
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Group Psychotherapy valueset (2.16.840.1.113883.3.526.3.1187).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Group Psychotherapy
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Guanfacine valueset (2.16.840.1.113883.3.464.1003.196.12.1341).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Guanfacine
(Clinical Focus: This grouping of value sets identifies patients who have procedures of gynecologic surgery.),(Data Element Scope: The intent of this data element is to identify patients who have a gynecologic surgery procedure. Using the Quality Data Model, this particular element will map to the Procedure category.),(Inclusion Criteria: Only use codes which represent gynecologic surgery procedures.),(Exclusion Criteria: None.) -- ObservableCode constrained to codes in the Gynecological Surgery valueset (2.16.840.1.113883.3.117.1.7.1.257).
(Clinical Focus: This grouping of value sets identifies patients who have procedures of gynecologic surgery.),(Data Element Scope: The intent of this data element is to identify patients who have a gynecologic surgery procedure. Using the Quality Data Model, this particular element will map to the Procedure category.),(Inclusion Criteria: Only use codes which represent gynecologic surgery procedures.),(Exclusion Criteria: None.) -- Subject constrained to the Gynecological Surgery
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Haemophilus Influenzae Type B (HiB) Vaccine valueset (2.16.840.1.113883.3.464.1003.196.12.1217).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Haemophilus Influenzae Type B (HiB) Vaccine Administered valueset (2.16.840.1.113883.3.464.1003.110.12.1043).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Haemophilus Influenzae Type B (HiB) Vaccine Administered
A hash code of the data (sha-1, base64ed)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the HbA1c Laboratory Test valueset (2.16.840.1.113883.3.464.1003.198.12.1013).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the HbA1c Laboratory Test
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- ObservableCode constrained to codes in the HBsAg valueset (2.16.840.1.113883.3.67.1.101.1.279).
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- Subject constrained to the HBsAg
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Health and Behavioral Assessment - Initial valueset (2.16.840.1.113883.3.526.3.1245).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Health and Behavioral Assessment - Initial
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Health and Behavioral Assessment, Reassessment valueset (2.16.840.1.113883.3.526.3.1529).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Health and Behavioral Assessment, Reassessment
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Health & Behavioral Assessment - Individual valueset (2.16.840.1.113883.3.526.3.1020).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Health & Behavioral Assessment - Individual
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Heart Failure valueset (2.16.840.1.113883.3.526.3.376)
-- ObservableCode constrained to codes in the Heart rate valueset (drc-6815def8ee9fb6107af4a29a9d28a09d954d2b03eade747240bdcce562809ccb).
-- Subject constrained to the Heart rate
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Height valueset (2.16.840.1.113883.3.464.1003.121.12.1014).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Height
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Hemodialysis valueset (2.16.840.1.113883.3.526.3.1083).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Hemodialysis
(Clinical Focus: This grouping of value sets identifies patients who have had a hemorrhagic stroke, or stroke caused by hemorrhage.),(Data Element Scope: The intent of this data element is to identify patients who have a diagnosis of hemorrhagic stroke, or stroke caused by a hemorrhage. Using the Quality Data Model, this particular element would map to the Principal Diagnosis attribute for the Encounter category.),(Inclusion Criteria: Only use codes which represent a diagnosis of hemorrhagic stroke, or stroke caused by hemorrhage. This is a grouping of ICD10CM and SNOMED-CT codes.),(Exclusion Criteria: None.)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Hepatitis A valueset (2.16.840.1.113883.3.464.1003.110.12.1024)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Hepatitis A Vaccine valueset (2.16.840.1.113883.3.464.1003.196.12.1215).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Hepatitis A Vaccine Administered valueset (2.16.840.1.113883.3.464.1003.110.12.1041).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Hepatitis A Vaccine Administered
(Clinical Focus: This set of values contain codes commonly used to identify patients with acute or chronic Hepatitis B infection.),(Data Element Scope: The intent of this data element is identify patients with acute or chronic Hepatitis B infection. Using the Quality Data Model, this particular element would map to the 'Diagnosis, Active'.),(Inclusion Criteria: The codes used in this value set can be reasonably used to identify patients with acute or chronic Hepatitis B infection.),(Exclusion Criteria: Patients with evidence of current or past acute or chronic Hepatitis B infection.) -- ResultValue constrained to codes in the Hepatitis B1 valueset (2.16.840.1.113883.3.67.1.101.1.269)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Hepatitis B valueset (2.16.840.1.113883.3.464.1003.110.12.1025)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Hepatitis B Vaccine valueset (2.16.840.1.113883.3.464.1003.196.12.1216).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Hepatitis B Vaccine Administered valueset (2.16.840.1.113883.3.464.1003.110.12.1042).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Hepatitis B Vaccine Administered
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Hereditary Choroidal Dystrophies valueset (2.16.840.1.113883.3.526.3.1462)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Hereditary Corneal Dystrophies valueset (2.16.840.1.113883.3.526.3.1424)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Hereditary Retinal Dystrophies valueset (2.16.840.1.113883.3.526.3.1463)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the High Hyperopia valueset (2.16.840.1.113883.3.526.3.1425)
(Clinical Focus: The intent of this value set is to incorporate high intensity statin medications as defined by the 2013 ACC/AHA guideline.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by medication codes.),(Inclusion Criteria: High intensity statin therapy is included in this set of values.),(Exclusion Criteria: Any other intensity of statin therapy is excluded.) -- ObjectTypeCode constrained to codes in the High intensity statin therapy valueset (2.16.840.1.113762.1.4.1047.97).
(Clinical Focus: The intent of this value set is to incorporate high intensity statin medications as defined by the 2013 ACC/AHA guideline.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by medication codes.),(Inclusion Criteria: High intensity statin therapy is included in this set of values.),(Exclusion Criteria: Any other intensity of statin therapy is excluded.) -- Subject constrained to the High intensity statin therapy
(Clinical Focus: The intent of this value set is to incorporate high intensity statin medications as defined by the 2013 ACC/AHA guideline.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by medication codes.),(Inclusion Criteria: High intensity statin therapy is included in this set of values.),(Exclusion Criteria: Any other intensity of statin therapy is excluded.) -- Subject constrained to the High intensity statin therapy
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the High Risk Medications for the Elderly valueset (2.16.840.1.113883.3.464.1003.196.12.1253).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the High Risk Medications for the Elderly
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the High-Risk Medications With Days Supply Criteria valueset (2.16.840.1.113883.3.464.1003.196.12.1254).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the High-Risk Medications With Days Supply Criteria
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Hip Dysfunction and Osteoarthritis Outcome Score for Joint Replacement [HOOSJR] valueset (2.16.840.1.113883.3.464.1003.118.12.1210).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Hip Dysfunction and Osteoarthritis Outcome Score for Joint Replacement [HOOSJR]
(Clinical Focus: This grouping of value sets identifies patients who have procedures of hip fracture surgery.),(Data Element Scope: The intent of this data element is to identify patients who have a hip fracture surgery procedure. Using the Quality Data Model, this particular element will map to the Procedure category.),(Inclusion Criteria: Only use codes which represent hip fracture surgery.),(Exclusion Criteria: None.) -- ObservableCode constrained to codes in the Hip Fracture Surgery valueset (2.16.840.1.113883.3.117.1.7.1.258).
(Clinical Focus: This grouping of value sets identifies patients who have procedures of hip fracture surgery.),(Data Element Scope: The intent of this data element is to identify patients who have a hip fracture surgery procedure. Using the Quality Data Model, this particular element will map to the Procedure category.),(Inclusion Criteria: Only use codes which represent hip fracture surgery.),(Exclusion Criteria: None.) -- Subject constrained to the Hip Fracture Surgery
(Clinical Focus: This grouping of value sets identifies patients who have total hip replacement procedures.),(Data Element Scope: The intent of this data element is to identify patients who have a total hip replacement procedure. Using the Quality Data Model, this particular element will map to the Procedure category.),(Inclusion Criteria: Only use codes which represent the surgical procedure of a total hip replacement.),(Exclusion Criteria: None.) -- ObservableCode constrained to codes in the Hip Replacement Surgery valueset (2.16.840.1.113883.3.117.1.7.1.259).
(Clinical Focus: This grouping of value sets identifies patients who have total hip replacement procedures.),(Data Element Scope: The intent of this data element is to identify patients who have a total hip replacement procedure. Using the Quality Data Model, this particular element will map to the Procedure category.),(Inclusion Criteria: Only use codes which represent the surgical procedure of a total hip replacement.),(Exclusion Criteria: None.) -- Subject constrained to the Hip Replacement Surgery
(Clinical Focus: This value set contains codes that identify a previous history of having a bilateral mastectomy.),(Data Element Scope: This value set was intended to identify patients who had a bilateral mastectomy.),(Inclusion Criteria: Includes codes that identify a bilateral mastectomy was performed in the past.),(Exclusion Criteria: Excludes codes that indicate a unilateral mastectomy or are unspecified.) -- ResultValue constrained to codes in the History of bilateral mastectomy valueset (2.16.840.1.113883.3.464.1003.198.12.1068)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the History of hip fracture in parent valueset (2.16.840.1.113883.3.464.1003.113.12.1040).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the History of hip fracture in parent
-- ObservableCode constrained to codes in the HIV 1 and 2 tests - Meaningful Use set valueset (drc-ed81586a626bc2b5d9f3dcda0c8c45ed7fa999f7951e24d5883a5585bbe0ad98).
-- Subject constrained to the HIV 1 and 2 tests - Meaningful Use set
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the HIV 1 valueset (2.16.840.1.113883.3.464.1003.120.12.1004)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the HIV valueset (2.16.840.1.113883.3.464.1003.120.12.1003)
(Clinical Focus: This value set identifies patients who have had a home health visit by a provider for the evaluation or management of a new or existing patient.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Include all home visits for the evaluation and management of a new or established patient.),(Exclusion Criteria: None) -- ActivityCode constrained to codes in the Home Healthcare Services valueset (2.16.840.1.113883.3.464.1003.101.12.1016).
(Clinical Focus: This value set identifies patients who have had a home health visit by a provider for the evaluation or management of a new or existing patient.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Include all home visits for the evaluation and management of a new or established patient.),(Exclusion Criteria: None) -- Subject constrained to the Home Healthcare Services
(Clinical Focus: Patients receiving hospice care outside of hospital or long term care facility.),(Data Element Scope: The intent of this value set is to identify all patients receiving hospice care outside of hospital or long term care facility . Using the quality data model this maps to 'Intervention, Order' and 'Procedure, Order'.),(Inclusion Criteria: All hospice care concepts should be included.),(Exclusion Criteria: Do not include concepts for palliative care or comfort measures.) -- ActivityCode constrained to codes in the Hospice care ambulatory valueset (2.16.840.1.113762.1.4.1108.15).
(Clinical Focus: Patients receiving hospice care outside of hospital or long term care facility.),(Data Element Scope: The intent of this value set is to identify all patients receiving hospice care outside of hospital or long term care facility . Using the quality data model this maps to 'Intervention, Order' and 'Procedure, Order'.),(Inclusion Criteria: All hospice care concepts should be included.),(Exclusion Criteria: Do not include concepts for palliative care or comfort measures.) -- Subject constrained to the Hospice care ambulatory
(Clinical Focus: Patients receiving hospice care outside of hospital or long term care facility.),(Data Element Scope: The intent of this value set is to identify all patients receiving hospice care outside of hospital or long term care facility . Using the quality data model this maps to 'Intervention, Order' and 'Procedure, Order'.),(Inclusion Criteria: All hospice care concepts should be included.),(Exclusion Criteria: Do not include concepts for palliative care or comfort measures.) -- Subject constrained to the Hospice care ambulatory
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Hospital Inpatient Visit - Initial valueset (2.16.840.1.113883.3.464.1003.101.12.1004).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Hospital Inpatient Visit - Initial
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Hospital Observation Care - Initial valueset (2.16.840.1.113883.3.464.1003.101.12.1002).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Hospital Observation Care - Initial
(Clinical Focus: This set of values identifies hospital environments where a patient may receive inpatient or outpatient care.),(Data Element Scope: The intent of this data element is to identify hospital environments where a patient may receive inpatient or outpatient care. Using the Quality Data Model, this particular element will map to the Transfer category.),(Inclusion Criteria: Use the concept of hospital environment (22232009) and all its children. Codes used are to be SNOMED-CT codes only.),(Exclusion Criteria: None.)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the HPV Test valueset (2.16.840.1.113883.3.464.1003.110.12.1059).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the HPV Test
(Clinical Focus: Screening for HIV infection),(Data Element Scope: Laboratory tests used for HIV screening. The scope of the value set is to include some secondary HIV tests that may be present in an EHR to assure a measure of screening does not miss patients who are tested and avoid unnecessary retesting to meet the expectations of a quality measure.),(Inclusion Criteria: Laboratory tests for HIV-1 and HIV-2 antibodies or antigens.),(Exclusion Criteria: Home HIV testing, HIV genotyping tests, HIV RNA tests, HIV cultures, clinical codes used to document care provided to HIV-infected patients.) -- ObservableCode constrained to codes in the Human Immunodeficiency Virus (HIV) Laboratory Test Codes (Ab and Ag) valueset (2.16.840.1.113762.1.4.1056.50).
(Clinical Focus: Screening for HIV infection),(Data Element Scope: Laboratory tests used for HIV screening. The scope of the value set is to include some secondary HIV tests that may be present in an EHR to assure a measure of screening does not miss patients who are tested and avoid unnecessary retesting to meet the expectations of a quality measure.),(Inclusion Criteria: Laboratory tests for HIV-1 and HIV-2 antibodies or antigens.),(Exclusion Criteria: Home HIV testing, HIV genotyping tests, HIV RNA tests, HIV cultures, clinical codes used to document care provided to HIV-infected patients.) -- Subject constrained to the Human Immunodeficiency Virus (HIV) Laboratory Test Codes (Ab and Ag)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Hydrochlorothiazide / Methyldopa valueset (2.16.840.1.113883.3.464.1003.196.12.1414).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Hydrochlorothiazide / Methyldopa
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Hydroxyzine valueset (2.16.840.1.113883.3.464.1003.196.12.1374).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Hydroxyzine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Hyoscyamine valueset (2.16.840.1.113883.3.464.1003.196.12.1501).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Hyoscyamine / Methenamine / Mblue / Phenyl Salicyl valueset (2.16.840.1.113883.3.464.1003.196.12.1503).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Hyoscyamine / Methenamine / Mblue / Phenyl Salicyl
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Hyoscyamine / Methenamine / Mblue / Phenyl Salicyl / Sodium Biphosphate valueset (2.16.840.1.113883.3.464.1003.196.12.1504).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Hyoscyamine / Methenamine / Mblue / Phenyl Salicyl / Sodium Biphosphate
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Hyoscyamine / Methenamine / Mblue / Sodium Biphosphate valueset (2.16.840.1.113883.3.464.1003.196.12.1505).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Hyoscyamine / Methenamine / Mblue / Sodium Biphosphate
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Hyoscyamine
(Clinical Focus: This value set is designed to capture that the patient has a diagnosis, past or present, of hypercholesterolemia.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by diagnosis codes.),(Inclusion Criteria: Included are diagnoses of hypercholesterolemia.),(Exclusion Criteria: Other diagnoses not related or used to identify patients with hypercholesterolemia are excluded.) -- ResultValue constrained to codes in the Hypercholesterolemia valueset (2.16.840.1.113762.1.4.1047.100)
(Clinical Focus: This set of values contains codes that are used to identify patients with a diagnosis of primary, secondary, tertiary, and all other types of hyperparathyroidism.),(Data Element Scope: This value set is developed for the diagnosis QDM datatype. It can potentially be used for other datatypes as well.),(Inclusion Criteria: Include all diagnosis codes associated with hyperparathyroidism, with or without reference to complications and comorbidities.),(Exclusion Criteria: Excludes diagnoses of autonomous thyroid function, Iatrogenic thyrotoxicosis factitia, neonatal thyrotoxicosis, and thyrotoxic crisis.) -- ResultValue constrained to codes in the Hyperparathyroidism valueset (2.16.840.1.113883.3.464.1003.117.12.1016)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Hypertensive Chronic Kidney Disease valueset (2.16.840.1.113883.3.464.1003.109.12.1017)
(Clinical Focus: This set of values contains codes that identify patients with a diagnosis of Hyperthyroidism.),(Data Element Scope: This value set is developed for the diagnosis QDM datatype. It can potentially be used for other datatypes as well.),(Inclusion Criteria: Includes diagnosis codes for thyrotoxicosis, both with and without thyrotoxic crisis or storm, and with and without presence of goiter.),(Exclusion Criteria: Excludes diagnosis codes for neonatal thyrotoxicosis.) -- ResultValue constrained to codes in the Hyperthyroidism valueset (2.16.840.1.113883.3.464.1003.117.12.1015)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Hypotension valueset (2.16.840.1.113883.3.526.3.370)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Hypotony of Eye valueset (2.16.840.1.113883.3.526.3.1426)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Hysterectomy with No Residual Cervix valueset (2.16.840.1.113883.3.464.1003.198.12.1014).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Hysterectomy with No Residual Cervix
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Imipramine valueset (2.16.840.1.113883.3.464.1003.196.12.1359).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Imipramine
Immunization represents vaccines administered to patients in healthcare settings but does not include non-vaccine agents.
Data elements that meet criteria using this datatype should document that the vaccine indicated by the QDM category and its corresponding value set was actually administered to the patient. Timing: The time the immunization is administered, i.e., a single point in time, or Author dateTime.
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Inactivated Polio Vaccine (IPV) valueset (2.16.840.1.113883.3.464.1003.196.12.1219).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Inactivated Polio Vaccine (IPV) Administered valueset (2.16.840.1.113883.3.464.1003.110.12.1045).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Inactivated Polio Vaccine (IPV) Administered
The date and time of the first incision of the procedure. Incision dateTime is a single point in time available from the Operating Room and/or Anesthesia Record.
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Indomethacin valueset (2.16.840.1.113883.3.464.1003.196.12.1366).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Indomethacin
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Inflammatory Diseases of Female Reproductive Organs valueset (2.16.840.1.113883.3.464.1003.112.12.1004)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Influenza Vaccination valueset (2.16.840.1.113883.3.526.3.402).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Influenza Vaccination valueset (2.16.840.1.113883.3.526.3.402)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Influenza Vaccination Declined valueset (2.16.840.1.113883.3.526.3.1255)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Influenza Vaccination
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObjectTypeCode constrained to codes in the Influenza Vaccine valueset (2.16.840.1.113883.3.526.3.1254).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Influenza Vaccine1 valueset (2.16.840.1.113883.3.464.1003.196.12.1218).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Influenza Vaccine1
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Influenza Vaccine Administered valueset (2.16.840.1.113883.3.464.1003.110.12.1044).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Influenza Vaccine Administered
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Influenza Vaccine valueset (2.16.840.1.113883.3.526.3.1254)
-- ResultValue constrained to codes in the Influenza virus vaccine adverse reaction (disorder) valueset (drc-7a824e1f480b8851627a8aedc92f10de7c6164f0138d54bc0d9eda454d711a78)
(Clinical Focus: This set of values contains codes which identify a select medication-an injectable Factor Xa inhibitor-which is used for VTE prophylaxis.),(Data Element Scope: The intent of this data element is to identify patients who are on a select Injectable Factor Xa Inhibitor as prophylaxis for VTE. Using the Quality Data Model, this data element maps to the Medication category.),(Inclusion Criteria: Only include codes which represent injectable Factor Xa inhibitor medications. These are RxNorm codes.),(Exclusion Criteria: None.) -- ObjectTypeCode constrained to codes in the Injectable Factor Xa Inhibitor for VTE Prophylaxis valueset (2.16.840.1.113883.3.117.1.7.1.211).
(Clinical Focus: This set of values contains codes which identify a select medication-an injectable Factor Xa inhibitor-which is used for VTE prophylaxis.),(Data Element Scope: The intent of this data element is to identify patients who are on a select Injectable Factor Xa Inhibitor as prophylaxis for VTE. Using the Quality Data Model, this data element maps to the Medication category.),(Inclusion Criteria: Only include codes which represent injectable Factor Xa inhibitor medications. These are RxNorm codes.),(Exclusion Criteria: None.) -- Subject constrained to the Injectable Factor Xa Inhibitor for VTE Prophylaxis
(Clinical Focus: This set of values contains codes which identify a select medication-an injectable Factor Xa inhibitor-which is used for VTE prophylaxis.),(Data Element Scope: The intent of this data element is to identify patients who are on a select Injectable Factor Xa Inhibitor as prophylaxis for VTE. Using the Quality Data Model, this data element maps to the Medication category.),(Inclusion Criteria: Only include codes which represent injectable Factor Xa inhibitor medications. These are RxNorm codes.),(Exclusion Criteria: None.) -- Subject constrained to the Injectable Factor Xa Inhibitor for VTE Prophylaxis
(Clinical Focus: HCPCS code fo injection of leuprolide acetate for intended twelve month period.),(Data Element Scope: The intent of this data element is to include androgen deprivation therapy for equal to or greater than 12 months. This is accomplished by indicating the CPT code and then a modifier such as J1950,cont which is non-billable but allows for reporting the intent.),(Inclusion Criteria: Injection of leuprolide acetate intended for 12 months or greater.),(Exclusion Criteria: Injection of leuprolude acetate intended for a period of less than 12 months.) -- ObservableCode constrained to codes in the Injection Leuprolide Acetate valueset (2.16.840.1.113762.1.4.1151.16).
(Clinical Focus: HCPCS code fo injection of leuprolide acetate for intended twelve month period.),(Data Element Scope: The intent of this data element is to include androgen deprivation therapy for equal to or greater than 12 months. This is accomplished by indicating the CPT code and then a modifier such as J1950,cont which is non-billable but allows for reporting the intent.),(Inclusion Criteria: Injection of leuprolide acetate intended for 12 months or greater.),(Exclusion Criteria: Injection of leuprolude acetate intended for a period of less than 12 months.) -- Subject constrained to the Injection Leuprolide Acetate
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Injury to Optic Nerve and Pathways valueset (2.16.840.1.113883.3.526.3.1427)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Inpatient Encounter valueset (2.16.840.1.113883.3.464.1003.101.12.1060).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Inpatient Encounter
(Clinical Focus: This set of values contains codes for laboratory test for INR, or International Normalized Ratio.),(Data Element Scope: The intent of this data element is to identify INR laboratory tests. Using the Quality Data Model, this data element maps to the Laboratory Test category.),(Inclusion Criteria: Only include codes which represent a laboratory test of INR (International Normalized Ratio). These are LOINC codes.),(Exclusion Criteria: None) -- ObservableCode constrained to codes in the INR valueset (2.16.840.1.113883.3.117.1.7.1.213).
(Clinical Focus: This set of values contains codes for laboratory test for INR, or International Normalized Ratio.),(Data Element Scope: The intent of this data element is to identify INR laboratory tests. Using the Quality Data Model, this data element maps to the Laboratory Test category.),(Inclusion Criteria: Only include codes which represent a laboratory test of INR (International Normalized Ratio). These are LOINC codes.),(Exclusion Criteria: None) -- Subject constrained to the INR
(Clinical Focus: This set of values is used to represent patients who receive instructions for follow up care after discharge or follow up care planned and scheduled.),(Data Element Scope: The intent of this data element is to identify patients who receive instructions for follow up after discharge or have follow up plans scheduled. Using the Quality Data Model, this particular element will map to the 'Communication' category.),(Inclusion Criteria: Only SNOMED CT codes representing instructions for follow up after discharge or follow up care planned and scheduled should be included.),(Exclusion Criteria: Exclude codes that do not meet the inclusion criteria.) -- ObservableCode constrained to codes in the Instructions for Follow Up After Discharge valueset (2.16.840.1.113883.3.117.1.7.1.378)
A Quantity that is an integer.
(Clinical Focus: This set of values represents the different types of intermittent pneumatic compression devices used for VTE prophylaxis.),(Data Element Scope: The intent of this data element is to represent the application of certain intermittent pneumatic compression devices. Using the Quality Data Model, this data element will map to the Device category.),(Inclusion Criteria: Only include codes which represent different types of intermittent pneumatic compression devices.),(Exclusion Criteria: None) -- ObjectTypeCode constrained to codes in the Intermittent pneumatic compression devices (IPC) valueset (2.16.840.1.113883.3.117.1.7.1.214).
(Clinical Focus: This set of values represents the different types of intermittent pneumatic compression devices used for VTE prophylaxis.),(Data Element Scope: The intent of this data element is to represent the application of certain intermittent pneumatic compression devices. Using the Quality Data Model, this data element will map to the Device category.),(Inclusion Criteria: Only include codes which represent different types of intermittent pneumatic compression devices.),(Exclusion Criteria: None) -- Subject constrained to the Intermittent pneumatic compression devices (IPC)
(Clinical Focus: This set of values represents the different types of intermittent pneumatic compression devices used for VTE prophylaxis.),(Data Element Scope: The intent of this data element is to represent the application of certain intermittent pneumatic compression devices. Using the Quality Data Model, this data element will map to the Device category.),(Inclusion Criteria: Only include codes which represent different types of intermittent pneumatic compression devices.),(Exclusion Criteria: None) -- Subject constrained to the Intermittent pneumatic compression devices (IPC)
Intervention represents a course of action intended to achieve a result in the care of persons with health problems that does not involve direct physical contact with a patient. Examples include patient education and therapeutic communication.
Data elements that meet criteria using this datatype should document a request to perform the intervention indicated by the QDM category and its corresponding value set. Timing: The time the order is signed; Author dateTime
Data elements that meet criteria using this datatype should document the completion of the intervention indicated by the QDM category and its corresponding value set. Timing: The Relevant Period addresses: startTime – The time the intervention begins stopTime – The time the intervention ends NOTE - timing refers to a single instance of an intervention. If a measure seeks to evaluate multiple interventions over a period of time, the measure developer should use CQL logic to represent the query request.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Intolerance to ACE Inhibitor or ARB valueset (2.16.840.1.113883.3.526.3.1212)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Intolerance to Beta Blocker Therapy valueset (2.16.840.1.113883.3.526.3.1178)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Intolerance to Influenza Vaccine valueset (2.16.840.1.113883.3.526.3.1257)
(Clinical Focus: This grouping of value sets identifies patients who have procedures of intracranial neurosurgery.),(Data Element Scope: The intent of this data element is to identify patients who have an intracranial neurosurgery procedure. Using the Quality Data Model, this particular element will map to the Procedure category.),(Inclusion Criteria: Only use codes which represent intracranial neurosurgery.),(Exclusion Criteria: None.) -- ObservableCode constrained to codes in the Intracranial Neurosurgery valueset (2.16.840.1.113883.3.117.1.7.1.260).
(Clinical Focus: This grouping of value sets identifies patients who have procedures of intracranial neurosurgery.),(Data Element Scope: The intent of this data element is to identify patients who have an intracranial neurosurgery procedure. Using the Quality Data Model, this particular element will map to the Procedure category.),(Inclusion Criteria: Only use codes which represent intracranial neurosurgery.),(Exclusion Criteria: None.) -- Subject constrained to the Intracranial Neurosurgery
(Clinical Focus: This grouping value set contain procedures that represent intravenous or intra-arterial thrombolytic (t-PA) therapy.),(Data Element Scope: The intent of this data element is to identify intravenous or intra-arterial thrombolytic (t-PA) therapy procedures. Using the Quality Data Model, this particular element will map to the 'Procedure' category.),(Inclusion Criteria: Include codes that identify intravenous or intra-arterial thrombolytic (t-PA) therapy procedures.),(Exclusion Criteria: None) -- ObservableCode constrained to codes in the Intravenous or Intra-arterial Thrombolytic (t-PA) Therapy valueset (2.16.840.1.113762.1.4.1045.21).
(Clinical Focus: This grouping value set contain procedures that represent intravenous or intra-arterial thrombolytic (t-PA) therapy.),(Data Element Scope: The intent of this data element is to identify intravenous or intra-arterial thrombolytic (t-PA) therapy procedures. Using the Quality Data Model, this particular element will map to the 'Procedure' category.),(Inclusion Criteria: Include codes that identify intravenous or intra-arterial thrombolytic (t-PA) therapy procedures.),(Exclusion Criteria: None) -- Subject constrained to the Intravenous or Intra-arterial Thrombolytic (t-PA) Therapy
(Clinical Focus: This set of values identifies the route by which a medication is administered, in this case an intravenous route.),(Data Element Scope: The intent of this data element is to identify the route by which a medication is administered, in this case an intravenous route. Using the Quality Data Model, this particular element is an attribute.),(Inclusion Criteria: Only use codes which identify an intravenous route for giving a medication. Codes used are to be SNOMED-CT codes only.),(Exclusion Criteria: None)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Intussusception valueset (2.16.840.1.113883.3.464.1003.199.12.1056)
(Clinical Focus: The intent of this set of values is to capture ischemic heart disease and associated diagnoses as related to Atherosclerotic Cardiovascular Disease (ASCVD).),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by diagnosis codes.),(Inclusion Criteria: Included are acute and chronic forms of ischemic heart disease as well as coronary occlusion, thrombosis, or rupture that can be related to ASCVD.),(Exclusion Criteria: Excluded are acute coronary occlusion related directly to myocardial infarction and myocardial ischemia.) -- ResultValue constrained to codes in the Ischemic heart disease or coronary occlusion, rupture, or thrombosis valueset (2.16.840.1.113762.1.4.1047.46)
(Clinical Focus: This grouping of value sets identifies patients who have had a stroke caused by ischemia, where the blood supply is restricted to an area of the brain by something like thrombosis or an embolism.),(Data Element Scope: The intent of this data element is to identify patients who have a diagnosis of ischemic stroke, or stroke caused by ischemia. Using the Quality Data Model, this particular element would map to the Principal Diagnosis attribute for the Encounter category or to the Diagnosis Category.),(Inclusion Criteria: Only use codes which represent a diagnosis of ischemic stroke, or stroke caused by ischemia. This is a grouping of ICD10CM and SNOMED-CT codes and concepts.),(Exclusion Criteria: None.)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Ischemic Vascular Disease valueset (2.16.840.1.113883.3.464.1003.104.12.1003)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Isotretinoin valueset (2.16.840.1.113883.3.464.1003.196.12.1143).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Isotretinoin
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Isoxsuprine valueset (2.16.840.1.113883.3.464.1003.196.12.1422).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Isoxsuprine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the KCCQ Physical Limitation Score valueset (2.16.840.1.113883.3.464.1003.118.12.1220).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the KCCQ Physical Limitation Score
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the KCCQ Self Efficacy Score valueset (2.16.840.1.113883.3.464.1003.118.12.1221).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the KCCQ Self Efficacy Score
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the KCCQ Social Limitation Score valueset (2.16.840.1.113883.3.464.1003.118.12.1222).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the KCCQ Social Limitation Score
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the KCCQ Total Symptom Score valueset (2.16.840.1.113883.3.464.1003.118.12.1223).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the KCCQ Total Symptom Score
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Ketorolac Tromethamine valueset (2.16.840.1.113883.3.464.1003.196.12.1364).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Ketorolac Tromethamine
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Kidney Failure valueset (2.16.840.1.113883.3.464.1003.109.12.1028)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Kidney Transplant valueset (2.16.840.1.113883.3.464.1003.109.12.1012).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Kidney Transplant
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Kidney Transplant Recipient valueset (2.16.840.1.113883.3.464.1003.109.12.1029)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Knee Dysfunction and Osteoarthritis Outcome Score [KOOS] Activities of Daily Living Score valueset (2.16.840.1.113883.3.464.1003.118.12.1153).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Knee Dysfunction and Osteoarthritis Outcome Score [KOOS] Activities of Daily Living Score
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Knee Dysfunction and Osteoarthritis Outcome Score [KOOS] Pain Score valueset (2.16.840.1.113883.3.464.1003.118.12.1180).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Knee Dysfunction and Osteoarthritis Outcome Score [KOOS] Pain Score
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Knee Dysfunction and Osteoarthritis Outcome Score [KOOS] Sport Recreation Score valueset (2.16.840.1.113883.3.464.1003.118.12.1152).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Knee Dysfunction and Osteoarthritis Outcome Score [KOOS] Sport Recreation Score
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Knee Dysfunction and Osteoarthritis Outcome Score [KOOS] Symptoms Score valueset (2.16.840.1.113883.3.464.1003.118.12.1182).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Knee Dysfunction and Osteoarthritis Outcome Score [KOOS] Symptoms Score
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Knee Injury and Osteoarthritis Outcome Score for Joint Replacement [KOOSJR] valueset (2.16.840.1.113883.3.464.1003.118.12.1218).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Knee Injury and Osteoarthritis Outcome Score for Joint Replacement [KOOSJR]
(Clinical Focus: This grouping of value sets identifies patients who have total knee replacement procedures.),(Data Element Scope: The intent of this data element is to identify patients who have a total knee replacement procedure. Using the Quality Data Model, this particular element will map to the Procedure category.),(Inclusion Criteria: Only use codes which represent the surgical procedure of a total knee replacement.),(Exclusion Criteria: None.) -- ObservableCode constrained to codes in the Knee Replacement Surgery valueset (2.16.840.1.113883.3.117.1.7.1.261).
(Clinical Focus: This grouping of value sets identifies patients who have total knee replacement procedures.),(Data Element Scope: The intent of this data element is to identify patients who have a total knee replacement procedure. Using the Quality Data Model, this particular element will map to the Procedure category.),(Inclusion Criteria: Only use codes which represent the surgical procedure of a total knee replacement.),(Exclusion Criteria: None.) -- Subject constrained to the Knee Replacement Surgery
(Clinical Focus: This set of values represent the concept of labor.),(Data Element Scope: The intent of this data element is to identify that a patient is in labor. Using the Quality Data Model, this particular element will map to the 'Physical Exam' category.),(Inclusion Criteria: Include SNOMED CT codes that identify onset and establishment of labor.),(Exclusion Criteria: Exclude codes describing later stages of labor and latent labor.) -- ObservableCode constrained to codes in the Labor valueset (2.16.840.1.113883.3.117.1.7.1.281).
LaboratoryTLaboratory Test represents a medical procedure that involves testing a sample of blood, urine, or other substance from the body. Tests can help determine a diagnosis, plan treatment, check to see if treatment is working, or monitor the disease over time.14 This QDM data category for Laboratory Test is only used for information about the subject of record.est
Data elements that meet criteria using this datatype should document a request for the laboratory test indicated by the QDM category and its corresponding value set. Timing: The time the order is signed; Author dateTime.
Data elements that meet criteria using this datatype should document the laboratory test indicated by the QDM category and its corresponding value set was performed. Timing: The Relevant Period addresses: startTime – When the laboratory test is initiated (i.e., the time the specimen collection begins). stopTime – when the laboratory test is completed (i.e., the time the specimen collection ends). Examples: 1) Initiation of a venipuncture for a fasting blood glucose to the time venipuncture for the fasting blood glucose is completed – basically a single point in time for many specimen collections. 2) Initiation of a 24-hour urine collection for measured creatinine clearance until completion of the 24-hour urine collection Note – the time that the result report is available is a separate attribute than the time of the study (specimen collection)
(Clinical Focus: This set of values contains laboratory tests, including a series of panels and urine testing that may be collected in patients that have a diagnosis of hypertension.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Laboratory Tests for Hypertension valueset (2.16.840.1.113883.3.600.1482).
(Clinical Focus: This set of values contains laboratory tests, including a series of panels and urine testing that may be collected in patients that have a diagnosis of hypertension.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Laboratory Tests for Hypertension
(Clinical Focus: This set of values represent the concept of labor.),(Data Element Scope: The intent of this data element is to identify that a patient is in labor. Using the Quality Data Model, this particular element will map to the 'Physical Exam' category.),(Inclusion Criteria: Include SNOMED CT codes that identify onset and establishment of labor.),(Exclusion Criteria: Exclude codes describing later stages of labor and latent labor.) -- Subject constrained to the Labor
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Lab Tests During Pregnancy valueset (2.16.840.1.113883.3.464.1003.111.12.1007).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Lab Tests During Pregnancy
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Lab Tests for Sexually Transmitted Infections valueset (2.16.840.1.113883.3.464.1003.110.12.1051).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Lab Tests for Sexually Transmitted Infections
A human language, spoken or written.
The most recent date the entry was changed.
(Clinical Focus: This set of values contains lab tests commonly used for LDL cholesterol measurement.),(Data Element Scope: The intent of this data element is to identify patients who had a lab test on a source of serum or plasma. Using the Quality Data Model, this particular element would map to Laboratory Test category.),(Inclusion Criteria: Include LDL c tests using the source of serum or plasma based on a measurement scale of mass per volume.),(Exclusion Criteria: None) -- ObservableCode constrained to codes in the LDL-c valueset (2.16.840.1.113883.3.117.1.7.1.215).
(Clinical Focus: This set of values contains lab tests commonly used for LDL cholesterol measurement.),(Data Element Scope: The intent of this data element is to identify patients who had a lab test on a source of serum or plasma. Using the Quality Data Model, this particular element would map to Laboratory Test category.),(Inclusion Criteria: Include LDL c tests using the source of serum or plasma based on a measurement scale of mass per volume.),(Exclusion Criteria: None) -- Subject constrained to the LDL-c
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the LDL Test valueset (2.16.840.1.113883.3.464.1003.198.11.1029).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the LDL Test
(Clinical Focus: This set of values represents a patient leaving against medical advice.),(Data Element Scope: The intent of this data element is to identify the final place or setting to which the patient was discharged on the day of discharge from a particular inpatient encounter. This particular value set intends to identify patients who left against medical advice. Using the Quality Data Model, this particular value set is used with the Attribute of 'Discharge status' used with the 'Encounter' category.),(Inclusion Criteria: Only SNOMED CT codes representing leaving against medical advice should be included.),(Exclusion Criteria: None)
(Clinical Focus: Concepts that represent the left side),(Data Element Scope: Left),(Inclusion Criteria: Appropriate left concepts),(Exclusion Criteria: Concepts representing Right)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Left Unilateral Amputation Above or Below Knee valueset (2.16.840.1.113883.3.464.1003.113.12.1058)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Left Unilateral Amputation Procedure Above or Below Knee valueset (2.16.840.1.113883.3.464.1003.113.12.1072).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Left Unilateral Amputation Procedure Above or Below Knee
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Left Ventricular Systolic Dysfunction valueset (2.16.840.1.113883.3.526.3.1091)
The difference of the admission date/time and the discharge date/time for the encounter. This attribute should not be used for outpatient encounters.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Lens Procedure valueset (2.16.840.1.113883.3.526.3.1429).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Lens Procedure
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObjectTypeCode constrained to codes in the Leucovorin valueset (2.16.840.1.113883.3.464.1003.196.12.1205).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Leucovorin
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Level of Severity of Retinopathy Findings valueset (2.16.840.1.113883.3.526.3.1283)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development)
A time in minutes before or after a given life event, for example, 30 minutes before a meal. Whether this means before or after is carried by the life event code.
(Clinical Focus: This set of values contains lifestyle education related to hypertension that is documented by the health care professional.),(Data Element Scope: ),(Inclusion Criteria: Included is education provided regarding lifestyle modification as related to the diagnosis or finding of hypertension.),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Lifestyle Recommendation valueset (2.16.840.1.113883.3.600.1508).
(Clinical Focus: This set of values contains lifestyle education related to hypertension that is documented by the health care professional.),(Data Element Scope: ),(Inclusion Criteria: Included is education provided regarding lifestyle modification as related to the diagnosis or finding of hypertension.),(Exclusion Criteria: ) -- Subject constrained to the Lifestyle Recommendation
(Clinical Focus: This value set contains concepts related to limited life expectancy, including poor prognosis or terminal illness.),(Data Element Scope: The intent of this data element is to identify patients who are deemed to have limited life expectancy. Using the Quality Data Model, this data element would map to the Diagnosis category.),(Inclusion Criteria: Includes concepts which convey a poor prognosis for patient’s health status, as well as terminal or pre-terminal illness.),(Exclusion Criteria: None) -- ResultValue constrained to codes in the Limited Life Expectancy valueset (2.16.840.1.113883.3.526.3.1259)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the List of Single RxNorm Code Concepts for High Risk Drugs for the Elderly valueset (2.16.840.1.113883.3.464.1003.196.12.1272).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the List of Single RxNorm Code Concepts for High Risk Drugs for the Elderly
(Clinical Focus: This set of values contains diagnoses that are commonly used in the inpatient setting for newborn live born, and born in hospital. This value set is a grouping value set composed of ICD-10-CM and SNOMED CT value sets.),(Data Element Scope: The intent of this data element is to identify patients who have active diagnosis, mapped to QDM 'Diagnosis' or to the 'Principal Diagnosis' or 'Diagnosis' attributes of the QDM 'Encounter' datatype.),(Inclusion Criteria: This value set includes ICD-10-CM and SNOMED CT value sets.),(Exclusion Criteria: None.)
(Clinical Focus: This set of values contains diagnoses that are commonly used in the inpatient setting for newborn live born, and born in hospital. This value set is a grouping value set composed of ICD-10-CM and SNOMED CT value sets.),(Data Element Scope: The intent of this data element is to identify patients who have active diagnosis, mapped to QDM 'Diagnosis' or to the 'Principal Diagnosis' or 'Diagnosis' attributes of the QDM 'Encounter' datatype.),(Inclusion Criteria: This value set includes ICD-10-CM and SNOMED CT value sets.),(Exclusion Criteria: None.) -- ResultValue constrained to codes in the Live Birth Newborn Born in Hospital valueset (2.16.840.1.113762.1.4.1046.6)
(Clinical Focus: The focus of this value set is to capture a diagnosis of liver disease. The original intent of this value set is to capture liver disease that would indicate that a statin medication may not be appropriate.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by diagnosis codes.),(Inclusion Criteria: This value set includes chronic and acute liver conditions that may represent the liver is failing. Examples of conditions include, but are not limited to the following: alcoholic liver damage, cirrhosis, hepatitis C and E, and liver necrosis.),(Exclusion Criteria: This value set does not contain Hepatitis A and Hepatitis B.) -- ResultValue constrained to codes in the Liver Disease valueset (2.16.840.1.113762.1.4.1047.42)
(Clinical Focus: This set of values contains unfractionated heparin medications with strengths that could reasonably be used for VTE prophylaxis.),(Data Element Scope: The intent of this data element is to identify patients who are on low-dose unfractionated heparin as VTE prophylaxis. Using the Quality Data Model, this data element maps to the Medication category.),(Inclusion Criteria: Injectable products that could reasonably be used to achieve a dose of at least 5000 units when administered subcutaneously.),(Exclusion Criteria: Concentrations less than 250 UNT/ML.) -- ObjectTypeCode constrained to codes in the Low Dose Unfractionated Heparin for VTE Prophylaxis valueset (2.16.840.1.113762.1.4.1045.39).
(Clinical Focus: This set of values contains unfractionated heparin medications with strengths that could reasonably be used for VTE prophylaxis.),(Data Element Scope: The intent of this data element is to identify patients who are on low-dose unfractionated heparin as VTE prophylaxis. Using the Quality Data Model, this data element maps to the Medication category.),(Inclusion Criteria: Injectable products that could reasonably be used to achieve a dose of at least 5000 units when administered subcutaneously.),(Exclusion Criteria: Concentrations less than 250 UNT/ML.) -- Subject constrained to the Low Dose Unfractionated Heparin for VTE Prophylaxis
(Clinical Focus: This set of values contains unfractionated heparin medications with strengths that could reasonably be used for VTE prophylaxis.),(Data Element Scope: The intent of this data element is to identify patients who are on low-dose unfractionated heparin as VTE prophylaxis. Using the Quality Data Model, this data element maps to the Medication category.),(Inclusion Criteria: Injectable products that could reasonably be used to achieve a dose of at least 5000 units when administered subcutaneously.),(Exclusion Criteria: Concentrations less than 250 UNT/ML.) -- Subject constrained to the Low Dose Unfractionated Heparin for VTE Prophylaxis
The lower limit on a range
The lower limit of detection of the measured points. This is needed if any of the data points have the value 'L' (lower than detection limit).
(Clinical Focus: The intent of this value set is to incorporate low intensity statin medications as defined by the 2013 ACC/AHA guideline.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by medication codes.),(Inclusion Criteria: Low intensity statin therapy is included in this set of values.),(Exclusion Criteria: Any other intensity of statin therapy is excluded.) -- ObjectTypeCode constrained to codes in the Low intensity statin therapy valueset (2.16.840.1.113762.1.4.1047.107).
(Clinical Focus: The intent of this value set is to incorporate low intensity statin medications as defined by the 2013 ACC/AHA guideline.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by medication codes.),(Inclusion Criteria: Low intensity statin therapy is included in this set of values.),(Exclusion Criteria: Any other intensity of statin therapy is excluded.) -- Subject constrained to the Low intensity statin therapy
(Clinical Focus: The intent of this value set is to incorporate low intensity statin medications as defined by the 2013 ACC/AHA guideline.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by medication codes.),(Inclusion Criteria: Low intensity statin therapy is included in this set of values.),(Exclusion Criteria: Any other intensity of statin therapy is excluded.) -- Subject constrained to the Low intensity statin therapy
(Clinical Focus: This set of values represents medications used for VTE prophylaxis. The medications are low molecular weight heparins. The medications included in this value set are administered parenterally.),(Data Element Scope: The intent of this data element is to identify patients who are on low molecular weight heparin therapy as VTE prophylaxis. Using the Quality Data Model, this data element maps to the Medication category.),(Inclusion Criteria: Only include RxNorm codes which specifically represent low molecular weight heparins which are administered parenterally.),(Exclusion Criteria: None.) -- ObjectTypeCode constrained to codes in the Low Molecular Weight Heparin for VTE Prophylaxis valueset (2.16.840.1.113883.3.117.1.7.1.219).
(Clinical Focus: This set of values represents medications used for VTE prophylaxis. The medications are low molecular weight heparins. The medications included in this value set are administered parenterally.),(Data Element Scope: The intent of this data element is to identify patients who are on low molecular weight heparin therapy as VTE prophylaxis. Using the Quality Data Model, this data element maps to the Medication category.),(Inclusion Criteria: Only include RxNorm codes which specifically represent low molecular weight heparins which are administered parenterally.),(Exclusion Criteria: None.) -- Subject constrained to the Low Molecular Weight Heparin for VTE Prophylaxis
(Clinical Focus: This set of values represents medications used for VTE prophylaxis. The medications are low molecular weight heparins. The medications included in this value set are administered parenterally.),(Data Element Scope: The intent of this data element is to identify patients who are on low molecular weight heparin therapy as VTE prophylaxis. Using the Quality Data Model, this data element maps to the Medication category.),(Inclusion Criteria: Only include RxNorm codes which specifically represent low molecular weight heparins which are administered parenterally.),(Exclusion Criteria: None.) -- Subject constrained to the Low Molecular Weight Heparin for VTE Prophylaxis
(Clinical Focus: This set of values contains codes that identify patients with a diagnosis of lupus (lupus erythematosus).),(Data Element Scope: This value set is developed for the diagnosis QDM datatype. It can potentially be used for other datatypes as well.),(Inclusion Criteria: Includes diagnosis codes for systemic, discoid, and drug-induced lupus erythematosus.),(Exclusion Criteria: Excludes diagnosis codes for systemic lupus erythematosus in childhood or in remission.) -- ResultValue constrained to codes in the Lupus valueset (2.16.840.1.113883.3.464.1003.117.12.1010)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Macular Edema Findings Absent valueset (2.16.840.1.113883.3.526.3.1284)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Macular Edema Findings Present valueset (2.16.840.1.113883.3.526.3.1320)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Macular Exam valueset (2.16.840.1.113883.3.526.3.1251).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Macular Exam
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Major Depression valueset (2.16.840.1.113883.3.464.1003.105.12.1007)
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- ResultValue constrained to codes in the Major Depression Including Remission valueset (2.16.840.113883.3.67.1.101.3.2444)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development)
(Clinical Focus: This set of values contains codes that are used to identify patients with a diagnosis of chronic intestinal malabsorption.),(Data Element Scope: This value set is developed for the diagnosis QDM datatype. It can potentially be used for other datatypes as well.),(Inclusion Criteria: Includes regional enteritis, ulcerative enterocolitis, celiac disease, tropical sprue, blind loop syndrome, Pancreatic steatorrhea, and other specified or unspecified intestinal malabsorption disorders.),(Exclusion Criteria: Excludes diagnoses of specified disorders of the intestine, including fistula of intesting, ulceration of intesting, performation of intestine, angiodysplasia (with or without hemmorrhage), dieulafoy lesion, and vomiting of fecal matter.) -- ResultValue constrained to codes in the Malabsorption Syndromes valueset (2.16.840.1.113883.3.464.1003.199.12.1050)
(Clinical Focus: Concepts that represent Male when assessing quality measures),(Data Element Scope: Gender),(Inclusion Criteria: Appropriate male gender concepts),(Exclusion Criteria: concepts representing Female gender) -- ResultValue constrained to codes in the Male valueset (2.16.840.1.113883.3.560.100.1)
(Clinical Focus: This value set contains codes to identify malignant neoplasms of the colon.),(Data Element Scope: This value set was intended to identify patients who had malignant neoplasms of the colon.),(Inclusion Criteria: Includes codes that indicate malignant neoplasms of the colon, rectum and anus.),(Exclusion Criteria: None.) -- ResultValue constrained to codes in the Malignant Neoplasm of Colon valueset (2.16.840.1.113883.3.464.1003.108.12.1001)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Malignant Neoplasm of Lymphatic and Hematopoietic Tissue valueset (2.16.840.1.113883.3.464.1003.108.12.1009)
(Clinical Focus: This value set contains codes that identify a mammogram.),(Data Element Scope: This value set was intended to identify patients who had a mammogram.),(Inclusion Criteria: Includes codes that identify a mammogram.),(Exclusion Criteria: None) -- ObservableCode constrained to codes in the Mammography valueset (2.16.840.1.113883.3.464.1003.108.12.1018).
(Clinical Focus: This value set contains codes that identify a mammogram.),(Data Element Scope: This value set was intended to identify patients who had a mammogram.),(Inclusion Criteria: Includes codes that identify a mammogram.),(Exclusion Criteria: None) -- Subject constrained to the Mammography
(Clinical Focus: This value set identifies patients with a diagnosis of marfan's syndrome.),(Data Element Scope: This value set is developed for the diagnosis QDM datatype. It can potentially be used for other datatypes as well.),(Inclusion Criteria: Includes diagnosis codes for marfan's syndome with or without cardiovascular, occular, skeletal, or epithelial manifestations.),(Exclusion Criteria: N/A) -- ResultValue constrained to codes in the Marfan's Syndrome valueset (2.16.840.1.113883.3.464.1003.113.12.1048)
-- ActivityCode constrained to codes in the Maternal postpartum depression care (regime/therapy) valueset (drc-8f89ba1789e82b1865ea7952ebb8114cb7b569eb7a63c89889db7eed55d789f5).
-- Subject constrained to the Maternal postpartum depression care (regime/therapy)
-- ObservableCode constrained to codes in the Maternal postpartum depression screening (procedure) valueset (drc-e64de69923f30351dcf463016bdd5d965bb040a20e2112670a50d33a5a0ccc8c).
-- Subject constrained to the Maternal postpartum depression screening (procedure)
Upper bound on a count.
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Measles Antibody Test (IgG Antibody presence) valueset (2.16.840.1.113883.3.464.1003.198.12.1060).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Measles Antibody Test (IgG Antibody presence)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Measles Antibody Test (IgG Antibody Titer) valueset (2.16.840.1.113883.3.464.1003.198.12.1059).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Measles Antibody Test (IgG Antibody Titer)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Measles valueset (2.16.840.1.113883.3.464.1003.110.12.1053)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Measles, Mumps and Rubella (MMR) Vaccine valueset (2.16.840.1.113883.3.464.1003.196.12.1224).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Measles, Mumps and Rubella (MMR) Vaccine Administered valueset (2.16.840.1.113883.3.464.1003.110.12.1031).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Measles, Mumps and Rubella (MMR) Vaccine Administered
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Meclizine valueset (2.16.840.1.113883.3.464.1003.196.12.1506).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Meclizine
A file that contains audio, video, image, or similar content.
(Clinical Focus: This set of values contains procedures that represent the medical induction of labor.),(Data Element Scope: The intent of this data element is to identify medical induction of labor. Using the Quality Data Model, this particular element will map to the 'Procedure' category.),(Inclusion Criteria: Include ICD 9 CM and SNOMED CT codes that identify the medical induction of labor.),(Exclusion Criteria: None.) -- ObservableCode constrained to codes in the Medical Induction of Labor valueset (2.16.840.1.113883.3.117.1.7.1.288).
(Clinical Focus: This set of values contains procedures that represent the medical induction of labor.),(Data Element Scope: The intent of this data element is to identify medical induction of labor. Using the Quality Data Model, this particular element will map to the 'Procedure' category.),(Inclusion Criteria: Include ICD 9 CM and SNOMED CT codes that identify the medical induction of labor.),(Exclusion Criteria: None.) -- Subject constrained to the Medical Induction of Labor
(Clinical Focus: The intent of this value set is to specify a situation or finding was not done by indicating a medical reason a procedure or treatment is contraindicated, not tolerated, or not indicated.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: )
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development)
(Clinical Focus: This set of values contains situations that represent medical reasons for not providing treatment.),(Data Element Scope: The intent of this data element is to identify medical reasons for not providing treatment. Using the Quality Data Model, this particular element will map to the 'Reason' attribute.),(Inclusion Criteria: Only SNOMED CT codes representing medical reasons for not providing treatment should be included.),(Exclusion Criteria: None.)
Medication represents clinical drugs or chemical substances intended for use in the medical diagnosis, cure, treatment, or prevention of disease. Medications are defined as direct referenced values or value sets containing values derived from code systems such as RxNorm.
Data elements that meet criteria using this datatype should document that the medication indicated by the QDM category and its corresponding value set is being taken by the patient. Keep in mind that when this datatype is used with timing relationships, the criterion is looking for a medication being taken for the time frame indicated by the timing relationships. Timing: The Relevant Period addresses: StartTime = when the medication is first known to be used (generally the time of entry on the medication list); StopTime = when the medication is discontinued (generally, the time discontinuation is recorded on the medication list)
Data elements that meet criteria using this datatype should document that the medication indicated by the QDM category and its corresponding value set was actually administered to the patient. Timing: The Relevant Period addresses: startTime = when a single medication administration event starts (e.g., the initiation of an intravenous infusion, or administering a pill or IM injection to a patient); stopTime = when a single medication administration event ends (e.g., the end time of the intravenous infusion, or the administration of a pill or IM injection is completed - for pills and IM injections, the start and stop times are the same) NOTE – Measure developers should address multiple administrations over a period of time using CQL logic. Refer to Special Cases in Appendix A (Section A.3) for scenarios to consider in calculating cumulative medication duration.
Data elements that meet criteria using this datatype should document that the medications indicated by the QDM category and its corresponding value set should be taken by or given to the patient after being discharged from an inpatient encounter. Timing: The time the discharge medication list on the discharge instruction form is authored.
Data elements that meet criteria using this datatype should document that a prescription for the medication indicated by the QDM category and its corresponding value set has been dispensed and provided to the patient or patient proxy. In the ambulatory setting, medications are primarily taken directly by patients and not directly observed. Hence, dispensed, or fulfillment, information is the closest health provider documentation of medication compliance. In settings where patients attest to taking medications in electronic format (perhaps a Personal Health Record), patient attestation of medication taken may be available. The QDM datatype, Medication, Administered addresses medication taken; to address the source of the information, a measure addressing such patient attestation would require use of the dataflow attribute, source. Timing: The time the medication dispensing event occurs; the Author dateTime. Timing: The Relevant Period addresses: startTime = when the first administration of the medication is expected. If not specified. the startTime defaults to the Author dateTime (the time the medication dispensing event occurs). stopTime = when the medication supply provided by the dispensing event is expected to be completed. Note that when calculating cumulative medication duration, the medication dispensed stopTime may be present directly in the fulfillment record. If the stopTime is not available, the duration in days is the difference between the Relevant Period start and stop times. The record may indicate which of the available refills the fulfillment represents but each dispensing event is unique. Therefore, the measure developer should use CQL logic to address multiple dispensing events over a period of time. Refer to Special Cases in Appendix A (Section A.3) for scenarios to consider in calculating cumulative medication duration.
Data elements that meet criteria using this datatype should document a request to a pharmacy to provide the medication indicated by the QDM category and its corresponding value set. Timing: The Author dateTime is the time the order is signed. Timing: The Relevant Period addresses: startTime = when the first administration of the medication is expected. The first administration may be expected at the time of the order or at a specified future date (i.e., the active time for the order); such information should be identified in the medication order. If the startTime is not specified in the order, the startTime defaults to the Author dateTime (the time the order is signed). stopTime = when the medication supply provided by the medication order is expected to be completed, including all fulfillments covered by the number of refills. Note that when calculating cumulative medication duration, the stopTime may be present directly in the medication order. If the stopTime is not available, the duration in days is the difference between the Relevant Period start and stop times multiplied by (1 + the number of refills). Refer to Special Cases in Appendix A (Section A.3) for scenarios to consider in calculating cumulative medication duration.
(Clinical Focus: This set of values contains encounters where a medication list would be reviewed, updated, or transcribed as a current medication list.),(Data Element Scope: ),(Inclusion Criteria: Included are specific encounters from multiple specialty physicians, primary care physicians, as well as therapist and nutritionists; this value set also includes assessments and tasks that would prompt documentation of current medications.),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Medications Encounter Code Set valueset (2.16.840.1.113883.3.600.1.1834).
(Clinical Focus: This set of values contains encounters where a medication list would be reviewed, updated, or transcribed as a current medication list.),(Data Element Scope: ),(Inclusion Criteria: Included are specific encounters from multiple specialty physicians, primary care physicians, as well as therapist and nutritionists; this value set also includes assessments and tasks that would prompt documentation of current medications.),(Exclusion Criteria: ) -- Subject constrained to the Medications Encounter Code Set
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Megestrol valueset (2.16.840.1.113883.3.464.1003.196.12.1342).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Megestrol
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: )
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Meperidine valueset (2.16.840.1.113883.3.464.1003.196.12.1351).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Meperidine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Meprobamate valueset (2.16.840.1.113883.3.464.1003.196.12.1284).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Meprobamate
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Metaxalone valueset (2.16.840.1.113883.3.464.1003.196.12.1358).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Metaxalone
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Methocarbamol valueset (2.16.840.1.113883.3.464.1003.196.12.1370).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Methocarbamol
Indicates the procedure or technique used in its performance.
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Methyldopa valueset (2.16.840.1.113883.3.464.1003.196.12.1331).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Methyldopa
(Clinical Focus: This set of values contains repair of the uterus procedures performed by any approach.),(Data Element Scope: The intent of this value set is to identify patients who have had a metroplasty, uteroplasty, hysteroplasty, or repair of the uterus procedure.),(Inclusion Criteria: Metroplasty, uteroplasty, hysteroplasty, and repair of uterus procedures by any approach are included.),(Exclusion Criteria: All other procedures.) -- ObservableCode constrained to codes in the Metroplasty valueset (2.16.840.1.113762.1.4.1110.25).
(Clinical Focus: This set of values contains repair of the uterus procedures performed by any approach.),(Data Element Scope: The intent of this value set is to identify patients who have had a metroplasty, uteroplasty, hysteroplasty, or repair of the uterus procedure.),(Inclusion Criteria: Metroplasty, uteroplasty, hysteroplasty, and repair of uterus procedures by any approach are included.),(Exclusion Criteria: All other procedures.) -- Subject constrained to the Metroplasty
The length of time between sampling times, measured in milliseconds.
Lower bound on a count.
(Clinical Focus: The intent of this value set is to incorporate moderate intensity statin medications as defined by the 2013 ACC/AHA guideline.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by medication codes.),(Inclusion Criteria: Moderate intensity statin therapy is included in this set of values.),(Exclusion Criteria: Any other intensity of statin therapy is excluded.) -- ObjectTypeCode constrained to codes in the Moderate intensity statin therapy valueset (2.16.840.1.113762.1.4.1047.98).
(Clinical Focus: The intent of this value set is to incorporate moderate intensity statin medications as defined by the 2013 ACC/AHA guideline.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by medication codes.),(Inclusion Criteria: Moderate intensity statin therapy is included in this set of values.),(Exclusion Criteria: Any other intensity of statin therapy is excluded.) -- Subject constrained to the Moderate intensity statin therapy
(Clinical Focus: The intent of this value set is to incorporate moderate intensity statin medications as defined by the 2013 ACC/AHA guideline.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by medication codes.),(Inclusion Criteria: Moderate intensity statin therapy is included in this set of values.),(Exclusion Criteria: Any other intensity of statin therapy is excluded.) -- Subject constrained to the Moderate intensity statin therapy
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Moderate or Severe Impairment, Better Eye, Profound Impairment Lesser Eye valueset (2.16.840.1.113883.3.526.3.1464)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Moderate or Severe LVSD valueset (2.16.840.1.113883.3.526.3.1090)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development)
(Clinical Focus: This set of values contains lifestyle modification issues in relation to alcohol consumption; that alcoholism was addressed through education, counseling, or referral.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Moderation of ETOH Consumption Recommendation valueset (2.16.840.1.113883.3.600.823).
(Clinical Focus: This set of values contains lifestyle modification issues in relation to alcohol consumption; that alcoholism was addressed through education, counseling, or referral.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Moderation of ETOH Consumption Recommendation
Representation of an amount of currency or monetary value.
-- ObservableCode constrained to codes in the Monofilament foot sensation test (procedure) valueset (drc-37129ce483571cc63df7966e306dcddb2c35dd3bf3aa768a1ce357089d34706b).
-- Subject constrained to the Monofilament foot sensation test (procedure)
(Clinical Focus: This value set includes concepts related to 'morgagnian cataract'.),(Data Element Scope: This value set includes concepts related to 'morgagnian cataract'.),(Inclusion Criteria: This value set includes concepts related to 'morgagnian cataract'.),(Exclusion Criteria: Concepts not related to 'morgagnian cataract.') -- ResultValue constrained to codes in the Morgagnian Cataract valueset (2.16.840.1.113883.3.526.3.1558)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Mumps Antibody Test (IgG Antibody presence) valueset (2.16.840.1.113883.3.464.1003.198.12.1062).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Mumps Antibody Test (IgG Antibody presence)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Mumps Antibody Test (IgG Antibody Titer) valueset (2.16.840.1.113883.3.464.1003.198.12.1061).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Mumps Antibody Test (IgG Antibody Titer)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Mumps valueset (2.16.840.1.113883.3.464.1003.110.12.1032)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Myocardial Infarction valueset (2.16.840.1.113883.3.526.3.403)
(Clinical Focus: This set of values contains procedures that represent a myomectomy.),(Data Element Scope: The intent of this data element is to identify a myomectomy. Using the Quality Data Model, this particular element will map to the 'Procedure' category.),(Inclusion Criteria: Include SNOMED CT codes that identify a myomectomy.),(Exclusion Criteria: None) -- ObservableCode constrained to codes in the Myomectomy valueset (2.16.840.1.113883.3.117.1.7.1.422).
(Clinical Focus: This set of values contains procedures that represent a myomectomy.),(Data Element Scope: The intent of this data element is to identify a myomectomy. Using the Quality Data Model, this particular element will map to the 'Procedure' category.),(Inclusion Criteria: Include SNOMED CT codes that identify a myomectomy.),(Exclusion Criteria: None) -- Subject constrained to the Myomectomy
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Narcolepsy valueset (2.16.840.1.113883.3.464.1003.114.12.1011)
A human-readable narrative that contains a summary of the resource, and may be used to represent the content of the resource to a human.
Additional information on how the narrative was generated, and the scope of information contained.
Indicates the reason that an action was not performed. Only QDM datatypes that represent actions (e.g., performed, recommended, communication, order, dispensed) allow the “negation rationale” attribute. The intent is to indicate a justification that such action did not happen as expected. This attribute specifically does not address the presence or absence of information in a clinical record (e.g., documented absence of allergies Vs lack of documentation about allergies). The syntax in the human readable HQMF is address in CQL examples and in the MAT User Guide. Prior versions of QDM used the syntax, “Procedure, Performed not done.” QDM 5.0 DRAFT uses the syntax, “Procedure, not Performed.” Note: Some datatypes include both Relevant Time and Author dateTime attributes. The purpose is to accommodate Author dateTime if the actual start and stop times are not available when evaluating for feasibility, and also to allow specification of a time for Negation Rationale.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development)
-- ResultValue constrained to codes in the Neomycin adverse reaction (disorder) valueset (drc-4dac8fcacd00b2a701c8cf840724d1b5dcfea3b31a507b04fe72bb8c4d38f810)
(Clinical Focus: This set of values represent a neonatal intensive care unit (NICU) location.),(Data Element Scope: The intent of this data element is to identify the NICU. Using the Quality Data Model, this particular element will map as an attribute to an encounter.),(Inclusion Criteria: Include SNOMED CT codes that identify the NICU.),(Exclusion Criteria: None)
(Clinical Focus: This set of values contains procedures or evaluations for newborn hearing screening conducted on left ear. This value set contains LOINC codes.),(Data Element Scope: The intent of this data element is to identify patients who have received newborn hearing screening on his/her left ear, mapped to QDM 'Diagnostic Study, Performed.'),(Inclusion Criteria: Includes LOINC codes.),(Exclusion Criteria: None.) -- ObservableCode constrained to codes in the Newborn Hearing Screen Left valueset (2.16.840.1.114222.4.1.214079.1.1.3).
(Clinical Focus: This set of values contains procedures or evaluations for newborn hearing screening conducted on left ear. This value set contains LOINC codes.),(Data Element Scope: The intent of this data element is to identify patients who have received newborn hearing screening on his/her left ear, mapped to QDM 'Diagnostic Study, Performed.'),(Inclusion Criteria: Includes LOINC codes.),(Exclusion Criteria: None.) -- Subject constrained to the Newborn Hearing Screen Left
(Clinical Focus: This set of values contains procedures or evaluations for newborn hearing screening conducted on right ear. This value set contains LOINC codes.),(Data Element Scope: The intent of this data element is to identify patients who have received newborn hearing screening on his/her right ear, mapped to QDM 'Diagnostic Study, Performed.'),(Inclusion Criteria: Includes LOINC codes.),(Exclusion Criteria: None.) -- ObservableCode constrained to codes in the Newborn Hearing Screen Right valueset (2.16.840.1.114222.4.1.214079.1.1.4).
(Clinical Focus: This set of values contains procedures or evaluations for newborn hearing screening conducted on right ear. This value set contains LOINC codes.),(Data Element Scope: The intent of this data element is to identify patients who have received newborn hearing screening on his/her right ear, mapped to QDM 'Diagnostic Study, Performed.'),(Inclusion Criteria: Includes LOINC codes.),(Exclusion Criteria: None.) -- Subject constrained to the Newborn Hearing Screen Right
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Nifedipine valueset (2.16.840.1.113883.3.464.1003.196.12.1353).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Nifedipine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Nonbenzodiazepine hypnotics valueset (2.16.840.1.113883.3.464.1003.196.12.1480).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Nonbenzodiazepine hypnotics
(Clinical Focus: This set of values contains procedures that represent non-elective inpatient encounters.),(Data Element Scope: The intent of this data element is to identify non-elective inpatient encounters. Using the Quality Data Model, this particular element will map to the 'Encounter' category.),(Inclusion Criteria: Only SNOMED CT codes representing non-elective inpatient encounter should be included.),(Exclusion Criteria: None) -- ActivityCode constrained to codes in the Non-Elective Inpatient Encounter valueset (2.16.840.1.113883.3.117.1.7.1.424).
(Clinical Focus: This set of values contains procedures that represent non-elective inpatient encounters.),(Data Element Scope: The intent of this data element is to identify non-elective inpatient encounters. Using the Quality Data Model, this particular element will map to the 'Encounter' category.),(Inclusion Criteria: Only SNOMED CT codes representing non-elective inpatient encounter should be included.),(Exclusion Criteria: None) -- Subject constrained to the Non-Elective Inpatient Encounter
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Nortriptyline valueset (2.16.840.1.113883.3.464.1003.196.12.1507).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Nortriptyline
How many times the action should be repeated.
The dividend of a fraction.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Nursing Facility Visit valueset (2.16.840.1.113883.3.464.1003.101.12.1012).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Nursing Facility Visit
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Nystagmus and Other Irregular Eye Movements valueset (2.16.840.1.113883.3.526.3.1465)
The phenomenon (person, place, event, condition, other statement) that the subject of this statement addresses or belongs to.
For later reference, an identifier for the object implied by the assertion, which allows the object to be tracked over time. For example, a wound number is used to track a specific wound's condition over time.
An assertion of a physical or conceptual entity, relationship, role, situation, condition, or phenomenon present or absent.
A code representing the type of entity, person, role, condition, or phenomenon that is being asserted to exist or not exist.
A code describing the aspect or property of the subject being observed or measured. The ObservableCode is the 'question code' that pairs to the 'answer' contained in the ResultValue.
A statement that asserts the value of a property (observable) of the subject. The subject is often the patient, but may be a condition, a physical structure, or another clinical statement. For example, an interpretation is a finding about an observation.
(Clinical Focus: This set of values identify the observation encounter types.),(Data Element Scope: The intent of this data element is to identify patients who have had an observation encounter. Using the Quality Data Model, this particular element will map to the 'encounter' category.),(Inclusion Criteria: Only SNOMED CT codes representing inpatient encounter should be included.),(Exclusion Criteria: None.) -- ActivityCode constrained to codes in the Observation Services valueset (2.16.840.1.113762.1.4.1111.143).
(Clinical Focus: This set of values identify the observation encounter types.),(Data Element Scope: The intent of this data element is to identify patients who have had an observation encounter. Using the Quality Data Model, this particular element will map to the 'encounter' category.),(Inclusion Criteria: Only SNOMED CT codes representing inpatient encounter should be included.),(Exclusion Criteria: None.) -- Subject constrained to the Observation Services
(Clinical Focus: This grouping of value sets identifies patients who have a condition related to pregnancy or obstetrics.),(Data Element Scope: The intent of this data element is to identify patients who have a condition, problem or diagnosis related to pregnancy or obstetrics. Using the Quality Data Model, this particular element will map to either the Diagnosis category.),(Inclusion Criteria: Only use codes which represent a condition, problem or diagnosis related to pregnancy or obstetrics.),(Exclusion Criteria: None.) -- ResultValue constrained to codes in the Obstetrics valueset (2.16.840.1.113883.3.117.1.7.1.263)
(Clinical Focus: This grouping of value sets identifies patients who have a venous thromboembolism related to pregnancy or obstetrics.),(Data Element Scope: The intent of this data element is to identify patients who have a venous thromboembolism related to pregnancy or obstetrics. Using the Quality Data Model, this particular element would map to the Diagnosis category or the Diagnosis attribute for the Encounter category.),(Inclusion Criteria: Only use codes which represent a venous thromboembolism related to pregnancy or obstetrics.),(Exclusion Criteria: None.) -- ResultValue constrained to codes in the Obstetrics VTE valueset (2.16.840.1.113883.3.117.1.7.1.264)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Occupational Therapy Evaluation valueset (2.16.840.1.113883.3.526.3.1011).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Occupational Therapy Evaluation
The point in time in which something happens.
The point in time or span of time in which something happens.
(Clinical Focus: This value set indentifies patients who have had an office or other outpatient visit.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Includes comprehensive history, evaluation, and management of a patient in an office or outpatient facility. Patient can be presenting with problems that are minor to high severity.),(Exclusion Criteria: Excludes non-office visits, including telehealth services.) -- ActivityCode constrained to codes in the Office Visit valueset (2.16.840.1.113883.3.464.1003.101.11.1005).
(Clinical Focus: This value set identifies patients who have had an office or other outpatient visit.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Includes comprehensive history, evaluation, and management of a patient in an office or outpatient facility. Patient can be presenting with problems that are minor to high severity.),(Exclusion Criteria: Excludes non-office visits, including telehealth services.) -- ActivityCode constrained to codes in the Office Visit1 valueset (2.16.840.1.113883.3.464.1003.101.12.1001).
(Clinical Focus: This value set identifies patients who have had an office or other outpatient visit.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Includes comprehensive history, evaluation, and management of a patient in an office or outpatient facility. Patient can be presenting with problems that are minor to high severity.),(Exclusion Criteria: Excludes non-office visits, including telehealth services.) -- Subject constrained to the Office Visit1
(Clinical Focus: This value set indentifies patients who have had an office or other outpatient visit.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Includes comprehensive history, evaluation, and management of a patient in an office or outpatient facility. Patient can be presenting with problems that are minor to high severity.),(Exclusion Criteria: Excludes non-office visits, including telehealth services.) -- Subject constrained to the Office Visit
(Clinical Focus: Gender identity restricted to only Male and Female used in administrative situations requiring a restriction to these two categories.),(Data Element Scope: Gender),(Inclusion Criteria: Male and Female only.),(Exclusion Criteria: Any gender identity that is not male or female.) -- ResultValue constrained to codes in the ONC Administrative Sex valueset (2.16.840.1.113762.1.4.1)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Open Wound of Eyeball valueset (2.16.840.1.113883.3.526.3.1430)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Ophthalmological Services valueset (2.16.840.1.113883.3.526.3.1285).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Ophthalmological Services
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Ophthalmologic Outpatient Visit valueset (2.16.840.1.113883.3.464.1003.101.11.1206).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Ophthalmologic Outpatient Visit
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Optic Atrophy valueset (2.16.840.1.113883.3.526.3.1466)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Optic Disc Exam for Structural Abnormalities valueset (2.16.840.1.113883.3.526.3.1334).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Optic Disc Exam for Structural Abnormalities
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Optic Neuritis valueset (2.16.840.1.113883.3.526.3.1467)
(Clinical Focus: This set of values identifies oral Factor Xa inhibitors indicated for VTE prophylaxis and treatment.),(Data Element Scope: The intent of this data element is to identify patients who receive oral factor Xa inhibitors for VTE prophylaxis. Using the Quality Data Model, this particular element will map to the Medication category.),(Inclusion Criteria: Oral forms of factor Xa inhibitors.),(Exclusion Criteria: Other dose forms of factor Xa inhibitors.) -- ObjectTypeCode constrained to codes in the Oral Factor Xa Inhibitor for VTE Prophylaxis or VTE Treatment valueset (2.16.840.1.113883.3.117.1.7.1.134).
(Clinical Focus: This set of values identifies oral Factor Xa inhibitors indicated for VTE prophylaxis and treatment.),(Data Element Scope: The intent of this data element is to identify patients who receive oral factor Xa inhibitors for VTE prophylaxis. Using the Quality Data Model, this particular element will map to the Medication category.),(Inclusion Criteria: Oral forms of factor Xa inhibitors.),(Exclusion Criteria: Other dose forms of factor Xa inhibitors.) -- Subject constrained to the Oral Factor Xa Inhibitor for VTE Prophylaxis or VTE Treatment
The scale in which different procedures are ordered in terms of the qualitative value, as opposed to a ranking performed strictly numerically or quantitatively.
The base quantity that a measured value of zero represents. In addition, this provides the units of the entire measurement series.
(Clinical Focus: This value set identifies patients with a diagnosis of osteogenesis imperfecta.),(Data Element Scope: This value set is developed for the diagnosis QDM datatype. It can potentially be used for other datatypes as well.),(Inclusion Criteria: Includes diagnosis codes for osteogenesis imperfecta disease classifications 1-4. Does include diagnoses in perinatal population.),(Exclusion Criteria: Excludes diagnosis of osteoporosis with pseudoglioma.) -- ResultValue constrained to codes in the Osteogenesis Imperfecta valueset (2.16.840.1.113883.3.464.1003.113.12.1044)
(Clinical Focus: This value set identifies patients with a diagnosis of osteopenia.),(Data Element Scope: This value set is developed for the diagnosis QDM datatype. It can potentially be used for other datatypes as well.),(Inclusion Criteria: Includes diagnosis codes for specified and unspecified disorder of bones and cartilage. Includes osteopenia of prematurity, drug-induced osteopenia, and senile osteopenia.),(Exclusion Criteria: Excludes diagnosis of arrest of bone development or growth, chondromalacia, or stress fracture of bone.) -- ResultValue constrained to codes in the Osteopenia valueset (2.16.840.1.113883.3.464.1003.113.12.1049)
(Clinical Focus: This value set contains codes to identify osteoporosis.),(Data Element Scope: This value set was intended to identify patients who had osteoporosis.),(Inclusion Criteria: Include diagnosis codes for idiopathic, senile, disuse, and other/unspecified osteoporosis. Includes localized, transient, and regional migrating osteoporosis.),(Exclusion Criteria: Exclude diagnosis codes for osteoporosis due to cystic fibrosis.) -- ResultValue constrained to codes in the Osteoporosis valueset (2.16.840.1.113883.3.464.1003.113.12.1038)
(Clinical Focus: This set of values contains codes that are used to identify patients with a diagnosis of pathological fracture with or without occurrence of osteoporosis.),(Data Element Scope: This value set is developed for the diagnosis QDM datatype. It can potentially be used for other datatypes as well.),(Inclusion Criteria: Include all diagnosis codes associated with pathological fracture, with or without reference to osteoporosis.),(Exclusion Criteria: Exclude all diagnosis codes for fractures that are not pathological.) -- ResultValue constrained to codes in the Osteoporotic Fractures valueset (2.16.840.1.113883.3.464.1003.113.12.1050)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Other and Unspecified Forms of Chorioretinitis and Retinochoroiditis valueset (2.16.840.1.113883.3.526.3.1468)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Other Background Retinopathy and Retinal Vascular Changes valueset (2.16.840.1.113883.3.526.3.1469)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Other Corneal Deformities valueset (2.16.840.1.113883.3.526.3.1470)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Other Disorders of Optic Nerve valueset (2.16.840.1.113883.3.526.3.1471)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Other Disorders of Sclera valueset (2.16.840.1.113883.3.526.3.1472)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Other Endophthalmitis valueset (2.16.840.1.113883.3.526.3.1473)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Other Female Reproductive Conditions valueset (2.16.840.1.113883.3.464.1003.111.12.1006)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Other Proliferative Retinopathy valueset (2.16.840.1.113883.3.526.3.1480)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Other Retinal Disorders valueset (2.16.840.1.113883.3.526.3.1474)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Other Services Related to Dialysis valueset (2.16.840.1.113883.3.464.1003.109.12.1015).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Other Services Related to Dialysis
(Clinical Focus: This value set indentifies patients who have had an outpatient interaction at an office with a member of their medical care team.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Includes comprehensive history, evaluation, and management of a patient in an office or outpatient facility. Patient can be presenting with problems that are minor to high severity.),(Exclusion Criteria: Excludes non-office visits, including telehealth services.) -- ActivityCode constrained to codes in the Outpatient Consultation valueset (2.16.840.1.113883.3.464.1003.101.12.1008).
(Clinical Focus: This value set indentifies patients who have had an outpatient interaction at an office with a member of their medical care team.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Includes comprehensive history, evaluation, and management of a patient in an office or outpatient facility. Patient can be presenting with problems that are minor to high severity.),(Exclusion Criteria: Excludes non-office visits, including telehealth services.) -- ActivityCode constrained to codes in the Outpatient Consultation1 valueset (2.16.840.1.113883.3.464.1003.101.11.1040).
(Clinical Focus: This value set indentifies patients who have had an outpatient interaction at an office with a member of their medical care team.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Includes comprehensive history, evaluation, and management of a patient in an office or outpatient facility. Patient can be presenting with problems that are minor to high severity.),(Exclusion Criteria: Excludes non-office visits, including telehealth services.) -- Subject constrained to the Outpatient Consultation1
(Clinical Focus: This value set indentifies patients who have had an outpatient interaction at an office with a member of their medical care team.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Includes comprehensive history, evaluation, and management of a patient in an office or outpatient facility. Patient can be presenting with problems that are minor to high severity.),(Exclusion Criteria: Excludes non-office visits, including telehealth services.) -- Subject constrained to the Outpatient Consultation
(Clinical Focus: The intent of this value set is to capture outpatient encounters.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by encounter codes.),(Inclusion Criteria: Included are evaluation and management of a new or established patient through an encounter for annual visit, preventative evaluation, follow-up, or periodic re-evaluations that would occur in the outpatient setting.),(Exclusion Criteria: Any encounters that do not meet the inclusion criteria are excluded.) -- ActivityCode constrained to codes in the Outpatient Encounters for Preventive Care valueset (2.16.840.1.113762.1.4.1047.9).
(Clinical Focus: The intent of this value set is to capture outpatient encounters.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by encounter codes.),(Inclusion Criteria: Included are evaluation and management of a new or established patient through an encounter for annual visit, preventative evaluation, follow-up, or periodic re-evaluations that would occur in the outpatient setting.),(Exclusion Criteria: Any encounters that do not meet the inclusion criteria are excluded.) -- Subject constrained to the Outpatient Encounters for Preventive Care
(Clinical Focus: The intent of this value set is to identify patients that are overweight or obese as a finding documented by the healthcare provider in the medical record.),(Data Element Scope: The intent of this data element is to identify patients who are currently overweight or obese. Using the Quality Data Model, this particular element would map to the Attribute: Reason element.),(Inclusion Criteria: ),(Exclusion Criteria: )
(Clinical Focus: This set of values contains medications that represent Oxytocin.),(Data Element Scope: The intent of this data element is to identify medications that represent Oxytocin. Using the Quality Data Model, this particular element will map to the 'Medication' category.),(Inclusion Criteria: Include RxNorm codes that identify medications that represent Oxytocin as a single ingredient, administered in an injectable form.),(Exclusion Criteria: Exclude drugs that have multiple ingredients. In addition, drugs with dose forms not consistent with injectable administration should not be included. The codes should be limited to those which are for human use and which are able to be prescribed in the US.) -- ObjectTypeCode constrained to codes in the Oxytocin valueset (2.16.840.1.113762.1.4.1045.55).
(Clinical Focus: This set of values contains medications that represent Oxytocin.),(Data Element Scope: The intent of this data element is to identify medications that represent Oxytocin. Using the Quality Data Model, this particular element will map to the 'Medication' category.),(Inclusion Criteria: Include RxNorm codes that identify medications that represent Oxytocin as a single ingredient, administered in an injectable form.),(Exclusion Criteria: Exclude drugs that have multiple ingredients. In addition, drugs with dose forms not consistent with injectable administration should not be included. The codes should be limited to those which are for human use and which are able to be prescribed in the US.) -- Subject constrained to the Oxytocin
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Pain Related to Prostate Cancer valueset (2.16.840.1.113883.3.526.3.451)
-- ObservableCode constrained to codes in the Pain score [HOOS] valueset (drc-a0c6d71e74ffe9153ddeedcb7e0b8aafadf18b96d8f87a952805837293192662).
-- Subject constrained to the Pain score [HOOS]
(Clinical Focus: This set of values is intended to capture that a patient is ordered, admitted to, or referred to palliative care, comfort measures, or Hospice care.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by procedure codes.),(Inclusion Criteria: This includes a referral or admission for palliative care or the health care provider is seeing this patient for palliative care.),(Exclusion Criteria: Excludes codes that do not meet the inclusion criteria.) -- ActivityCode constrained to codes in the Palliative Care valueset (2.16.840.1.113883.3.600.1.1579).
(Clinical Focus: This value set is intended to capture an encounter for palliative care.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by procedure codes.),(Inclusion Criteria: Includes palliative care encounter.),(Exclusion Criteria: Excludes codes that do not meet the inclusion criteria.) -- ActivityCode constrained to codes in the Palliative care encounter valueset (2.16.840.1.113883.3.600.1.1575).
(Clinical Focus: This value set is intended to capture an encounter for palliative care.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by procedure codes.),(Inclusion Criteria: Includes palliative care encounter.),(Exclusion Criteria: Excludes codes that do not meet the inclusion criteria.) -- Subject constrained to the Palliative care encounter
(Clinical Focus: This set of values is intended to capture that a patient is ordered, admitted to, or referred to palliative care, comfort measures, or Hospice care.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by procedure codes.),(Inclusion Criteria: This includes a referral or admission for palliative care or the health care provider is seeing this patient for palliative care.),(Exclusion Criteria: Excludes codes that do not meet the inclusion criteria.) -- Subject constrained to the Palliative Care
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Pap Test valueset (2.16.840.1.113883.3.464.1003.108.12.1017).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Pap Test
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Pap Test
(Clinical Focus: This grouping value set contains procedures that represent parenteral infusion.),(Data Element Scope: The intent of this data element is to identify parenteral infusion procedures. Using the Quality Data Model, this particular element will map to the 'Procedure' category.),(Inclusion Criteria: Include ICD 10 PCS, and SNOMED CT codes that identify parenteral infusion.),(Exclusion Criteria: Exclude codes that do not meet the inclusion criteria.) -- ObservableCode constrained to codes in the Parenteral Nutrition valueset (2.16.840.1.113883.3.117.1.7.1.38).
(Clinical Focus: This grouping value set contains procedures that represent parenteral infusion.),(Data Element Scope: The intent of this data element is to identify parenteral infusion procedures. Using the Quality Data Model, this particular element will map to the 'Procedure' category.),(Inclusion Criteria: Include ICD 10 PCS, and SNOMED CT codes that identify parenteral infusion.),(Exclusion Criteria: Exclude codes that do not meet the inclusion criteria.) -- Subject constrained to the Parenteral Nutrition
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Paroxetine valueset (2.16.840.1.113883.3.464.1003.196.12.1508).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Paroxetine
(Clinical Focus: This set of values contains findings that indicate the normal findings on hearing examination or referral is needed. This value set contains SNOMED-CT codes.),(Data Element Scope: The intent of this data element is to identify patients who have received newborn hearing screening with result of pass or refer, mapped to QDM attribute of result.),(Inclusion Criteria: Includes SNOMED-CT codes. Includes normal finding on hearing examination and referral.),(Exclusion Criteria: None.)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Pathologic Myopia valueset (2.16.840.1.113883.3.526.3.1432)
The role of patient in a healthcare context.
Data elements that meet criteria using this datatype should document that the patient has one or more of the ethnicities indicated by the QDM category and its corresponding value set. Timing: Ethnicity does not have a specific timing. Measures using Patient Characteristic, Ethnicity should address the most recent entry in the clinical record.
Data elements that meet criteria using this datatype should document that the patient's sex matches the QDM category and its corresponding value set. Timing: Birth (administrative) sex does not have a specific timing.
Data elements that meet criteria using this datatype should document that the patient has one or more of the payers indicated by the QDM category and its corresponding value set. Timing: The Relevant Period addresses: startTime – The first day of insurance coverage with the referenced payer stopTime – The last day of insurance coverage with the referenced payer
Data elements that meet criteria using this datatype should document the patient’s race. Timing: Race does not have a specific timing. Measures using Patient Characteristic, Race should address the most recent entry in the clinical record.
(Clinical Focus: This value set identifies a patient who has died in the hospital.),(Data Element Scope: The intent of this data element is to identify the discharge status of patient expired as an attribute of the inpatient encounter. Using the Quality Data Model, this value set is used for this attribute.),(Inclusion Criteria: Only include codes for a patient who had died in the hospital. Codes used are to be SNOMED-CT codes only.),(Exclusion Criteria: None)
-- ObservableCode constrained to codes in the Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] valueset (drc-da9071720e893683cdde0cc3aaa1bc49e05e169bdeda96800c723f8563830965).
-- Subject constrained to the Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]
(Clinical Focus: This value set contains codes that indicate a patient is not ambulatory),(Data Element Scope: This value set was intended to identify patients who are not ambulatory.),(Inclusion Criteria: Includes codes that identify a patient as not ambulatory.),(Exclusion Criteria: None)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Patient Provider Interaction valueset (2.16.840.1.113883.3.526.3.1012).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Patient Provider Interaction
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Patient Reason for ACE Inhibitor or ARB Decline valueset (2.16.840.1.113883.3.526.3.1140)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development)
(Clinical Focus: This set of values contains situations in which a patient may refuse a treatment or service.),(Data Element Scope: ),(Inclusion Criteria: Included are situations related to a treatment or procedure refused, or refusal due to religion or non-compliance.),(Exclusion Criteria: )
(Clinical Focus: This set of values contains situations representing a patient's refusal for treatment.),(Data Element Scope: The intent of this data element is to identify reasons a patient refuses treatment. Using the Quality Data Model, this particular element will map to the ' reason' attribute.),(Inclusion Criteria: This value set includes concepts that identify refusal of any intervention (including procedures, treatment, medication, counseling, screening).‚Äã),(Exclusion Criteria: None.)
(Clinical Focus: Categories of types of health care payor entities as defined by the US Public Health Data Consortium SOP code system),(Data Element Scope: @code in CCDA r2.1 template Planned Coverage [act: identifier urn:oid:2.16.840.1.113883.10.20.22.4.129 (open)] DYNAMIC),(Inclusion Criteria: All codes in the code system),(Exclusion Criteria: none) -- ResultValue constrained to codes in the Payer valueset (2.16.840.1.114222.4.11.3591)
(Clinical Focus: This grouping value set contains procedures used to define percutaneous coronary intervention (PCI).),(Data Element Scope: The intent of this data element is to identify patients who had percutaneous coronary intervention (PCI) during an episode of acute myocardial infarction. Using the Quality Data Model, this particular element would map to the Procedure, Performed datatype.),(Inclusion Criteria: Include codes that identify patients receiving percutaneous coronary intervention (PCI). This is a grouping of ICD10PCS and SNOMEDCT codes.),(Exclusion Criteria: None) -- ObservableCode constrained to codes in the PCI valueset (2.16.840.1.113762.1.4.1045.67).
(Clinical Focus: This grouping value set contains procedures used to define percutaneous coronary intervention (PCI).),(Data Element Scope: The intent of this data element is to identify patients who had percutaneous coronary intervention (PCI) during an episode of acute myocardial infarction. Using the Quality Data Model, this particular element would map to the Procedure, Performed datatype.),(Inclusion Criteria: Include codes that identify patients receiving percutaneous coronary intervention (PCI). This is a grouping of ICD10PCS and SNOMEDCT codes.),(Exclusion Criteria: None) -- Subject constrained to the PCI
-- ObservableCode constrained to codes in the Pedal pulse taking (procedure) valueset (drc-33211b1978e0fee5a3a65e4ecd35fe3f70cd065128690cbc4530e298f87c742c).
-- Subject constrained to the Pedal pulse taking (procedure)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Percutaneous Coronary Interventions valueset (2.16.840.1.113883.3.464.1003.104.12.1010).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Percutaneous Coronary Interventions
(Clinical Focus: This set of values contains diagnoses that represent perforation of the uterus.),(Data Element Scope: The intent of this data element is to identify perforation of the uterus.),(Inclusion Criteria: Includes codes that identify perforation of the uterus.),(Exclusion Criteria: Excludes codes indentifying perforation to body structures other than the uterus.) -- ResultValue constrained to codes in the Perforation of Uterus valueset (2.16.840.1.113762.1.4.1110.14)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Peritoneal Dialysis valueset (2.16.840.1.113883.3.526.3.1084).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Peritoneal Dialysis
(Clinical Focus: Under development),(Data Element Scope: Under development),(Inclusion Criteria: Under development),(Exclusion Criteria: Under development) -- ResultValue constrained to codes in the Personality Disorder valueset (2.16.840.1.113883.3.67.1.101.1.246)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Pervasive Developmental Disorder valueset (2.16.840.1.113883.3.464.1003.105.12.1152)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Phenobarbital valueset (2.16.840.1.113883.3.464.1003.196.12.1348).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Phenobarbital
(Clinical Focus: This set of values indicates that education, recommendation, or counseling was given in order to increase physical activity as necessary.),(Data Element Scope: ),(Inclusion Criteria: Nutritional therapy, encouragement to exercise, and actual prescribed exercise is included in this set of values.),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Physical Activity Recommendation valueset (2.16.840.1.113883.3.600.1518).
(Clinical Focus: This set of values indicates that education, recommendation, or counseling was given in order to increase physical activity as necessary.),(Data Element Scope: ),(Inclusion Criteria: Nutritional therapy, encouragement to exercise, and actual prescribed exercise is included in this set of values.),(Exclusion Criteria: ) -- Subject constrained to the Physical Activity Recommendation
Physical Exam represents the evaluation of the patient's body and/or mental status exam to determine its state of health. The techniques of examination can include palpation (feeling with the hands or fingers), percussion (tapping with the fingers), auscultation (listening), visual inspection or observation, inquisition and smell. Measurements may include vital signs (blood pressure, pulse, respiration) as well as other clinical measures (such as expiratory flow rate and size of lesion). Physical exam includes psychiatric examinations.
Data elements that meet criteria using this datatype should document the completion of the physical exam indicated by the QDM category and its corresponding value set. Timing: The Relevant Period addresses: startTime – The time the physical examination activity begins. stopTime – The time the physical examination activity ends. NOTE - timing refers to a single instance of a physical examination activity. If a measure seeks to evaluate multiple physical examination activities over a period of time, the measure developer should use CQL logic to represent the query request.
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Pneumococcal Conjugate Vaccine valueset (2.16.840.1.113883.3.464.1003.196.12.1221).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Pneumococcal Conjugate Vaccine Administered valueset (2.16.840.1.113883.3.464.1003.110.12.1046).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Pneumococcal Conjugate Vaccine Administered
(Clinical Focus: This value set contains codes that identify the pneumococcal conjugate vaccine.),(Data Element Scope: This value set was intended to identify patients who received a pneumococcal vaccine.),(Inclusion Criteria: Includes the pneumococcal conjugate 13-valent and the pneumococcal polysaccharide 23-valent.),(Exclusion Criteria: Excludes the pneumococcal conjugate 7-valent.) -- ObjectTypeCode constrained to codes in the Pneumococcal Vaccine valueset (2.16.840.1.113883.3.464.1003.110.12.1027).
(Clinical Focus: This value set contains codes that identify the pneumococcal conjugate vaccine was given to a patient.),(Data Element Scope: This value set was intended to identify patients who received a pneumococcal vaccine.),(Inclusion Criteria: Includes the pneumococcal conjugate 13-valent and the pneumococcal polysaccharide 23-valent.),(Exclusion Criteria: Excludes the pneumococcal conjugate 7-valent.) -- ObservableCode constrained to codes in the Pneumococcal Vaccine Administered valueset (2.16.840.1.113883.3.464.1003.110.12.1034).
(Clinical Focus: This value set contains codes that identify the pneumococcal conjugate vaccine was given to a patient.),(Data Element Scope: This value set was intended to identify patients who received a pneumococcal vaccine.),(Inclusion Criteria: Includes the pneumococcal conjugate 13-valent and the pneumococcal polysaccharide 23-valent.),(Exclusion Criteria: Excludes the pneumococcal conjugate 7-valent.) -- Subject constrained to the Pneumococcal Vaccine Administered
-- ResultValue constrained to codes in the Pneumococcal vaccine adverse reaction (disorder) valueset (drc-6621a2eaea7ce3cd48eb4ab9ebb0e88ace7b0dc68e7013b434af66263eee4dcd)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObjectTypeCode constrained to codes in the Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis valueset (2.16.840.1.113883.3.464.1003.196.12.1076).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis
-- ResultValue constrained to codes in the Poliomyelitis vaccine adverse reaction (disorder) valueset (drc-be3e22fef9c7ce13a776d2225e933c1f650348e17dbd8bac6c67d53fc8c57013)
-- ResultValue constrained to codes in the Polymyxin B adverse reaction (disorder) valueset (drc-6a2083e13d02b9cc9c0828593a237d34e2b893ae206b9774aeaa242312d25785)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: )
A sequence of letters and digits used as part of a postal address, often designating a geographic region
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Posterior Lenticonus valueset (2.16.840.1.113883.3.526.3.1433)
-- ActivityCode constrained to codes in the Postoperative follow-up visit, normally included in the surgical package, to indicate that an evaluation and management service was performed during a postoperative period for a reason(s) related to the original procedure valueset (drc-bc08643b62dc8c9ef50b5a8ab5595190086b5f7be562a4effa14f405461c1271).
-- Subject constrained to the Postoperative follow-up visit, normally included in the surgical package, to indicate that an evaluation and management service was performed during a postoperative period for a reason(s) related to the original procedure
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Pregnancy valueset (2.16.840.1.113883.3.526.3.378)
(Clinical Focus: The purpose of this value set it to incorporate all possible pregnancy findings that would indicate a positive pregnancy test.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by diagnosis codes.),(Inclusion Criteria: This set of values includes abdominal and normal pregnancy as well as abortion, tubal, ectopic pregnancy and various other diagnoses that could indicate a patient is pregnant.),(Exclusion Criteria: Previously conceived and past delivered pregnancies are not included.) -- ResultValue constrained to codes in the Pregnancy Dx valueset (2.16.840.1.113883.3.600.1.1623)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Pregnancy Test valueset (2.16.840.1.113883.3.464.1003.111.12.1011).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Pregnancy Test
(Clinical Focus: This set of values contains procedures used to represent patients who receive prescribed medications education.),(Data Element Scope: The intent of this data element is to identify patients who receive education on the medications they were prescribed to take. Using the Quality Data Model, this particular element will map to the 'Communication' category.),(Inclusion Criteria: Only SNOMED CT codes representing prescribed medications education should be included.),(Exclusion Criteria: None) -- ObservableCode constrained to codes in the Prescribed Medications Education valueset (2.16.840.1.113883.3.117.1.7.1.379)
Whether the object is present or absent, exists or does not exist.
Prevalance Period is the time from onset dateTime to abatement dateTime.
(Clinical Focus: Initial comprehensive preventive medical evaluation, including regular preventive care or care of small problem or preexisting condition that requires no extra work, for a patient that received prior outpatient professional services from the physician practice in the last 3 years.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Include only codes that indicate initial comprehensive preventive medical evaluation, including regular preventive care or care of small problem or preexisting condition that requires no extra work, for a patient that received prior outpatient professional services from the physician practice in the last 3 years.),(Exclusion Criteria: Exclude codes that are not for comprehensive preventive medical evaluations and codes that are for patients who have not been seen in the last 3 years.) -- ActivityCode constrained to codes in the Preventive Care, Established Office Visit, 0 to 17 valueset (2.16.840.1.113883.3.464.1003.101.12.1024).
(Clinical Focus: Initial comprehensive preventive medical evaluation, including regular preventive care or care of small problem or preexisting condition that requires no extra work, for a patient that received prior outpatient professional services from the physician practice in the last 3 years.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Include only codes that indicate initial comprehensive preventive medical evaluation, including regular preventive care or care of small problem or preexisting condition that requires no extra work, for a patient that received prior outpatient professional services from the physician practice in the last 3 years.),(Exclusion Criteria: Exclude codes that are not for comprehensive preventive medical evaluations and codes that are for patients who have not been seen in the last 3 years.) -- Subject constrained to the Preventive Care, Established Office Visit, 0 to 17
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Preventive Care - Initial Office Visit, 0 to 17 valueset (2.16.840.1.113883.3.464.1003.101.11.1110).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Preventive Care - Initial Office Visit, 0 to 17
(Clinical Focus: This value set indentifies patients over the age of 18 who have had an established preventive care office visit.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Includes comprehensive preventive medicine reevaluation and management of an individual over the age of 18.),(Exclusion Criteria: Excludes non-office visits, including telehealth services.) -- ActivityCode constrained to codes in the Preventive Care Services - Established Office Visit, 18 and Up valueset (2.16.840.1.113883.3.464.1003.101.11.1125).
(Clinical Focus: This value set identifies patients over the age of 18 who have had an established preventive care office visit.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Includes comprehensive preventive medicine reevaluation and management of an individual over the age of 18.),(Exclusion Criteria: Excludes non-office visits, including telehealth services.) -- ActivityCode constrained to codes in the Preventive Care Services - Established Office Visit, 18 and Up1 valueset (2.16.840.1.113883.3.464.1003.101.12.1025).
(Clinical Focus: This value set identifies patients over the age of 18 who have had an established preventive care office visit.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Includes comprehensive preventive medicine reevaluation and management of an individual over the age of 18.),(Exclusion Criteria: Excludes non-office visits, including telehealth services.) -- Subject constrained to the Preventive Care Services - Established Office Visit, 18 and Up1
(Clinical Focus: This value set indentifies patients over the age of 18 who have had an established preventive care office visit.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Includes comprehensive preventive medicine reevaluation and management of an individual over the age of 18.),(Exclusion Criteria: Excludes non-office visits, including telehealth services.) -- Subject constrained to the Preventive Care Services - Established Office Visit, 18 and Up
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Preventive Care Services - Group Counseling valueset (2.16.840.1.113883.3.464.1003.101.12.1027).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Preventive Care Services - Group Counseling
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Preventive Care Services-Individual Counseling valueset (2.16.840.1.113883.3.464.1003.101.12.1026).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Preventive Care Services-Individual Counseling
(Clinical Focus: Initial comprehensive preventive medical evaluation, including regular preventive care or care of small problem or preexisting condition that requires no extra work, for a patient that has no prior outpatient professional services from the physician practice in the last 3 years.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Include only codes that indicate initial comprehensive preventive medical evaluation, including regular preventive care or care of small problem or preexisting condition that requires no extra work, for a patient that has no prior outpatient professional services from the physician practice in the last 3 years.),(Exclusion Criteria: Exclude codes that are not for comprehensive preventive medical evaluations and codes that are for patients who have been seen in the last 3 years.) -- ActivityCode constrained to codes in the Preventive Care Services, Initial Office Visit, 0 to 17 valueset (2.16.840.1.113883.3.464.1003.101.12.1022).
(Clinical Focus: Initial comprehensive preventive medical evaluation, including regular preventive care or care of small problem or preexisting condition that requires no extra work, for a patient that has no prior outpatient professional services from the physician practice in the last 3 years.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Include only codes that indicate initial comprehensive preventive medical evaluation, including regular preventive care or care of small problem or preexisting condition that requires no extra work, for a patient that has no prior outpatient professional services from the physician practice in the last 3 years.),(Exclusion Criteria: Exclude codes that are not for comprehensive preventive medical evaluations and codes that are for patients who have been seen in the last 3 years.) -- Subject constrained to the Preventive Care Services, Initial Office Visit, 0 to 17
(Clinical Focus: This value set indentifies patients over the age of 18 who have had an initial preventive care office visit.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Includes comprehensive preventive medicine reevaluation and management of an individual over the age of 18.),(Exclusion Criteria: Excludes non-office visits, including telehealth services.) -- ActivityCode constrained to codes in the Preventive Care Services-Initial Office Visit, 18 and Up valueset (2.16.840.1.113883.3.464.1003.101.11.1115).
(Clinical Focus: This value set identifies patients over the age of 18 who have had an initial preventive care office visit.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Includes comprehensive preventive medicine reevaluation and management of an individual over the age of 18.),(Exclusion Criteria: Excludes non-office visits, including telehealth services.) -- ActivityCode constrained to codes in the Preventive Care Services-Initial Office Visit, 18 and Up1 valueset (2.16.840.1.113883.3.464.1003.101.12.1023).
(Clinical Focus: This value set identifies patients over the age of 18 who have had an initial preventive care office visit.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Includes comprehensive preventive medicine reevaluation and management of an individual over the age of 18.),(Exclusion Criteria: Excludes non-office visits, including telehealth services.) -- Subject constrained to the Preventive Care Services-Initial Office Visit, 18 and Up1
(Clinical Focus: This value set indentifies patients over the age of 18 who have had an initial preventive care office visit.),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Includes comprehensive preventive medicine reevaluation and management of an individual over the age of 18.),(Exclusion Criteria: Excludes non-office visits, including telehealth services.) -- Subject constrained to the Preventive Care Services-Initial Office Visit, 18 and Up
(Clinical Focus: This value set identifies patients who patients who had an unlisted preventive medicine service. Inclusion: Includes unlisted preventive medicine services),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Includes unlisted preventive medicine services.),(Exclusion Criteria: Excludes visits that are not performed in-person, including telehealth services.) -- ActivityCode constrained to codes in the Preventive Care Services - Other valueset (2.16.840.1.113883.3.464.1003.101.12.1030).
(Clinical Focus: This value set identifies patients who patients who had an unlisted preventive medicine service. Inclusion: Includes unlisted preventive medicine services),(Data Element Scope: This value set was intended to map to the QDM data type of encounter.),(Inclusion Criteria: Includes unlisted preventive medicine services.),(Exclusion Criteria: Excludes visits that are not performed in-person, including telehealth services.) -- Subject constrained to the Preventive Care Services - Other
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Previous Receipt of Influenza Vaccine valueset (2.16.840.1.113883.3.526.3.1185)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Primary Open-Angle Glaucoma valueset (2.16.840.1.113883.3.526.3.326)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Primary THA Procedure valueset (2.16.840.1.113883.3.464.1003.198.12.1006).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Primary THA Procedure
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Primary TKA Procedure valueset (2.16.840.1.113883.3.464.1003.198.12.1007).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Primary TKA Procedure
The coded diagnosis/problem established after study to be chiefly responsible for occasioning the admission of the patient to the hospital for care.
(Clinical Focus: This set of values contains the qualifier value used to identify the term principal.),(Data Element Scope: The intent of this data element is to identify and define the qualifier value principal. Using the Quality Data Model, this particular element would map to the ordinality attribute.),(Inclusion Criteria: Include SNOMEDCT codes that define the principal qualifier value.),(Exclusion Criteria: Exclude codes that do not meet the inclusion criteria.)
An indication of the importance of an action.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Prior Pars Plana Vitrectomy valueset (2.16.840.1.113883.3.526.3.1434).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Prior Pars Plana Vitrectomy
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Prior Penetrating Keratoplasty valueset (2.16.840.1.113883.3.526.3.1475)
Procedure is derived directly from HL7 and Canada Health Infoway: “An Act whose immediate and primary outcome (post-condition) is the alteration of the physical condition of the subject. … Procedure is but one among several types of clinical activities such as observation, substance- administrations, and communicative interactions … Procedure does not comprise all acts of [sic] whose intent is intervention or treatment.”17 A procedure may be a surgery or other type of physical manipulation of a person’s body in whole or in part for purposes of making observations and diagnoses or providing treatment
Data elements that meet criteria using this datatype should document a request for the procedure indicated by the QDM category and its corresponding value set. Timing: The time the order is signed; Author dateTime.
Data elements that meet criteria using this datatype should document the completion of the procedure indicated by the QDM category and its corresponding value set. Timing: The Relevant Period addresses: StartTime = the time the procedure begins; StopTime = the time the procedure is completed NOTE: 1) Timing refers to a single instance of a procedure. If a measure seeks to evaluate multiple procedures over a period of time, the measure developer should use CQL logic to represent the query request. 2) The Incision dateTime is a single point in time available from the Operating Room and/or Anesthesia Record.
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Procedures During Pregnancy valueset (2.16.840.1.113883.3.464.1003.111.12.1009).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Procedures During Pregnancy
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Procedures Involving Contraceptive Devices valueset (2.16.840.1.113883.3.464.1003.111.12.1010).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Procedures Involving Contraceptive Devices
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Profound Impairment, Both Eyes valueset (2.16.840.1.113883.3.526.3.1476)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Promethazine Hydrochloride valueset (2.16.840.1.113883.3.464.1003.196.12.1367).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Promethazine Hydrochloride
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the PROMIS 10 Global Mental Health Score valueset (2.16.840.1.113883.3.464.1003.118.12.1138).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the PROMIS 10 Global Mental Health Score
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the PROMIS 10 Global Physical Health Score valueset (2.16.840.1.113883.3.464.1003.118.12.1139).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the PROMIS 10 Global Physical Health Score
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the PROMIS 29 Anxiety Score valueset (2.16.840.1.113883.3.464.1003.118.12.1216).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the PROMIS 29 Anxiety Score
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the PROMIS 29 Depression Score valueset (2.16.840.1.113883.3.464.1003.118.12.1215).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the PROMIS 29 Depression Score
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the PROMIS 29 Fatigue Score valueset (2.16.840.1.113883.3.464.1003.118.12.1214).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the PROMIS 29 Fatigue Score
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the PROMIS 29 Pain Interference Score valueset (2.16.840.1.113883.3.464.1003.118.12.1213).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the PROMIS 29 Pain Interference Score
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the PROMIS 29 Physical Function Score valueset (2.16.840.1.113883.3.464.1003.118.12.1212).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the PROMIS 29 Physical Function Score
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the PROMIS 29 Sleep Disturbance Score valueset (2.16.840.1.113883.3.464.1003.118.12.1211).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the PROMIS 29 Sleep Disturbance Score
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the PROMIS 29 Social Roles Score valueset (2.16.840.1.113883.3.464.1003.118.12.1217).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the PROMIS 29 Social Roles Score
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Prostate Cancer valueset (2.16.840.1.113883.3.526.3.319)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Prostate Cancer Treatment valueset (2.16.840.1.113883.3.526.3.398).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Prostate Cancer Treatment
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Prostate Specific Antigen Test valueset (2.16.840.1.113883.3.526.3.401).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Prostate Specific Antigen Test
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Proteinuria valueset (2.16.840.1.113883.3.526.3.1003)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Protriptyline valueset (2.16.840.1.113883.3.464.1003.196.12.1509).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Protriptyline
The role of provider in a healthcare context, which can be a person or an organization.
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Pseudoephedrine / Triprolidine valueset (2.16.840.1.113883.3.464.1003.196.12.1345).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Pseudoephedrine / Triprolidine
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Pseudoexfoliation Syndrome valueset (2.16.840.1.113883.3.526.3.1435)
(Clinical Focus: This value set identifies patients with a diagnosis of psoriatic arthritis.),(Data Element Scope: This value set is developed for the diagnosis QDM datatype. It can potentially be used for other datatypes as well.),(Inclusion Criteria: Includes diagnosis codes for psoriatic arthritis, arthritis mutilans, psoriatic spondylitis, and other unspecified psoriatic arthropathy.),(Exclusion Criteria: Excludes diagnosis codes for juvenile psoriatic arthritis and dactylitis.) -- ResultValue constrained to codes in the Psoriatic Arthritis valueset (2.16.840.1.113883.3.464.1003.113.12.1046)
(Clinical Focus: This grouping value set identifies diagnoses that are commonly used in the inpatient setting for psychiatric and mental health disorders.),(Data Element Scope: The intent of this data element is to identify patients who have an active diagnosis for a psychiatric or mental health disorder. Using the Quality Data Model, this particular element will map to the 'diagnosis' category.),(Inclusion Criteria: Include codes representing an active diagnosis for psychiatric and mental health disorders utilizing ICD 10 CM and SNOMED CT codes systems.),(Exclusion Criteria: None.)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Psychoanalysis valueset (2.16.840.1.113883.3.526.3.1141).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Psychoanalysis
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Psychotherapy and Pharmacologic Management valueset (2.16.840.1.113883.3.464.1003.101.12.1055).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Psychotherapy and Pharmacologic Management
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Psych Visit - Diagnostic Evaluation valueset (2.16.840.1.113883.3.526.3.1492).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Psych Visit - Diagnostic Evaluation
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Psych Visit - Family Psychotherapy valueset (2.16.840.1.113883.3.526.3.1018).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Psych Visit - Family Psychotherapy
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Psych Visit - Psychotherapy valueset (2.16.840.1.113883.3.526.3.1496).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Psych Visit - Psychotherapy
Why the item is used.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Purulent Endophthalmitis valueset (2.16.840.1.113883.3.526.3.1477)
A condition or circumstance associated with an observation that affects the interpretation of the result value.
-- ObservableCode constrained to codes in the Quality of life score [HOOS] valueset (drc-70e795b1fe63f1b98ac0eedc0e03f9b5a8746cdca458608ba4465dc459be59b3).
-- Subject constrained to the Quality of life score [HOOS]
-- ObservableCode constrained to codes in the Quality of life score [KCCQ] valueset (drc-af9a6724ea262b5d0f9c1e53e721b496d8e43f325139bdb5a0efeb684ae69683).
-- Subject constrained to the Quality of life score [KCCQ]
-- ObservableCode constrained to codes in the Quality of life score [KOOS] valueset (drc-6bacb446c606b92de72b0c89b7d886b0e5679e2886df1750f4de4cffafd649c2).
-- Subject constrained to the Quality of life score [KOOS]
A quantity with units, whose value may be bounded from above or below, as defined in FHIR
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Race valueset (2.16.840.1.114222.4.11.836)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Radiation Treatment Management valueset (2.16.840.1.113883.3.526.3.1026).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Radiation Treatment Management
An interval defined by a quantitative upper and/or lower bound. One of the two bounds must be specified, and the lower bound must be less than the upper bound. When Quantities are specified, the units of measure must be the same.
A unit of measurement for the quotient of the amount of one entity to another.
The thought process or justification for the datatype. In some measures, specific treatments are acceptable inclusion criteria only if a justified reason is present. Each of these measures uses a value set (often, but not exclusively, using SNOMED- CT®) to express acceptable justification reasons. Other measures specify reasons as justification for exclusions. Examples include patient, system, or medical-related reasons for declining to perform specific actions. Each of these measures also uses a value set to express acceptable justification reasons for declining to perform expected actions.
The period of time after which the pattern repeats, for example, each day. To specify an event should take place every other Monday, the recurrence interval should be two weeks, and DayOfWeek should be Monday.
A set of rules that describe when a recurring event is scheduled.
The start and end of the overall recurrence pattern in terms of dates/times or in terms of number of repeats. Could also be an event, such as when all doses are taken.
The low and high bound (inclusive) of values that are considered normal.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Referral valueset (2.16.840.1.113883.3.464.1003.101.12.1046).
(Clinical Focus: This set of values contains referrals that would commonly be used for management of depression in an adolescent, which includes mental health clinics (mental health worker, counselor or team), psychiatry, psychologists, emergency clinics, or depression management programs.),(Data Element Scope: ),(Inclusion Criteria: Included are appropriate referrals as specific to the child and adolescent age group for depression management.),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Referral for Depression Adolescent valueset (2.16.840.1.113883.3.600.537).
(Clinical Focus: This set of values contains referrals that would commonly be used for management of depression in an adolescent, which includes mental health clinics (mental health worker, counselor or team), psychiatry, psychologists, emergency clinics, or depression management programs.),(Data Element Scope: ),(Inclusion Criteria: Included are appropriate referrals as specific to the child and adolescent age group for depression management.),(Exclusion Criteria: ) -- Subject constrained to the Referral for Depression Adolescent
(Clinical Focus: This set of values contains referrals that would commonly be used for management of depression in an adult, which includes mental health clinics (mental health worker, counselor or team), psychiatry, psychologists, emergency clinics, or depression management programs.),(Data Element Scope: ),(Inclusion Criteria: Appropriate referrals for depression management of the adult population are included in this set of values.),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Referral for Depression Adult valueset (2.16.840.1.113883.3.600.538).
(Clinical Focus: This set of values contains referrals that would commonly be used for management of depression in an adult, which includes mental health clinics (mental health worker, counselor or team), psychiatry, psychologists, emergency clinics, or depression management programs.),(Data Element Scope: ),(Inclusion Criteria: Appropriate referrals for depression management of the adult population are included in this set of values.),(Exclusion Criteria: ) -- Subject constrained to the Referral for Depression Adult
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Referral
(Clinical Focus: This value set is intended to capture any referral encounter that a weight may be obtained; this set of values indicates that the referral would be able to contribute to weight management.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Referrals where weight assessment may occur valueset (2.16.840.1.113883.3.600.1.1527).
(Clinical Focus: This value set is intended to capture any referral encounter that a weight may be obtained; this set of values indicates that the referral would be able to contribute to weight management.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Referrals where weight assessment may occur
(Clinical Focus: This set of values incorporates that a referral to another physician or practitioner, service, or clinic is documented by the primary care provider.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Referral to Alternative Provider / Primary Care Provider valueset (2.16.840.1.113883.3.600.1475).
(Clinical Focus: This set of values incorporates that a referral to another physician or practitioner, service, or clinic is documented by the primary care provider.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Referral to Alternative Provider / Primary Care Provider
The number of refills allowed by the prescription.
(Clinical Focus: This set of values contains procedures that represent rehabilitation assessment of patients post stroke.),(Data Element Scope: The intent of this data element is to identify assessments for rehabilitation assessment following a stroke. Using the Quality Data Model, this particular element will map to the 'Procedure' category.),(Inclusion Criteria: Include SNOMED CT codes that identify a rehabilitation assessment procedures post stroke.),(Exclusion Criteria: Exclude codes that do not meet the inclusion criteria.) -- ObservableCode constrained to codes in the Rehabilitation Assessment valueset (2.16.840.1.113762.1.4.1045.18).
(Clinical Focus: This set of values contains procedures that represent rehabilitation assessment of patients post stroke.),(Data Element Scope: The intent of this data element is to identify assessments for rehabilitation assessment following a stroke. Using the Quality Data Model, this particular element will map to the 'Procedure' category.),(Inclusion Criteria: Include SNOMED CT codes that identify a rehabilitation assessment procedures post stroke.),(Exclusion Criteria: Exclude codes that do not meet the inclusion criteria.) -- Subject constrained to the Rehabilitation Assessment
(Clinical Focus: This set of values contain procedures that represent rehabilitation therapy post stroke.),(Data Element Scope: The intent of this data element is to identify stroke rehabilitation therapies. Using the Quality Data Model, this particular element will map to the 'Procedure' category.),(Inclusion Criteria: Include SNOMED CT codes that identify rehabilitation therapies used appropriate for stroke rehabilitation.),(Exclusion Criteria: Exclude codes that do not meet the inclusion criteria.) -- ObservableCode constrained to codes in the Rehabilitation Therapy valueset (2.16.840.1.113762.1.4.1045.19).
(Clinical Focus: This set of values contain procedures that represent rehabilitation therapy post stroke.),(Data Element Scope: The intent of this data element is to identify stroke rehabilitation therapies. Using the Quality Data Model, this particular element will map to the 'Procedure' category.),(Inclusion Criteria: Include SNOMED CT codes that identify rehabilitation therapies used appropriate for stroke rehabilitation.),(Exclusion Criteria: Exclude codes that do not meet the inclusion criteria.) -- Subject constrained to the Rehabilitation Therapy
An attribute that indicates one QDM data element fulfills the expecations of another QDM data element. See Appendix A.4 for examples for using relatedTo.
The code describing the relationship asserted between the two objects.
An assertion of a realtionship between two things, either present or absent.
Relevant Period addresses the time between the start of an action to the end of an action. Each datatype using relevant period defines specific definitions for the start and stop time for the action listed.
The time or time period that the statement addresses.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Removal Procedures valueset (2.16.840.1.113883.3.526.3.1436).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Removal Procedures
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Renal Failure Due to ACE Inhibitor valueset (2.16.840.1.113883.3.526.3.1151)
URI where data can be found.
Number of bytes of content in the resource (if url provided)
The final consequences or data collected from the datatype. Results can be used in five ways, to express: That a result is present in the electronic record but any entry is acceptable. A numerical result is reported directly as a value. Values may be integers or decimal numbers without units, or as a quantity with a value and units – examples: 100 mg/dL for a lab test, 140 mmHg for blood pressure, as a percentage (actually a quantity with % as units), as a ratio (e.g., 1:4, 1:80). Beginning with QDM 5.3 measures use CQL logic to express the mathematical operators to constrain desired results to those above or below a certain threshold. A result that matches one of a specific set of coded concepts in a value set or a code that matches a direct referenced code. A result as a dateTime (Assessment, Performed and components).
The time the result report is generated and saved in the database.
The finding itself, such as the blood pressure value recorded.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Retinal Detachment with Retinal Defect valueset (2.16.840.1.113883.3.526.3.1478)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Retinal or Dilated Eye Exam valueset (2.16.840.1.113883.3.464.1003.115.12.1088).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Retinal or Dilated Eye Exam
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Retinal Repair Procedures valueset (2.16.840.1.113883.3.526.3.1437).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Retinal Repair Procedures
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Retinal Vascular Occlusion valueset (2.16.840.1.113883.3.526.3.1479)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Retrolental Fibroplasias valueset (2.16.840.1.113883.3.526.3.1438)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Revision Procedures valueset (2.16.840.1.113883.3.526.3.1439).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Revision Procedures
(Clinical Focus: The set of values is intended to capture the diagnosis or condition of Rhabdomyolysis.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by diagnosis codes.),(Inclusion Criteria: Only the diagnosis of Rhabdomyolysis is included.),(Exclusion Criteria: Excludes any other diagnoses not related to Rhabdomyolysis.) -- ResultValue constrained to codes in the Rhabdomyolysis valueset (2.16.840.1.113762.1.4.1047.102)
(Clinical Focus: This set of values contains diagnosis codes that are used to identify patients with Rheumatoid arthritis.),(Data Element Scope: This value set is developed for the diagnosis QDM datatype. It can potentially be used for other datatypes as well.),(Inclusion Criteria: Includes rheumatoid arthritis and felty's syndrome. Includes comorbidities occuring with rheumatoid arthritis, such as rheumatoid polyneuropathy, rheumatoid myopathy, rheumatoid heart disease, rheumatoid vasculitis, and rheumatoid lung disease.),(Exclusion Criteria: Exclude codes for Juvenile chronic polyarthritis, Chronic postrheumatic arthropathy, or inflammatory polyarhtropathy.) -- ResultValue constrained to codes in the Rheumatoid Arthritis valueset (2.16.840.1.113883.3.464.1003.113.12.1005)
(Clinical Focus: Concepts that represent the right side),(Data Element Scope: Right),(Inclusion Criteria: Appropriate right concepts),(Exclusion Criteria: Concepts representing left)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Right Unilateral Amputation Above or Below Knee valueset (2.16.840.1.113883.3.464.1003.113.12.1057)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Right Unilateral Amputation Procedure Above or Below Knee valueset (2.16.840.1.113883.3.464.1003.113.12.1073).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Right Unilateral Amputation Procedure Above or Below Knee
(Clinical Focus: This set of values contains procedures used to represent patients who receive risk factor education.),(Data Element Scope: The intent of this data element is to identify patients who receive education on risk factors. Using the Quality Data Model, this particular element will map to the 'Communication' category.),(Inclusion Criteria: Only SNOMED CT codes representing risk factor education should be included.),(Exclusion Criteria: None) -- ObservableCode constrained to codes in the Risk Factors Education valueset (2.16.840.1.113883.3.117.1.7.1.380)
-- ObservableCode constrained to codes in the Risk for venous thromboembolism valueset (drc-522a38859e8337cb6214742610b449c149172dccc97f176b0b580b4d3f975004).
-- Subject constrained to the Risk for venous thromboembolism
The capacity in which an actor is involved in an activity or environment. For instance, 'attending physician' or 'research subject'. The difference between role and type is that type is constant, while role can change depending on the activity or setting. Note that attributes of the actor (the subject) remain constant regardless of the role the actor plays should be part of the subject and not the role. For instance, a person may be a practitioner and a patient. In both cases their date of birth will be the same and thus such information should not be part of the role.
-- ObjectTypeCode constrained to codes in the rotavirus, live, monovalent vaccine valueset (drc-a4fce6c07a6e4e9917fadf92ae9ed22c66d9e0efc5fef78f02d17bb776b888f2).
-- Subject constrained to the rotavirus, live, monovalent vaccine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Rotavirus Vaccine (3 dose schedule) valueset (2.16.840.1.113883.3.464.1003.196.12.1223).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Rotavirus Vaccine (3 dose schedule)
-- ObservableCode constrained to codes in the Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use valueset (drc-e0349078490b253b08a9a6c03e15592ebae60849fc26c6ca0874d6b6fe0403c1).
-- Subject constrained to the Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use
-- ObservableCode constrained to codes in the Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use valueset (drc-da0526efb838d456869a95aeb48c08b75f3c3085226eb236b6584feb0b80023d).
-- Subject constrained to the Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use
Refers to the path by which the medication or substance should be taken into the body systems, such as intradermally, intrathecally, intramuscularly, intranasally, intravenously, orally, rectally, subcutaneously, sublingually, topically, or vaginally.
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Rubella Antibody Test (IgG Antibody presence) valueset (2.16.840.1.113883.3.464.1003.198.12.1064).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Rubella Antibody Test (IgG Antibody presence)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Rubella Antibody Test (IgG Antibody Titer) valueset (2.16.840.1.113883.3.464.1003.198.12.1063).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Rubella Antibody Test (IgG Antibody Titer)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Rubella valueset (2.16.840.1.113883.3.464.1003.110.12.1037)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Salvage Therapy valueset (2.16.840.1.113883.3.526.3.399).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Salvage Therapy
Data that comes from a series of measurements taken by a device, which may have upper and lower limits. The data type also supports more than one dimension in the data.
(Clinical Focus: This value set identifies patients with all types of schizophrenia and schizoaffective disorders.),(Data Element Scope: This value set was intended to map to the QDM data type of diagnosis.),(Inclusion Criteria: Include codes that identify all types of schizophrenia and schizoaffective disorders.),(Exclusion Criteria: None) -- ResultValue constrained to codes in the Schizophrenia or Psychotic Disorder valueset (2.16.840.1.113883.3.464.1003.105.12.1104)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Scleral Procedures valueset (2.16.840.1.113883.3.526.3.1440).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Scleral Procedures
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Scleritis and Episcleritis valueset (2.16.840.1.113883.3.526.3.1481)
A code that connects the entry to a security policy. Security labels can be updated when the resource changes, or whenever the security sub-system chooses to.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Separation of Retinal Layers valueset (2.16.840.1.113883.3.526.3.1482)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Severe Combined Immunodeficiency valueset (2.16.840.1.113883.3.464.1003.120.12.1007)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Severe Dementia valueset (2.16.840.1.113883.3.526.3.1025)
-- ResultValue constrained to codes in the Severe dementia (disorder) valueset (drc-4bbf4abed15122216ab9eb4448a76aac2a50a6eb3589f945bf561286c6788354)
Indicates the intensity of the specified datatype (e.g., persistent, moderate, or severe).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Sexually Active valueset (2.16.840.1.113883.3.464.1003.121.12.1040).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Sexually Active
A unique, persistent, permanent identifier for the overall health record belonging to the PersonOfRecord.
A quantity where the comparator is not used, as defined in FHIR
(Clinical Focus: This set of values contains types of delivery that represent the single live birth.),(Data Element Scope: The intent of this data element is to identify single live born newborn. Using the Quality Data Model, this particular element will map to the 'Diagnosis' category or the attribute of 'Diagnoses' for Encounter category.),(Inclusion Criteria: Include codes that identify single live born newborn.),(Exclusion Criteria: Exclude codes indicating the birth took place outside of the hospital.)
(Clinical Focus: This set of values contains types of delivery that represent the single live birth.),(Data Element Scope: The intent of this data element is to identify single live born newborn. Using the Quality Data Model, this particular element will map to the 'Diagnosis' category or the attribute of 'Diagnoses' for Encounter category.),(Inclusion Criteria: Include codes that identify single live born newborn.),(Exclusion Criteria: Exclude codes indicating the birth took place outside of the hospital.) -- ResultValue constrained to codes in the Single Live Born Newborn Born in Hospital valueset (2.16.840.1.113883.3.117.1.7.1.26)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Speech and Hearing Evaluation valueset (2.16.840.1.113883.3.526.3.1530).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Speech and Hearing Evaluation
-- ObservableCode constrained to codes in the Sport-recreation score [HOOS] valueset (drc-a83df97a3d21028aa87ecefaf03f250f42886831114995d0df0fe0adc31bd74e).
-- Subject constrained to the Sport-recreation score [HOOS]
(Clinical Focus: The intent of this set of values is to capture the diagnosis of angina.),(Data Element Scope: Appropriate for use with data elements in QDM Categories or Attributes represented by diagnosis codes.),(Inclusion Criteria: Included are stable and unstable angina, pre and post infarction angina, angina decubitus, intermediate coronary syndrome, other unspecified angina or sequelae of myocardial infarction, and other forms of angina pectoris.),(Exclusion Criteria: Excluded is any form of angina that does not define Atherosclerotic Cardiovascular Disease (ASCVD).) -- ResultValue constrained to codes in the Stable and Unstable Angina valueset (2.16.840.1.113762.1.4.1047.47)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Standardized Pain Assessment Tool valueset (2.16.840.1.113883.3.526.3.1028).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Standardized Pain Assessment Tool
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Standardized Tools for Assessment of Cognition valueset (2.16.840.1.113883.3.526.3.1006).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Standardized Tools for Assessment of Cognition
Sub-unit of a country with limited sovereignty in a federally organized country. A code may be used if codes are in common use (i.e. US 2 letter state codes). (Source: HL7 FHIR).
Base class for all types of clinical statements.
(Clinical Focus: Identifies patients with an allergy to statin medications.),(Data Element Scope: Statin Allergens as structured in RXNORM),(Inclusion Criteria: Only includes codes that use the IN term type for statins.),(Exclusion Criteria: Does not include non-statin medications.) -- ResultValue constrained to codes in the Statin Allergen valueset (2.16.840.1.113883.3.117.1.7.1.423)
(Clinical Focus: Identifies patients with an allergy to statin medications.),(Data Element Scope: Statin Allergens as structured in RXNORM),(Inclusion Criteria: Only includes codes that use the IN term type for statins.),(Exclusion Criteria: Does not include non-statin medications.) -- ResultValue constrained to codes in the Statin Allergen valueset (2.16.840.1.113883.3.117.1.7.1.423)
(Clinical Focus: This set of values contains statin medications that are prescribed for therapy at hospital discharge.),(Data Element Scope: The intent of this data element is to identify patients who are prescribed statin medications at discharge. Using the Quality Data Model, this particular element would map to the Medication category.),(Inclusion Criteria: Include single and multiple ingredient prescribable statin medications. Oral dose forms should be included. Generic only.),(Exclusion Criteria: None.) -- ObjectTypeCode constrained to codes in the Statin Grouper valueset (2.16.840.1.113762.1.4.1110.19).
(Clinical Focus: This set of values contains statin medications that are prescribed for therapy at hospital discharge.),(Data Element Scope: The intent of this data element is to identify patients who are prescribed statin medications at discharge. Using the Quality Data Model, this particular element would map to the Medication category.),(Inclusion Criteria: Include single and multiple ingredient prescribable statin medications. Oral dose forms should be included. Generic only.),(Exclusion Criteria: None.) -- Subject constrained to the Statin Grouper
Indicates the particular stage of the action represented by the datatype.
(Clinical Focus: This value set contains codes that identify a previous history of having a left mastectomy.),(Data Element Scope: This value set was intended to identify patients who had a left mastectomy.),(Inclusion Criteria: Includes codes that identify a left mastectomy was performed in the past.),(Exclusion Criteria: Excludes codes that indicate a right or bilateral mastectomy or are unspecified.) -- ResultValue constrained to codes in the Status Post Left Mastectomy valueset (2.16.840.1.113883.3.464.1003.198.12.1069)
(Clinical Focus: This value set contains codes to identify a right mastectomy.),(Data Element Scope: This value set was intended to identify patients who had a right mastectomy.),(Inclusion Criteria: Includes codes that indicate a right mastectomy.),(Exclusion Criteria: Excludes codes that indicate a left or bilateral mastectomy or are unspecified.) -- ResultValue constrained to codes in the Status Post Right Mastectomy valueset (2.16.840.1.113883.3.464.1003.198.12.1070)
-- ResultValue constrained to codes in the Streptomycin adverse reaction (disorder) valueset (drc-bf49ef626cbfd7fd417720fcd9ca97199a85ec02467842b246e643556aecad6b)
(Clinical Focus: This set of values identifies the route by which a medication is administered, in this case a subcutaneous route.),(Data Element Scope: The intent of this data element is to identify the route by which a medication is administered, in this case a subcutaneous route. Using the Quality Data Model, this particular element is an attribute.),(Inclusion Criteria: Only use codes which identify a subcutaneous route for giving a medication. These are SNOMED-CT codes.),(Exclusion Criteria: None)
The person, place, event, condition, other statement that this statement addresses or belongs to. For an existential finding, the Subject is the 'owner' of the object said to exist or not exist. For example, the subject for a condition is a patient; the subject for wound size is a wound. Subjects are themselves statements.
Substance represents a homogeneous material with definite composition that includes allergens, biological materials, chemicals, foods, drugs and materials.19 QDM distinguishes between medications from non-medication substances by separately listing medication datatypes. Substance may or may not have a code or be classified by a code system such RxNorm. Examples of a substance may include environmental agents (e.g., pollen, dust) and food (e.g., vitamins).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: )
SubstaData elements that meet criteria using this datatype should document that the substance indicated by the QDM category and its corresponding value set was actually given to the patient. Timing: The Relevant Period addresses: StartTime = when a single substance administration event starts (e.g., the initiation of an intravenous infusion, or administering the substance orally or topically to a patient); StopTime = when a single substance administration event ends (e.g., the end time of the intravenous infusion, or the administration of a substance orally or topically is completed - for oral or topical administration, the start and stop times are the same)nceAdministered
(Clinical Focus: The purpose of this set of values is to assess that a suicide risk assessment is collected; that the actual procedure of collecting a suicide assessment is completed and documented.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Suicide Risk Assessment valueset (2.16.840.1.113883.3.600.559).
(Clinical Focus: The purpose of this set of values is to assess that a suicide risk assessment is collected; that the actual procedure of collecting a suicide assessment is completed and documented.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Suicide Risk Assessment
-- ActivityCode constrained to codes in the Suicide risk assessment (procedure) valueset (drc-c81885cf80013c9f1448d7aa50939c05011af25021a47bb98df44ec175ebe707).
-- Subject constrained to the Suicide risk assessment (procedure)
The quantity (amount) of therapeutic agent that was provided to a patient (i.e., number of doses, number of tablets or pills, volume of medication). Indicated to be given during a procedure, diagnostic test, or medication or substance administration. Note: Prior versions of the QDM (4.3 and earlier) addressed “dose” with two potential interpretations – (1) the quantity to be taken or administered with each administration and (2) the quantity of medication supplied (i.e., number of doses). QDM 5.0 and subsequent versions clarify the difference by defining “dosage” and “supply,” respectively. Note: Medication, Discharge includes medications the provider has indicated the patient should take after dischange from the hospital. This medication list is part of the discharge instructions provided to a patient. The list may include medication supply if it incorporates medication orders written at discharge even though the supply will not be present for medications the patient already has at home or purchases over- the-counter (without a prescription).
-- ObservableCode constrained to codes in the Symptoms score [HOOS] valueset (drc-b5dd36a85d7719e9a76c842dfe7566230ceb1cb218634b62b4f26ec02772d0e6).
-- Subject constrained to the Symptoms score [HOOS]
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Syphilis valueset (2.16.840.1.113883.3.464.1003.112.12.1002)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development)
-- ObservableCode constrained to codes in the Systolic blood pressure valueset (drc-f6a92d7503c3bf27d99920eb885363b716972c2aeeac8a6e69d4d8682291e7f4).
-- Subject constrained to the Systolic blood pressure
A code used to relate entries to categories or workflows. Applications are not required to consider the tags when interpreting the meaning of an entry.
A user name or other identifier on a telecommunication network, such as a telephone number (including country code and extension, if necessary), email address, or SkypeID.
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Telehealth Services valueset (2.16.840.1.113883.3.464.1003.101.12.1031).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Telehealth Services
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Telephone Evaluation valueset (2.16.840.1.113883.3.464.1003.101.12.1082).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Telephone Evaluation
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Telephone Management valueset (2.16.840.1.113883.3.464.1003.101.12.1053).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Telephone Management
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Ten-year probability of all major osteoporosis related fracture valueset (2.16.840.1.113883.3.464.1003.118.12.1081).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Ten-year probability of all major osteoporosis related fracture
(Clinical Focus: This set of values contains medications that are prescribed for Thrombolytic (t-PA) Therapy for treatment of ischemic stroke.),(Data Element Scope: The intent of this data element is to identify patients who are administered appropriate Thrombolytic (t-PA) Therapy for stroke. Using the Quality Data Model, this particular element would map to the 'Medication' category.),(Inclusion Criteria: Include RxNorm thombolytic medications appropriate for stroke treatment consistent with administration by IV route.),(Exclusion Criteria: None.) -- ObjectTypeCode constrained to codes in the Thrombolytic (t-PA) Therapy valueset (2.16.840.1.113883.3.117.1.7.1.226).
(Clinical Focus: This set of values contains medications that are prescribed for Thrombolytic (t-PA) Therapy for treatment of ischemic stroke.),(Data Element Scope: The intent of this data element is to identify patients who are administered appropriate Thrombolytic (t-PA) Therapy for stroke. Using the Quality Data Model, this particular element would map to the 'Medication' category.),(Inclusion Criteria: Include RxNorm thombolytic medications appropriate for stroke treatment consistent with administration by IV route.),(Exclusion Criteria: None.) -- Subject constrained to the Thrombolytic (t-PA) Therapy
The end, remission or resolution of a disease.
Time of day the event should take place on the designated day(s). TimeOfDay should only be specified if the RecurrenceInterval and/or DayOfWeek establishes the day when the event should take place.
(Clinical Focus: This set of values that represent the time of delivery.),(Data Element Scope: The intent of this data element is to identify the time of delivery. Using the Quality Data Model, this particular element will map to the 'Assessment' category.),(Inclusion Criteria: Include SNOMED CT codes that identify time of delivery.),(Exclusion Criteria: None) -- ObservableCode constrained to codes in the Time of Delivery valueset (2.16.840.1.113762.1.4.1045.28).
(Clinical Focus: This set of values that represent the time of delivery.),(Data Element Scope: The intent of this data element is to identify the time of delivery. Using the Quality Data Model, this particular element will map to the 'Assessment' category.),(Inclusion Criteria: Include SNOMED CT codes that identify time of delivery.),(Exclusion Criteria: None) -- Subject constrained to the Time of Delivery
The beginning or first appearance of a mental or physical disorder.
A period of time defined by a start and end time, date, or year. If the start element is missing, the start of the period is not known. If the end element is missing, it means that the period is ongoing, or the start may be in the past, and the end date in the future, which means that period is expected/planned to end at the specified time. The end value includes any matching date/time. For example, the period 2011-05-23 to 2011-05-27 includes all the times from the start of the 23rd May through to the end of the 27th of May.
The time at which something is to end or did end. Boundary is considered inclusive.
The time at which something is to take effect, start, or did start. Boundary is considered inclusive.
A timing schedule that specifies an event that may occur multiple times. Timing offers a choice of multiple OccurrenceTime (used is used to specify specific times), or recurrence patterns.
A code for the timing schedule. Some codes such as BID are ubiquitous, but many institutions define their own additional codes. If a code is provided, the code is understood to be a complete statement of whatever is specified in the structured timing data, and either the code or the data may be used to interpret the Timing, with the exception that .repeat.bounds still applies over the code (and is not contained in the code).
A distinguishing word or group of words naming an item.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ActivityCode constrained to codes in the Tobacco Use Cessation Counseling valueset (2.16.840.1.113883.3.526.3.509).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Tobacco Use Cessation Counseling
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObjectTypeCode constrained to codes in the Tobacco Use Cessation Pharmacotherapy valueset (2.16.840.1.113883.3.526.3.1190).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Tobacco Use Cessation Pharmacotherapy
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Tobacco Use Cessation Pharmacotherapy
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Tobacco Use Screening valueset (2.16.840.1.113883.3.526.3.1278).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Tobacco Use Screening
(Clinical Focus: This value set contains codes to identify a total colectomy.),(Data Element Scope: This value set was intended to identify patients who had a total colectomy.),(Inclusion Criteria: Includes codes that indicate a total colectomy, as an open or laparoscopic procedure.),(Exclusion Criteria: Excludes partial colectomies.) -- ObservableCode constrained to codes in the Total Colectomy valueset (2.16.840.1.113883.3.464.1003.198.12.1019).
(Clinical Focus: This value set contains codes to identify a total colectomy.),(Data Element Scope: This value set was intended to identify patients who had a total colectomy.),(Inclusion Criteria: Includes codes that indicate a total colectomy, as an open or laparoscopic procedure.),(Exclusion Criteria: Excludes partial colectomies.) -- Subject constrained to the Total Colectomy
(Clinical Focus: This set of values contains cervical cerclage procedures performed by the abdominal approach.),(Data Element Scope: The intent of this value set is to identify patients who have had a transabdominal cerclage.),(Inclusion Criteria: Cervical cerclage procedures performed by the abdominal approach should be included.),(Exclusion Criteria: None) -- ObservableCode constrained to codes in the Transabdominal Cerclage valueset (2.16.840.1.113762.1.4.1110.18).
(Clinical Focus: This set of values contains cervical cerclage procedures performed by the abdominal approach.),(Data Element Scope: The intent of this value set is to identify patients who have had a transabdominal cerclage.),(Inclusion Criteria: Cervical cerclage procedures performed by the abdominal approach should be included.),(Exclusion Criteria: None) -- Subject constrained to the Transabdominal Cerclage
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Traumatic Cataract valueset (2.16.840.1.113883.3.526.3.1443)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Trihexyphenidyl valueset (2.16.840.1.113883.3.464.1003.196.12.1334).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Trihexyphenidyl
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Trimipramine valueset (2.16.840.1.113883.3.464.1003.196.12.1285).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Trimipramine
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Triprolidine valueset (2.16.840.1.113883.3.464.1003.196.12.1408).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Triprolidine
The characterization of the reaction (e.g., hypersensitivity, rash, gastroenteric symptoms, etc.)
(Clinical Focus: This set of values contains codes that identify patients with a diagnosis of type 1 diabetes mellitus and distinguishes these patients from patients with other types of diabetes mellitus, including gestational, drug-induced or type 2 diabetes mellitus.),(Data Element Scope: This value set is developed for the diagnosis QDM datatype. It can potentially be used for other datatypes as well.),(Inclusion Criteria: Include all diagnosis codes associated with type 1 diabetes mellitus , with or without reference to complications and comorbidities.),(Exclusion Criteria: Exclude all diagnosis codes associated with gestational, drug-induced and type 2 diabetes mellitus without mention of type 1 diabetes mellitus.) -- ResultValue constrained to codes in the Type 1 Diabetes valueset (2.16.840.1.113883.3.464.1003.103.12.1020)
A code that describes the type of composition or section, such as a section or document type identifier.
(Clinical Focus: The intent of this value set is to identify patients that are underweight as a finding documented by the healthcare provider in the medical record.),(Data Element Scope: The intent of this data element is to identify patients who are currently underweight. Using the Quality Data Model, this particular element would map to the Attribute: ?Reason: underweight? element.),(Inclusion Criteria: ),(Exclusion Criteria: )
(Clinical Focus: This value set identifies heparin formulations that could reasonably be used to treat venous thromboembolism as a continuous infusion.),(Data Element Scope: The intent of this data element is to identify patients who receive unfractionated heparin as an intravenous infusion. Using the Quality Data Model, this particular element will map to the Medication category.),(Inclusion Criteria: Injectable products that could reasonably be used for continuous infusion of heparin and achieve therapeutic levels.),(Exclusion Criteria: Concentrations < 250 UNT/ML (except those representing premixed heparin infusion bags, per inclusion criteria).) -- ObjectTypeCode constrained to codes in the Unfractionated Heparin valueset (2.16.840.1.113883.3.117.1.7.1.218).
(Clinical Focus: This value set identifies heparin formulations that could reasonably be used to treat venous thromboembolism as a continuous infusion.),(Data Element Scope: The intent of this data element is to identify patients who receive unfractionated heparin as an intravenous infusion. Using the Quality Data Model, this particular element will map to the Medication category.),(Inclusion Criteria: Injectable products that could reasonably be used for continuous infusion of heparin and achieve therapeutic levels.),(Exclusion Criteria: Concentrations < 250 UNT/ML (except those representing premixed heparin infusion bags, per inclusion criteria).) -- Subject constrained to the Unfractionated Heparin
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Unilateral Amputation Below or Above Knee, Unspecified Laterality valueset (2.16.840.1.113883.3.464.1003.113.12.1059)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Unilateral Amputation Procedure Below or Above Knee, Unspecified Laterality valueset (2.16.840.1.113883.3.464.1003.103.12.1022).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Unilateral Amputation Procedure Below or Above Knee, Unspecified Laterality
(Clinical Focus: This value set contains codes to identify a unilateral mastectomy.),(Data Element Scope: This value set was intended to identify patients who had a unilateral mastectomy.),(Inclusion Criteria: Includes codes that indicate a unilateral mastectomy.),(Exclusion Criteria: Excludes codes that indicate a left, right or bilateral mastectomy.) -- ObservableCode constrained to codes in the Unilateral Mastectomy valueset (2.16.840.1.113883.3.464.1003.198.12.1020).
(Clinical Focus: This value set contains codes to identify a unilateral mastectomy.),(Data Element Scope: This value set was intended to identify patients who had a unilateral mastectomy.),(Inclusion Criteria: Includes codes that indicate a unilateral mastectomy.),(Exclusion Criteria: Excludes codes that indicate a left, right or bilateral mastectomy.) -- Subject constrained to the Unilateral Mastectomy
(Clinical Focus: This value set contains codes to identify a unilateral mastectomy where the side was not specified.),(Data Element Scope: This value set was intended to identify patients who had a unilateral mastectomy where the side was unspecified.),(Inclusion Criteria: Includes codes that for a unilateral mastectomy where the side was unspecified.),(Exclusion Criteria: Excludes codes that indicate a bilateral mastectomy or a unilateral mastectomy where the side is specified.) -- ResultValue constrained to codes in the Unilateral Mastectomy, Unspecified Laterality valueset (2.16.840.1.113883.3.464.1003.198.12.1071)
Code for the unit of measure of the quantity.
The upper limit on a quantitative value.
The upper limit of detection of the measured points. This is needed if any of the data points have the value 'U' (higher than detection limit).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Upper Respiratory Infection valueset (2.16.840.1.113883.3.464.1003.102.12.1022)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Urine Protein Tests valueset (2.16.840.1.113883.3.464.1003.109.12.1024).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Urine Protein Tests
(Clinical Focus: This grouping of value sets identifies patients who have urologic surgery procedures.),(Data Element Scope: The intent of this data element is to identify patients who have a urologic surgery procedure. Using the Quality Data Model, this particular element will map to the Procedure category.),(Inclusion Criteria: Only use codes which represent urologic surgery procedures.),(Exclusion Criteria: None.) -- ObservableCode constrained to codes in the Urological Surgery valueset (2.16.840.1.113883.3.117.1.7.1.272).
(Clinical Focus: This grouping of value sets identifies patients who have urologic surgery procedures.),(Data Element Scope: The intent of this data element is to identify patients who have a urologic surgery procedure. Using the Quality Data Model, this particular element will map to the Procedure category.),(Inclusion Criteria: Only use codes which represent urologic surgery procedures.),(Exclusion Criteria: None.) -- Subject constrained to the Urological Surgery
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObjectTypeCode constrained to codes in the Use of Systemic Sympathetic alpha-1a Antagonist Medication for Treatment of Prostatic Hypertrophy valueset (2.16.840.1.113883.3.526.3.1442).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Use of Systemic Sympathetic alpha-1a Antagonist Medication for Treatment of Prostatic Hypertrophy
(Clinical Focus: This set of values contains excision of the uterine horn procedures performed.),(Data Element Scope: The intent of this value set is to identify patients who have had an excision of the uterine horn procedure.),(Inclusion Criteria: Excision of the uterine horn procedures by any approach are included.),(Exclusion Criteria: All other procedures.) -- ObservableCode constrained to codes in the Uterine Horn valueset (2.16.840.1.113762.1.4.1110.24).
(Clinical Focus: This set of values contains excision of the uterine horn procedures performed.),(Data Element Scope: The intent of this value set is to identify patients who have had an excision of the uterine horn procedure.),(Inclusion Criteria: Excision of the uterine horn procedures by any approach are included.),(Exclusion Criteria: All other procedures.) -- Subject constrained to the Uterine Horn
(Clinical Focus: This set of values contains diagnoses that represent a uterine rupture),(Data Element Scope: The intent of this data element is to identify a uterine rupture.),(Inclusion Criteria: Include codes that identify a uterine rupture.),(Exclusion Criteria: None) -- ResultValue constrained to codes in the Uterine Rupture valueset (2.16.840.1.113762.1.4.1110.16)
(Clinical Focus: This set of values contains diagnoses that represent a uterine window.),(Data Element Scope: The intent of this data element is to identify a uterine window. Using the Quality Data Model, this particular element will map to the 'Diagnosis' category.),(Inclusion Criteria: Include SNOMED CT codes that identify a uterine window.),(Exclusion Criteria: None) -- ResultValue constrained to codes in the Uterine Window valueset (2.16.840.1.113883.3.117.1.7.1.137)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Uveitis valueset (2.16.840.1.113883.3.526.3.1444)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Varicella Zoster Antibody Test (IgG Antibody Presence) valueset (2.16.840.1.113883.3.464.1003.198.12.1067).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Varicella Zoster Antibody Test (IgG Antibody Presence)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Varicella Zoster Antibody Test (IgG Antibody Titer) valueset (2.16.840.1.113883.3.464.1003.198.12.1066).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Varicella Zoster Antibody Test (IgG Antibody Titer)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the Varicella Zoster valueset (2.16.840.1.113883.3.464.1003.110.12.1039)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObjectTypeCode constrained to codes in the Varicella Zoster Vaccine (VZV) valueset (2.16.840.1.113883.3.464.1003.196.12.1170).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Varicella Zoster Vaccine (VZV) Administered valueset (2.16.840.1.113883.3.464.1003.110.12.1040).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Varicella Zoster Vaccine (VZV) Administered
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Vascular Access for Dialysis valueset (2.16.840.1.113883.3.464.1003.109.12.1011).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Vascular Access for Dialysis
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Vascular Disorders of Iris and Ciliary Body valueset (2.16.840.1.113883.3.526.3.1445)
(Clinical Focus: This set of values identifies patients who have a venous foot pump device applied for VTE prophylaxis.),(Data Element Scope: The intent of this data element is to identify patients who have a venous foot pump device applied for VTE prophylaxis. Using the Quality Data Model, this particular element will map to the Device category.),(Inclusion Criteria: Only use codes which represent venous foot pump devices which are used for VTE prophylaxis.),(Exclusion Criteria: None) -- ObjectTypeCode constrained to codes in the Venous foot pumps (VFP) valueset (2.16.840.1.113883.3.117.1.7.1.230).
(Clinical Focus: This set of values identifies patients who have a venous foot pump device applied for VTE prophylaxis.),(Data Element Scope: The intent of this data element is to identify patients who have a venous foot pump device applied for VTE prophylaxis. Using the Quality Data Model, this particular element will map to the Device category.),(Inclusion Criteria: Only use codes which represent venous foot pump devices which are used for VTE prophylaxis.),(Exclusion Criteria: None) -- Subject constrained to the Venous foot pumps (VFP)
(Clinical Focus: This set of values identifies patients who have a venous foot pump device applied for VTE prophylaxis.),(Data Element Scope: The intent of this data element is to identify patients who have a venous foot pump device applied for VTE prophylaxis. Using the Quality Data Model, this particular element will map to the Device category.),(Inclusion Criteria: Only use codes which represent venous foot pump devices which are used for VTE prophylaxis.),(Exclusion Criteria: None) -- Subject constrained to the Venous foot pumps (VFP)
(Clinical Focus: This grouping of value sets identifies patients who have a venous thromboembolism, including those who have a pulmonary embolism.),(Data Element Scope: The intent of this data element is to identify patients who have a venous thromboembolism, including those who have a pulmonary embolism. Using the Quality Data Model, this particular element will map to the Diagnosis category, or the Diagnosis or Principal Diagnosis attribute for the Encounter category.),(Inclusion Criteria: Only use codes representing pulmonary embolism and proximal venous thromboembolisms, including specific proximal veins: popliteal vein, femoral/superficial femoral vein, deep femoral vein, ileofemoral vein, iliac vein and inferior vena cava.),(Exclusion Criteria: None.) -- ResultValue constrained to codes in the Venous Thromboembolism valueset (2.16.840.1.113883.3.117.1.7.1.279)
(Clinical Focus: This grouping value set contains procedures used to identify the placement of a ventricular assist device.),(Data Element Scope: The intent of this data element is to identify procedures for ventricular assist device placement. Using the Quality Data Model, this particular element would map to the Procedure, Performed datatype.),(Inclusion Criteria: Include codes that identify patients with ventricular assist device placement. This is a grouping of ICD-10-PCS and SNOMEDCT codes.),(Exclusion Criteria: None.) -- ObservableCode constrained to codes in the Ventricular Assist Device placement valueset (2.16.840.1.113883.3.666.5.3015).
(Clinical Focus: This grouping value set contains procedures used to identify the placement of a ventricular assist device.),(Data Element Scope: The intent of this data element is to identify procedures for ventricular assist device placement. Using the Quality Data Model, this particular element would map to the Procedure, Performed datatype.),(Inclusion Criteria: Include codes that identify patients with ventricular assist device placement. This is a grouping of ICD-10-PCS and SNOMEDCT codes.),(Exclusion Criteria: None.) -- Subject constrained to the Ventricular Assist Device placement
A number or code associated with the product that identifies a particular release iteration.
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ResultValue constrained to codes in the Visual Field Defects valueset (2.16.840.1.113883.3.526.3.1446)
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- ObservableCode constrained to codes in the Vitreous Procedures valueset (2.16.840.1.113883.3.526.3.1447).
(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development) -- Subject constrained to the Vitreous Procedures
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the VR12 Mental Component T Score valueset (2.16.840.1.113883.3.464.1003.118.12.1177).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the VR12 Mental Component T Score
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the VR12 Physical Component T Score valueset (2.16.840.1.113883.3.464.1003.118.12.1176).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the VR12 Physical Component T Score
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the VR 36 Mental Component Summary (MCS) Score valueset (2.16.840.1.113883.3.464.1003.118.12.1225).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the VR 36 Mental Component Summary (MCS) Score
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the VR 36 Physical Component Summary (PCS) Score valueset (2.16.840.1.113883.3.464.1003.118.12.1226).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the VR 36 Physical Component Summary (PCS) Score
(Clinical Focus: This set of values contains Warfarin medications that are administered to patients to reduce the risk of blood clot formation.),(Data Element Scope: The intent of this data element is to identify patients who are prescribed warfarin therapy at discharge following acute myocardial infarction. Using the Quality Data Model, this particular element would map to the Medication category.),(Inclusion Criteria: Drug forms that are consistent with oral administration should be included: tablets. Only single ingredient.),(Exclusion Criteria: None.) -- ObjectTypeCode constrained to codes in the Warfarin valueset (2.16.840.1.113883.3.117.1.7.1.232).
(Clinical Focus: This set of values contains Warfarin medications that are administered to patients to reduce the risk of blood clot formation.),(Data Element Scope: The intent of this data element is to identify patients who are prescribed warfarin therapy at discharge following acute myocardial infarction. Using the Quality Data Model, this particular element would map to the Medication category.),(Inclusion Criteria: Drug forms that are consistent with oral administration should be included: tablets. Only single ingredient.),(Exclusion Criteria: None.) -- Subject constrained to the Warfarin
(Clinical Focus: This set of values contains Warfarin medications that are administered to patients to reduce the risk of blood clot formation.),(Data Element Scope: The intent of this data element is to identify patients who are prescribed warfarin therapy at discharge following acute myocardial infarction. Using the Quality Data Model, this particular element would map to the Medication category.),(Inclusion Criteria: Drug forms that are consistent with oral administration should be included: tablets. Only single ingredient.),(Exclusion Criteria: None.) -- Subject constrained to the Warfarin
(Clinical Focus: This set of values contains procedures used to represent patients who receive warning signs and symptoms education.),(Data Element Scope: The intent of this data element is to identify patients who receive education on stroke warnings signs and symptoms. Using the Quality Data Model, this particular element will map to the 'Communication' category.),(Inclusion Criteria: Only SNOMED CT codes representing education on warning signs and symptoms should be included.),(Exclusion Criteria: None) -- ObservableCode constrained to codes in the Warning Signs and Symptoms Education valueset (2.16.840.1.113883.3.117.1.7.1.381)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the Weight valueset (2.16.840.1.113883.3.464.1003.121.12.1015).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Weight
(Clinical Focus: The general purpose of this value set is that obesity or the need to reduce weight is assessed, so that a target weight discussion can take place, or weight reduction education is provided, or a referral to a weight management program was given; also weight management classes could be ordered to be performed by a non- physician provider.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ActivityCode constrained to codes in the Weight Reduction Recommended valueset (2.16.840.1.113883.3.600.1510).
(Clinical Focus: The general purpose of this value set is that obesity or the need to reduce weight is assessed, so that a target weight discussion can take place, or weight reduction education is provided, or a referral to a weight management program was given; also weight management classes could be ordered to be performed by a non- physician provider.),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the Weight Reduction Recommended
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ResultValue constrained to codes in the White valueset (2.16.840.1.113883.3.464.1003.123.12.1007)
(Clinical Focus: This set of values contains qualifiers used to represent patients who receive written information.),(Data Element Scope: The intent of this data element is to identify patients who receive written information. Using the Quality Data Model, this particular element will map to the 'Communication' category.),(Inclusion Criteria: Only SNOMED CT codes representing written information given should be included.),(Exclusion Criteria: None) -- ObservableCode constrained to codes in the Written Information Given valueset (2.16.840.1.113883.3.117.1.7.1.415)
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- ObservableCode constrained to codes in the X-Ray Study (all inclusive) valueset (2.16.840.1.113883.3.464.1003.198.12.1034).
(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) -- Subject constrained to the X-Ray Study (all inclusive)